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ABSTRACT 
Malnutrition is a global health problem that affects infants and young children. It 
is frequently associated with infections and commonly affects children in 
developing countries. Malnutrition is the cellular imbalance between the supply 
of energy from macronutrients and micronutrients and the demand of the body 
for them in order to achieve normal growth, maintenance, and specific functions. 
Underweight (mild to moderate) and marasmus, marasmic-kwashiorkor, and 
kwashiorkor (severe) are the spectrum of malnutrition.  
Various pathophysiological changes, including fatty changes, abnormal 
rough endoplasmic reticula and mitochondria, decreased peroxisomes, and 
decreased quantity and quality of metabolising enzymes, are associated with 
malnutrition which may significantly influence hepatic drug metabolism. 
However, the effect of different categories of malnutrition on drug metabolism 
has not been extensively investigated. This research, therefore, aimed to 
determine the effect of malnutrition on drug metabolism. The specific objectives 
are (i) to perform a systematic review of the studies of drug pharmacokinetics in 
malnourished children, and (ii) to use the caffeine breath test to determine the 
effects of different types of malnutrition on the metabolising activity of hepatic 
CYP1A2 enzymes. 
The systematic review involved literature searches in the MEDLINE and 
EMBASE databases covering publications between January 1960 and December 
2009. Articles describing drug pharmacodynamics and pharmacokinetic 
parameters in the four categories of malnutrition, limited to children from 0 to 
17 years, were sought using both databases and by reference tracking. 
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Altogether, 42 publications evaluated the disposition of 34 drugs in malnourished 
children. The drug absorption rate (Ka) was reported for eight drugs, of which 
gentamicin, metronidazole, phenytoin, chloramphenicol, paracetamol, and 
sulphamethoxazole showed no difference in the values of Ka for malnourished 
children and the control groups. The AUC of seven drugs did not differ for 
malnourished children when compared to their control groups but significantly 
decreased for carbamazepine (p < 0.05) and chloroquine (p < 0.001). By 
contrast, there was a statistically significant increase in the AUC of six drugs: 
metronidazole (p < 0.05), caffeine (p < 0.05), paracetamol (p < 0.05), 
phenobarbitone (p < 0.05), sulphadiazine (p < 0.01), and sulphamethoxazole (p 
< 0.001). The plasma protein binding of 19 drugs was evaluated in seven in 
vitro and two in vivo studies. There was a statistically significant decrease in the 
protein binding of 17 drugs in kwashiorkor when compared to healthy adults (p-
values ranged from <0.0005 to <0.05). Nineteen studies evaluated the effects 
of malnutrition on the volume of distribution (VD) for 14 drugs. For most drugs, 
malnutrition had no statistically significant effect on VD. However, four drugs: 
gentamicin, quinine, streptomycin, and theophylline demonstrated contrasting 
results.  The effect of malnutrition on the total clearance (CL) and elimination 
half-life (t½) of nine drugs that are primarily metabolised in the liver was 
evaluated in 15 studies. There was a statistically significant decrease in the CL of 
six drugs: acetanilide (p < 0.025), antipyrine (p < 0.05, p < 0.0025, p < 0.05), 
caffeine (p < 0.01), sulphamethoxazole, isoniazid (p < 0.01), and metronidazole 
(p < 0.01). There was a corresponding statistically significant increase in their 
plasma half-lives. For six drugs that are primarily eliminated by the kidneys, 
malnutrition has a varying effect on their total CLs.  The total CL was 
significantly increased for penicillin in children with marasmus (p < 0.001), 
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marasmic-kwashiorkor (p < 0.01), and kwashiorkor (p < 0.01), as well as 
increased for streptomycin in children with kwashiorkor (p < 0.01). By contrast, 
the total CL was significantly decreased for penicillin in underweight children (p 
< 0.01). It was also significantly decreased for cefoxitin in children with 
kwashiorkor (p < 0.025). The significantly decreased total CL of most of the 
drugs primarily metabolised by the liver may reflect decreased activity of the 
intrinsic hepatic metabolising enzymes. This would suggest a need to reduce 
drug dosage in malnourished children. More studies are therefore required to 
assess the activities of the hepatic metabolising enzymes in malnourished 
children.  
Following the systematic review, the caffeine breath test (CBT) identified 
as a non-invasive approach to study the effects of the four categories of 
malnutrition on caffeine metabolism. Caffeine is a 1, 3, 7 trimethylxanthine 
compound that is metabolised in the liver by 1-N, 2-N and 7-N demethylation, 
and C-8 hydroxylation to 1, 3, 7 trimethyluric acid. CYP1A2 is responsible for the 
3-N demethylation of caffeine. The CBT involves oral administration of a non-
radioactive stable isotope of caffeine (13C on the 3-methyl group). The caffeine 
undergoes 3-N demethylation in the liver which is a CYP1A2 dependent reaction. 
After N-demethylation, the 13C methyl group enters the carbon pool as it is 
converted to formaldehyde, formate and bicarbonate. The bicarbonate is exhaled 
as carbon-dioxide. The exhaled labelled 13CO2 is known to correlate with CY1A2 
activity. 
Fifteen children each who were underweight or experiencing marasmus, 
marasmic-kwashiorkor or kwashiorkor were recruited from Lagos and Kano 
States in Nigeria. They were studied before and after nutritional rehabilitation. 
After ingesting labelled caffeine (3mg/kg) at 0900 hours, breath samples were 
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collected in duplicate at -20, -10, -1 minute and every 15 minutes over 2 hours. 
The cumulative mean percent 13C-caffeine dose exhaled as 13CO2 was measured 
RYHUKRXUV6WXGHQW¶Vt-test was used to compare the results for each category 
of malnutrition, before and after nutritional rehabilitation, at 5% level of 
significance. The mean cumulative percent 13C-caffeine dose recovered (CPDR) 
in underweight children was 7.56 ± 4.01% and 7.95 ± 3.68% before and after 
nutritional rehabilitation, respectively, and there was no significant difference in 
the mean values (p = 0.603). The CPDR significantly increased after nutritional 
rehabilitation in children with marasmus (from 6.80 ± 3.00% to 7.67 ± 2.81%, 
p < 0.001), marasmic-kwashiorkor (from 6.61 ± 2.26% to 7.56 ± 2.46%, p < 
0.041), and kwashiorkor (from 6.29 ± 1.06% to 7.20 ± 1.80%, p =0.002). It is 
concluded that the present study may not have been adequately powered to 
detect a statistically significant difference in the results for underweight children. 
Such a difference would have been the basis for validating the results in a larger 
population of underweight children. However, doses of drugs that are 
metabolised by CYP1A2 enzyme may require modification in severely 
malnourished children.  
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CHAPTER ONE:  
INTRODUCTION 
1.1. OVERVIEW OF MALNUTRITION 
Malnutrition is a major disease that affects children worldwide. It is sometimes 
referred to as protein-energy malnutrition (PEM) and, at other times, as protein-
calorie malnutrition (PCM). PEM is a common health problem, especially for 
children in developing countries whose inadequate nutritional intake derives 
from socioeconomic status (Abidoye & Sikabofori, 2000; WHO, 2004). The 
nutritional deficiency may be macronutrient (i.e., for proteins, carbohydrates, 
and fats), micronutrient (i.e., for electrolytes, minerals, and vitamins), or both 
(Müller & Krawinkel, 2005). Macronutrient deficiency rarely occurs alone; it is 
usually associated with micronutrient deficiency (Thanangkul et al., 1980). Since 
macronutrient deficiency is predominantly responsible for PEM (Müller & 
Krawinkel, 2005), PEM is thus typically accompanied by both deficiencies.  
According to the World Health Organization (WHO), malnutrition is a 
spectrum of pathological conditions associated with protein and calorie deficiency 
in infants and young children (WHO, 2000). It is frequently associated with 
infections and commonly affects children of developing countries (de Onís et al., 
1993). Using the WHO¶V global database on child growth, de Onís et al. (1993) 
have more broadly defined malnutrition as µthe cellular imbalance between the 
supply of energy from macronutrients and micronutrients and the demand of the 
body for them in order to achieve normal growth, maintenance, and specific 
functions¶. PEM ranges from underweight malnutrition (mild and moderate) to 
marasmus, marasmic-kwashiorkor, and kwashiorkor (severe) (Jahoor et al., 
2008).  
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1.2. EPIDEMIOLOGY 
PEM is a prevailing global public health problem that affects children in African, 
Asian, Latin American, and Caribbean regions (de Onís et al., 2000; Khor, 2003; 
Pelletier, 1994). Worldwide, approximately 800 million people were 
undernourished from 2000 to 2002; the majority of these people were living in 
developing countries (FAO, 2004). The prevalence of PEM is highest in South 
Asia and sub-Saharan Africa (FAO, 2004; Schofield & Ashworth, 1996). 
According to WHO, 11 million children under the age of 5 years die each 
year, and over 90% of these deaths occur in developing countries (WHO, 2002). 
As a result, malnutrition is responsible for about half of all childhood deaths in 
developing countries (Murray & Lopez, 1997). It is responsible for the direct 
mortality of 300,000 deaths per year and the indirect mortality of at least half of 
all deaths of young children (Figure 1.1) (Fernandez et al., 2002; Müller & 
Krawinkel, 2005). 
  
Figure 1.1: Causes of death among children under 5 years of age, 2000±2003, worldwide (Adapted 
from Muller & Krawinkel (2005) CMAJ. 173: 279-286) 
PEM usually manifests in early childhood between the age of 6 months 
and 2 years. It is frequently associated with early weaning, delayed introduction 
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of complementary foods, intake of a low-protein diet, and recurrent severe 
infections (Kleinman et al., 2003; Müller et al., 2003). 
Poverty is the primary cause of malnutrition. Factors associated with 
poverty are many and include poor socioeconomic status, high risk of infections, 
food insecurity, and inadequate household food (Müller & Krawinkel, 2005). 
These factors are also important determinants of severe malnutrition (Figure 
1.2). The types of PEM and their frequency in a given population depend on 
factors such as political and economic situations, the level of education of the 
parents, environmental sanitation, seasonal and climatic conditions, food 
production, cultural and religious food habits, breastfeeding habits, the 
prevalence of infectious diseases, the existence and effectiveness of nutrition 
programmes, and the availability and quality of health services (FAO, 2004; 
Young et al., 2004). 
 
Figure 1. 2: Direct and indirect causes of malnutrition (Adapted from Muller & Krawinkel (2005) 
CMAJ. 173: 279-286). 
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1.3. CLASSIFICATION OF PROTEIN-ENERGY MALNUTRITION 
Before WHO developed a unified method of classification for malnutrition, many 
methods had been used to describe D FKLOG¶V nutritional status. The various 
classifications were based on weight and height (Gómez et al., 1956a; Jelliffe, 
1966; McLaren & Read, 1975; Waterlow, 1972; Wellcome Trust Working Party, 
1970; WHO, 1999), as well as the presence or absence of clinical signs of 
malnutrition.  
There is no specific classification recommended for studies of drug 
disposition of children with PEM. However, in previous studies of drug disposition 
in children with PEM, the Gómez (1956a), Waterlow (1972), and Wellcome Trust 
Working Party (1970) classifications have been used more extensively than the 
WHO (1999) classification.  
1.3.1. Gómez classification  
The Gómez classification system is one of the first methods used to classify PEM. 
It is based on aged-related body deficit and compares the weight of a patient to 
that of a healthy child of the same age (Table 1.1).  
Table 1.1: Gomez classification of malnutrition 
Percentage of expected weight 
for age 
Interpretation 
> 90% Normal 
75- 90% Grade 1 (mild malnutrition) 
60- 75% Grade 2 (moderate malnutrition) 
< 60% Grade 3 (severe malnutrition) 
 
The method is useful for population screening and public health evaluations of 
malnutrition. Mathematically, the percentage of the expected weight for age = 
>SDWLHQW¶V REVHUYHGZHLJKW  ZHLJKW RI D KHDOWK\ FKLOG RI WKH VDPH DJH@î
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100. A major limitation of the Gómez classification is its assumption that all 
children of a certain age are of the same weight. Also included in the 
classification are actively malnourished children and underweight children who 
had previously suffered malnutrition. The Gómez classification may, therefore, 
overestimate the prevalence of PEM. 
1.3.2. Waterlow classification  
Waterlow (1972) reported that the weight-for-height anthropometry could 
measure the current status of malnutrition in a child better than the weight for 
age. This classification compares the weight of a patient to that of a healthy 
child of similar height to determine the extent of wasting. It also compares the 
height of the patient to that of a healthy child of similar age to determine the 
extent of stunting (Table 1.2). The relationship is presented mathematically as a 
percentage of weight-for-height for the patient = [(weight of the patient) / 
(weight of a healthy child of similar height)] × 100, as well as the percentage of 
height-for-age for the patient = [(height of the patient) / (height of a healthy 
child of similar age)] × 100. 
Table 1.2: Waterlow classification of malnutrition 
Percentage of 
weight for height 
(wasting) 
Percentage of height 
for age (stunting) 
Interpretation 
> 90% > 95% Normal (Grade 0) 
80- 90% 90- 95% Mild (Grade 1) 
70- 80% 85- 90% Moderate (Grade 2) 
<70% 85% Severe (Grade 3) 
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Stunting is a consequence of chronic malnutrition, while wasting is the 
effect of malnutrition on a large proportion of the body. The Waterlow 
classification is a very useful method of assessing the nutritional status of 
children in population-based studies. 
1.3.3. Wellcome Trust Working Party classification  
This Wellcome Trust Working Party (WTWP) classification is based on both the 
anthropometric measurement of the patient (using the Gómez classification) and 
a single clinical sign from physical examination. The percentage of body weight 
deficit in the presence or absence of oedema serves as the criterion for 
classification (Table 1.3). 
Table 1.3: Wellcome Trust Working Party classification of malnutrition 
Percentage 
expected weight for 
age (Gomez) 
Presence of oedema Absence of oedema 
60- 80% Kwashiorkor Underweight 
< 60% Marasmic- kwashiorkor Marasmus 
 
According to the WTWP classification, the major diseases along the 
spectrum of severe PEM are marasmus, marasmic-kwashiorkor, and kwashiorkor 
(Jahoor et al., 2008). Each disease in the spectrum presents with different 
clinical features. Thanangkul et al. (1980) have reported an experience with 
underestimating the diagnosis of kwashiorkor among Thai children, since many 
health workers wrongly classified kwashiorkor as marasmic-kwashiorkor because 
average Thai children were smaller than international reference standards. Thus, 
the WTWP classification tended to wrongly classify stunted but not wasted 
children as sufferers of severe PEM. 
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1.3.3.1. Marasmus  
Marasmus is derived from the Greek word marasmos, which means µwasting¶ 
(Scheinfeld et al., 2010). Marasmus refers to a state of chronic nutritional 
deficiency resulting from inadequate intake of macronutrients (proteins, calories, 
and fats) and is characterised by wasting (Haider & Haider, 1984). It is an 
adaptive response to starvation from both protein and calorie deficiency 
(Scheinfeld et al., 2010). During adaptation, all of the proteins and calories 
reserved in the body are depleted, which results in wasting of the skeletal 
muscle and the depletion of body fat. The major clinical features of marasmus 
are listed in Table 1.4. 
Table 1.4: Clinical features of marasmus (Haider & Haider, 1984) 
Marked weight loss resulting in prominent ribs, thinness of the body, marked loss of 
subcutaneous fat and muscle wasting 
Slowing of linear growth 
Impaired vital muscle functions resulting in behavioural changes such as irritability, 
apathy, decreased physical activity and social responsiveness 
Dried, wrinkled and loose skin 
The face looks older than the age due to a loss of buccal fat pads 
Inconsistent cutaneous findings include: 
x Fine, brittle hair 
x Alopecia 
x Fissuring of the nails.  
x Hairs are in the telogen (resting phase)rather than in the anagen (active phase): a 
reverse of normal  
x Occasionally, marked growth of lanugo hair may be present 
Decreased basal energy metabolism 
Diarrhoea and vomiting may be present 
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1.3.3.2. Kwashiorkor  
Cecily Williams, a British nurse, was the first to introduce the word kwashiorkor 
to medicine in 1933 (Williams, 1933). She took the word from the Ga language 
in Ghana, where it describes the illness resulting from improper weaning. 
Kwashiorkor now refers to the µdisease a first child gets when the second one is 
on the way¶ (Williams, 1933). Williams noted that kwashiorkor was dietary in 
origin but that infection, psychosocial problems, and cultural habits also played a 
significant role. Kwashiorkor is a consequence of physiological maladaptation to 
unbalanced deficiency of calories and proteins. Oedema is a major feature of 
kwashiorkor. It and other clinical features of kwashiorkor are presented in Table 
1.5. 
Table 1.5: Clinical features of kwashiorkor (Mukherjee & Jelliffe, 1955) 
Constant or typical features 
x Oedema 
x Failure to gain weight or growth retardation 
x Lethargy and apathy 
x Decreased muscle mass 
Usual presenting signs 
x Moon face 
x Anaemia 
x Hypoproteinaemia 
x Changes in skin pigmentation  
x Hair changes in both texture and colour: depigmentation of hair causes it to be reddish yellow to 
white; curly hair becomes straightened; if periods of poor nutrition are interspersed with good 
nutrition, alternating bands of pale and dark hair, respectively, called the flag sign may occur; hairs 
may also become dry, lustreless, sparse and brittle, and can be pulled out easily. 
Occasional presenting signs 
x Enlarged liver 
x Protruding abdomen   
x Cardiomyopathy and cardiac failure 
x Dehydration and shock from vomiting and diarrhoea 
x Features of avitaminosis: xerophthalmia from vitamin A deficiency, keratomalacia, glossitis, angular 
stomatitis, and cheilosis  
x Signs of infection due to impaired immunity 
x Signs of hypoglycaemia 
x Thin and soft, fissured or ridged nail plates 
x 6NLQFKDQJHVDQGUDVKHV³PRVDLFVNLQ´DQG³IODN\SDLQW´ 
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1.3.3.3. Marasmic-kwashiorkor  
A mixed form of marasmus and kwashiorkor may exist where kwashiorkor is 
superimposed upon some degree of marasmus. Under these circumstances, the 
term marasmic-kwashiorkor is considered to be more appropriate. The condition 
is characterised by features of both marasmus and kwashiorkor and occurs when 
oedema is present in a chronically ill and starved patient due to superimposed 
stress. As a result, body fat stores, as well as somatic and visceral protein 
stores, become depleted (Haider & Haider, 1984). This condition is marked by 
impaired immunity, risk of infections, and a high mortality rate. Clinical features 
usually consist of the typical features of kwashiorkor and some features of 
marasmus. 
1.3.4. Classification of malnutrition according to WHO 
After recommending the use of a universal method to assess the nutritional 
VWDWXVDQGJURZWKRIFKLOGUHQ:+2¶VFODVVLILFDWLRQ method harmonised all other 
classification systems of malnutrition. :+2¶VFODVVLILFDWLRQPHWKRG uses a growth 
reference based on the Z-scores of the anthropometric measures of children 
(WHO, 1999). In defining normal child anthropometry, WHO considered global 
ethnic diversities in regards to diet, growth, and environmental and genetic 
differences, as well as exclusive breastfeeding for the first 6 months of life 
(Manary & Sandige, 2008). 
The WHO classification of malnutrition is presented in Table 1.6. 
Assessment of the nutritional status of a patient is based on the weight-for-
height and height-for-age Z-VFRUHV7KLVPHWKRGFRPSDUHVWKHSDWLHQW¶VZHLJKW
to that of a healthy reference population of children of similar height. It also 
FRPSDUHV WKH SDWLHQW¶V KHLJKW WR WKDW RI D KHDOWK\ UHIHUHQFH SRSXODWLRQ RI
children of a similar age. The weight or height is usually expressed in a unit of 
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standard deviation (SD) and compared to the reference values for a paediatric 
population (WHO, 1999). 
Table 1.6: Classification of malnutrition according to the World Health Organization 
Index Classification 
Moderate malnutrition Severe malnutrition (type) 
Symmetrical 
oedema 
No Yes (oedematous malnutrition)** 
Weight-for-height -6'-score <- 2 SD-score < - 3 (severe wasting) 
Height-for-age -6'-score <- 2 SD-score < - 3 (severe stunting) 
** Includes kwashiorkor and marasmic-kwashiorkor in older classifications. SD= standard deviation with 
reference to the median NCHS/WHO reference values for weight-for-height or height-for-age respectively 
(WHO Multicentre Growth Reference Study Group, 2006). 
The calculated Z-scores are compared to the mean and SD of a reference 
population, thereby reflecting the reference distribution. As standardised 
quantities, Z-scores are comparable across ages, sexes, and anthropometric 
measures. Z-scores can be analysed as a continuous variable in studies, as well 
as quantify both under- and over-nutrition at both ends of the distribution. 
However, Z-scores are more useful in epidemiological studies than in clinical 
settings (Wang & Chen, 2012). 
In some health facilities it may be difficult to measure the height of a 
severely malnourished child. Therefore, the mid-upper-arm circumference 
(MUAC) can be used in place of the weight-for-height Z-score. MUAC measures 
lean body mass and its value rarely changes between the ages of six months 
and five years. A MUAC of <110 mm has been used to predict the risk of death 
from malnutrition (Briend & Zimicki, 1986). The value also has been used to 
define severe malnutrition in a study of the Bangladeshi context (Briend et al., 
1986).  
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The WHO classification differentiates acute malnutrition into moderate or 
severe. Moderate malnutrition is defined as a weight-for-height Z-score between 
2 and 3 standard deviations (SD) below the mean (WHO, 1999). Severe 
malnutrition occurs when the weight-for-height Z-score is below the mean for 
the general population by more than 3 SD, with a MUAC of <110 mm, or in the 
presence of nutritional oedema. Absence of nutritional oedema in moderate or 
severe malnutrition defines a child as marasmic, while when oedema is present, 
the child is said to have kwashiorkor. 
 
1.4. PATHOPHYSIOLOGY OF MALNUTRITION  
The pathophysiology of PEM is complex; its development is attributed to 
inadequate dietary intake, increased metabolic demands, or increased nutrient 
losses (Corish & Kennedy, 2000). The clinical features of PEM usually result from 
pathophysiological changes. An understanding of the pathophysiology is 
necessary to identify changes that may affect drug disposition in children with 
malnutrition. 
1.4.1. Infection and immunity 
The primary aetiology of malnutrition is the inadequate intake of macronutrients. 
However, the associated infections, particularly diarrhoeal disease and intestinal 
parasitosis, may play contributory roles (Müller & Krawinkel, 2005). An 
inadequate intake of macronutrients predisposes a patient to anorexia. It is also 
associated with intestinal mucosal damage, as well as decreased nutrient 
absorption, increased metabolic requirements, and direct nutrient losses 
(Brewster et al., 1997a; Pinstrup±Andersen et al., 1993). In such a case, the 
immune system is stimulated by infection that increases both catabolism and the 
demand for metabolically derived anabolic energy and associated substrates. 
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These increases may adversely affect the nutritional status of a patient and 
further increase susceptibility to infection. An inflammatory process is induced 
by sepsis and associated with a release of mediators, which further increases 
body catabolism, as demonstrated by an increased use of arginine. Arginine 
depletion is responsible for T-cell immune response impairment (Bronte & 
Zanovello, 2005). A negative nitrogen balance occurs after excessive 
endogenous arginine production (Kurpad, 2006).  
Due to protein deficiency, immunity (lymphocyte functions) and innate 
host defence mechanisms (macrophages and granulocytes) are impaired in 
severe malnutrition. Reduced immune functions predispose malnourished 
children to infections such as bronchopneumonia (Chisti et al., 2009), 
tuberculosis (Vijayakumar et al., 1990), sepsis (Sunguya et al., 2006), and 
HIV/AIDS (Scrimshaw & SanGiovanni, 1997). Following nutritional rehabilitation, 
there is a delay in the recovery of immunological functions compared to an early 
recovery of anthropometric and biochemical parameters (Chevalier et al., 1998). 
Intestinal parasitic infestation and shigellosis are common occurrences in 
PEM (Bastow, 1982; Schaible & Kaufmann, 2007; Van den Broek et al., 2005). 
The effects of intestinal parasitosis on drug absorption have not yet been studied 
in severely malnourished children. In addition to malaria, bronchopneumonia 
and measles that frequently complicate PEM in African children may occur, as 
well as urinary tract infection, gastrointestinal tract infection, and septicaemia 
(Brewster, 2006; Nnakwe, 1995; Phillips & Wharton, 1968). Most bacterial 
infections in children are caused by Gram-positive and Gram-negative organisms 
and are usually implicated by infections in severe PEM (Noorani et al., 2005; 
Purtilo & Connor, 1975; Shimeles & Lulseged, 1994).  
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1.4.2. Oedema and other body fluid distribution  
Despite many years of research, the aetiology of kwashiorkor is still uncertain. 
The pathophysiology of kwashiorkor was initially based on the hypotheses of 
prolonged breastfeeding, inadequate protein intake, severe anaemia, presence 
of aflatoxins (Hendrickse, 1991), and reduced dietary antioxidants (Jahoor et al., 
2008). These hypotheses are no longer tenable, since the diets of marasmic 
children are known to have similar deficiencies (Lin et al., 2007). Further 
research by Ciliberto et al. (2005) has shown that supplementing the diet of 
children at risk of kwashiorkor with proteins and antioxidants did not prevent the 
development of kwashiorkor. Golden (1982) has shown that a protein-restricted 
diet can lead to early oedema resolution in kwashiorkor. The presence of 
kwashiorkor in a paediatric population without evidence of aflatoxin ingestion 
and with evidence of aflatoxin in LWV PHPEHU¶V post-mortem tissues has 
invalidated the hypothesis that implicated aflatoxin intoxication in the aetiology 
of kwashiorkor (Golden, 1998). 
New potential mechanisms have been proposed for the formation of 
oedema in kwashiorkor. One mechanism is related to the release of water 
normally bound to glycosaminoglycans. Glycosaminoglycans are long-chain 
polysaccharides with repeated sulphated carbohydrate units that are bound to 
the short-protein core in all connective tissues and basement membranes 
throughout the body (Manary et al., 2009). They contain oxidisable and 
reducible moieties that strongly bind water by cohesive forces. Abnormal renal 
architecture is responsible for the loss of glycosaminoglycans in children with 
kwashiorkor (Golden et al., 1990). Glycosaminoglycans, in the form of heparan 
sulphate proteoglycans, are also lost in the intestines of children with 
kwashiorkor (Amadi et al., 2008). The inability to retain the gel-like shape of 
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water, due to decreased glycosaminoglycans levels, has been attributed to be 
the cause of oedema in kwashiorkor (Manary et al., 2009). 
There are reports suggesting that synergistic or antagonistic effects of the 
gut microflora on human hosts occur as the microflora metabolically consume 
and process nutrients (Karasov & Carey, 2009). Swann et al. (2009) have 
reported the ability of gut microbiota to render some dietary toxins harmless. 
However, the bacteria may also produce toxic metabolites capable of damaging 
the vital organs such as the brain, liver, or kidneys (Michalke et al., 2008). 
Manary et al. (2009) have postulated that kwashiorkor may be a consequence of 
either changes to the gut microbiota, which favours the production of 
metabolites causing insult and loss of integrity to the human cell membrane in 
malnourished hosts, or the disruption of the protective function of gut microbiota 
by environmental toxins. 
Another hypothesis derives from a change in vanadium metabolism. 
Vanadium, like other micronutrients, may be deficient in the diet of children with 
kwashiorkor, thus leading to sodium retention (Anonymous, 1981; Golden & 
Golden, 1981). At physiological concentrations, vanadium is a powerful sodium 
pump inhibitor. The sodium pump is responsible for transportation across cell 
membranes and the reabsorption of sodium from the kidneys. An inability to 
inhibit the sodium reabsorption, either due to vanadium deficiency or the 
ionisation of its molecules to the inactive vanadyl ion, could result in salt and 
water retention. This retention will eventually lead to oedema formation. Burger 
and Hogewind (1974) have reported a low serum level of vanadium in children 
suffering from kwashiorkor. 
The pathophysiology of kwashiorkor is broad and complex, for it affects 
most major organs and systems. The basic pathology in kwashiorkor is the 
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extensive damage to cell membranes throughout the body and an associated 
electrolyte imbalance. The damage results in a loss of potassium and water from 
all cell types, thus leading to dysfunction in all organ systems (Manary et al., 
2009). In such a case, an extreme reduction in whole-body intracellular ions 
(potassium, magnesium, and phosphorus) occurs (Golden, 1998). Life-
threatening hypokalaemia and hypophosphataemia are more common in severe 
kwashiorkor. Despite hyponatraemia, total body sodium increases. Cardiac 
output becomes reduced to about 30% in kwashiorkor, while adrenal fractional 
sodium excretion is diminished by up to 70%.  
Severe PEM may be complicated by dehydration and chronic 
hypovolaemia, as well as secondary hyperaldosteronism, all of which further 
aggravate fluid and electrolyte imbalance (Hansen et al., 1965). Muscular 
dystrophy in PEM triggers the PRELOLVDWLRQ RI PXFK RI WKH ERG\¶V SRWDVVLXP
which is then lost through urinary excretion. Therefore, affected children rarely 
show signs of hyperkalaemia (Brewster et al., 1997b; Manary et al., 2009). 
1.4.3. Plasma proteins 
Dietary protein is essential in providing amino acids for the synthesis of body 
proteins and other useful compounds necessary for various functions. Protein 
deficiency is a major problem of severe malnutrition. It is, however, more 
pronounced in kwashiorkor and marasmic-kwashiorkor than in marasmus 
(Thanangkul et al., 1980). Nevertheless, the role of hypoproteinaemia in 
oedema formation in kwashiorkor and marasmic-kwashiorkor has not been 
completely ruled out (Heikens & Manary, 2009). Hypoproteinaemic oedema is 
primarily caused by both a decrease in the amount of proteins, especially 
albumins, in the plasma and by a drop in the colloidal osmotic, or oncotic, 
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pressure of plasma, the latter of which is accompanied by a release of fluid from 
the capillary bed into the tissues (Zweifach, 1972).  
1.4.4. Changes in the gastrointestinal system 
Diarrhoea and vomiting are two important gastrointestinal features of severe 
PEM. Various degrees of intestinal malabsorption related to food, sugar, and milk 
have been reported in severely malnourished children (Arroyave et al., 1959; 
Gómez et al., 1956b). Generally, the malabsorptive state disappears after 
recovery from nutritional rehabilitation (Shakir & Morley, 1974), but some of the 
morphological changes in the gastrointestinal system persist despite improved 
nutritional status (Schneider & Viteri, 1972).  
Despite hepatomegaly in PEM, liver function tests remain normal (Porta & 
Hartroft, 1970; Tandon et al., 1974). However, fatty changes, abnormal rough 
endoplasmic reticula and mitochondria, and decreased peroxisomes have been 
major findings in liver biopsies of severely malnourished children (Brooks et al., 
1992; Brooks et al., 1994). The hepatic changes were completely reversed after 
nutritional rehabilitation.  
1.4.5. Changes in renal function 
Only a few studies have described the renal function of children with severe 
malnutrition. One study measured the serial clearance of inulin as a determinant 
of renal function and observed both a diminished renal blood flow and 
glomerular filtration rate (GFR), the latter of which was worsened by dehydration 
(Alleyne, 1967). However, both conditions reverted to normal after nutritional 
rehabilitation (Alleyne, 1967). Unfortunately, the time taken for the GFR to 
revert to normal was not determined in the cited study. Other studies used less 
precise measurements of renal function, such as creatinine clearance or serum 
creatinine, to study the effects of PEM on renal function. Results were similar to 
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those that used inulin (Klahr & Tripathy, 1966). Normal blood urea nitrogen and 
creatinine, an absence of glycosuria and proteinuria, and a lack of formed 
elements, such as casts, red blood cells, and epithelial cells in the urine of 
children with PEM, have also been documented (Klahr & Alleyne, 1973).  
Despite the lack of evidence of established renal damage in severely 
malnourished children, the oedema observed in marasmic-kwashiorkor and 
kwashiorkor has been attributed to the inability of the kidneys to adequately 
excrete excess fluid and sodium (Alleyne, 1967). Other studies have attributed 
the oedema to the presence of hypoproteinaemia and aflatoxins (Hendrickse, 
1991).  
1.4.6. Changes in the cardiovascular system 
Severely malnourished children have smaller and thinner hearts, which reduces 
stroke volume (Gillespie, 1999). The inability of the kidneys to adequately 
excrete excess fluid and sodium in children with nutritional oedema may also 
adversely affect the heart. Therefore, circulatory overload tends to occur more 
easily in children with marasmic-kwashiorkor and kwashiorkor. Oxidative stress 
is a potential cause of damage and leakage to the cell membrane of the heart 
(Gillespie, 1999). The Na-K pumps in the cell membrane are drastically reduced 
in malnutrition as a bodily adaptation affected to conserve energy. 
Consequently, intracellular sodium tends to accumulate, while leakages of 
potassium are enhanced, the latter of which leads to fluid and electrolyte 
imbalance (Gillespie, 1999).  
Inappropriate fluid therapy may contribute to cardiac failure in acute 
severe malnutrition (Ashworth, 2001; Rabinowitz et al., 2009). Circulatory 
insufficiency may be associated with a prolonged circulation time, inadequate 
absorption, and insufficient distribution of drugs and nutrients. Oedematous 
28 
 
malnutrition is characterised by sodium and water retention (Klahr & Alleyne, 
1973) and may contribute to heart failure (Rabinowitz et al., 2009). Fluid 
retention expands the extracellular fluid volume and increases the apparent 
volume of distribution of water-soluble drugs.  
1.4.7. Changes in endocrine function 
In acute, severe malnutrition, serum insulin levels were suppressed, while 
growth hormone (GH) was elevated among children suffering from kwashiorkor 
(Laditan, 1983). The values of growth hormones were also elevated in marasmic 
children, though the levels were much lower than those reported in children 
suffering from kwashiorkor. Studies have shown a steady fall in GH and a steady 
rise in insulin of severely malnourished children, especially those with 
kwashiorkor, after nutritional rehabilitation (Laditan, 1983). Brooks et al. (1992) 
have noted atrophic changes in the adrenal glands of children with malnutrition; 
however, these children exhibited elevated plasma cortisol concentrations that 
were unaltered by corticotrophin challenge. It was postulated that, since cortisol 
binds to serum proteins, hypoalbuminaemia would increase the free plasma 
cortisol level, thus contributing to the abnormal glucose tolerance and oedema 
seen in kwashiorkor and marasmic-kwashiorkor. The contrasting features of 
marasmus and kwashiorkor have been attributed to the variable response of the 
adrenal cortex in adapting to the diverse dietary stress that characterises 
marasmus and kwashiorkor (Rao, 1974). 
Hypopigmentation of the hair and skin is a common feature of PEM and 
results from protein substrate (tyrosine) and coenzyme deficiency, the two 
major substances required for pigment synthesis (Collins et al., 2006). 
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1.5. DIAGNOSIS OF PEM 
The diagnosis of PEM is based on diet history, a thorough physical examination, 
and anthropometric measurements (Haider & Haider, 1984). Dietary history 
includes a 24 h food recall and a food frequency history (Joyce et al., 1998). The 
physical examination should focus on the clinical features of the three types of 
severe malnutrition (marasmus, marasmic-kwashiorkor, and kwashiorkor) listed 
in Tables 1.4 and 1.5.  
Anthropometric measurement is a key feature of nutritional assessment of 
children with malnutrition. The anthropometric measures most relevant to the 
classification of PEM are weight (kg), height (m), and MUAC, the last of which 
can be used instead of the weight-for-height Z-score to identify malnutrition 
when measuring height proves difficult (Briend & Zimicki, 1986).  
Other causes of secondary malnutrition, such as HIV/AIDS, tuberculosis, 
cancer, liver disease, chronic renal failure, diabetes, pancreatic disease, and 
digestive or absorptive diseases, should be excluded during the process of 
diagnosing primary malnutrition (Haider & Haider, 1984). 
Laboratory investigations of plasma urea, electrolytes, and creatinine; 
glucose, proteins, and lipids; full blood count and differentials; and blood film for 
malaria parasites are necessary, as well as urinalysis, urine microscopy, and 
examinations of blood culture sensitivity and of the stool for ova and parasites. 
However, most laboratory results for these tests prove normal (Rabinowitz et 
al., 2009). WHO has also recommended laboratory investigations for associated 
diseases, such as HIV, pneumonia, and tuberculosis (WHO, 1999). 
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1.6. MANAGEMENT 
Children with severe PEM are exclusively managed as inpatients (Collins et al., 
2006). While underweight children and children with moderate marasmus can be 
managed as outpatients, children with severe marasmus and kwashiorkor 
require inpatient treatment (Rabinowitz et al., 2009). 
Fluid and electrolyte imbalances are major problems of PEM. 
Hypokalaemia, hypocalcaemia, hypomagnesaemia, and hypophosphataemia are 
the most common electrolyte imbalances and should therefore be monitored and 
corrected (Whitehead & Alleyne, 1972). Hypoglycaemia should be corrected with 
intravenous or oral glucose administration. Hypothermia should be prevented by 
being covered with warm clothes, by avoiding cold baths, and by being nursed in 
a warm environment.  
Broad-spectrum antibiotics (co-trimoxazole, chloramphenicol or ampicillin, 
and gentamicin) are used for the empirical treatment of infections stemming 
from malnutrition, even in the absence of typical symptoms since the 
inflammatory response to infection may be suppressed by PEM (WHO, 2000). 
However, specific infections should be treated with appropriate antibiotics based 
on the results of blood culture sensitivity pattern. Antimalarial (i.e., artemisinin-
based combination) therapies are recommended for use in malaria endemic 
regions (WHO, 2006). Tuberculosis and HIV infection may coexist with PEM and 
require additional drug treatment.  
Oral zinc supplements should be given in the cases of diarrhoea and skin 
ulcers in patients with malnutrition (Scheinfeld, et al., 2012). Multivitamin 
supplements are given daily to provide other micronutrients, such as iron, folate, 
and multivitamins. 
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Dietary therapy is important and requires the use of nutrient rich 
supplemental foods that will provide the recommended daily dietary allowance of 
all macronutrients (Manary & Sandige, 2008).  
Table 1.7 shows a list of the necessary management steps for 
malnutrition.  
Table 1.7: The WHO 10-step objectives of management of severe malnutrition 
(Ashworth et al., 2004) 
Treat or prevent hypothermia 
Treat or prevent hypoglycaemia 
Treat or prevent dehydration. 
Correct electrolyte imbalance 
Treat infection 
Correct micronutrient deficiencies 
Begin feeding and keep protein and volume load low 
Increase feeding to recover lost weight 
Stimulate emotional and sensorial development 
Discharge when stable and monitor at the follow up clinic. 
 
1.7. PRINCIPLES OF PHARMACOKINETICS AND 
PHARMACODYNAMICS 
On the one hand, pharmacokinetics (PK) relates the effects of the body on a 
drug. PK usually involves the measurement and interpretation of drug 
concentrations in the systemic circulation (Rang et al., 2007). On the other 
hand, pharmacodynamics (PD) describes the action of a drug on the body. PD 
relates the events that occur following the binding of a drug to its receptor at the 
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primary site of action (Baca & Golan, 2012). Both pharmacokinetics and 
pharmacodynamics help to elucidate the relationship between the dose of and 
the response to a drug. The pharmacological response elicited by a drug is 
determined by the drug¶V binding to its site of action. The concentration of the 
drug that binds to the target site determines its effect.  
This section focuses on the pharmacokinetic parameters: the 
determinants of the onset of action, the duration of action, and the intensity of 
the GUXJ¶Veffects. It also examines at the general relationship between a drug 
and its response, and emphasises how PK in children differs from that in adults.  
Several qualitative and quantitative differences exist in the basic anatomy, 
physiology, and metabolic processes of children and adults, accounting for the 
variation in their PK (Ginsberg et al., 2004). Pharmacokinetic differences are 
responsible for the age-related variations in the dose and dosing intervals 
needed to maintain the therapeutic concentrations of many drugs. The paediatric 
population is divided into several age groups: premature neonates (born before 
37 weeks gestation), neonates (less than 1 month old), infants (1to 24 months 
old), children (2 to 11 years old), and adolescents (12 to 17 years old) 
(Gennery, 2000). 
Irrespective of the route of administration, the pharmacological actions 
and effects of a drug are influenced by four PK parameters: absorption, 
distribution, metabolism, and elimination (Thomson, 2000). The PK parameters 
enable clinicians to design and optimise treatment regimens in regards to route 
of drug administration, as well as appropriate dosage, dose frequency, and 
treatment duration.  
The relationship between PK parameters and DGUXJ¶VPD is presented in 
Figure 1.3. To produce the pharmacological effect at the site of action, a drug 
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must be absorbed and distributed to its target tissues. Thereafter, the drug is 
metabolised and excreted.  
 
Figure 1.3: Drug absorption, distribution, metabolism, and elimination (Adapted from Baca & Golan 
(2012) in Principles of Pharmacology: The pathophysiologic Basis of Drug Therapy) 
1.7.1. Drug absorption 
The bioavailability of a drug (F) is one of the parameters that describe 
absorption. Bioavailability refers to the fraction of the administered drug dose 
that reaches the systemic circulation (Thomson, 2000). It is usually less than 
100% for all routes of drug administration, excepting the intravenous route.  
Traditionally, bioavailability is the ratio of the area under curve 
concentration (AUC) versus the time curve for a particular drug¶V administration 
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route to the AUC with intravenous route of administration (Rang et al., 2007). 
This ratio assumes no changes in drug elimination following the two routes of 
administration. AUC (mg × hr × L-1) represents the total amount of drug 
absorbed, defines the extent of absorption of a drug, and depends on a 
combination of dose, absorption, and clearance or elimination (Urso et al., 
2002).  
Bioavailability is particularly relevant for orally administered drugs 
because many physiological processes in the gastrointestinal system tend to 
affect absorption. For oral drugs, bioavailability is AUCoral / AUCiv (oral = oral 
route; i.v = intravenous route). First-pass metabolism contributes to the low 
bioavailability of orally administered drugs. It is the process of hepatic 
biotransformation of a drug during its first passage through the portal circulation 
before reaching the systemic circulation (Pond & Tozer, 1984).  
Other factors that may affect bioavailability include the physicochemical 
properties, formulation, and route of administration of a drug; concomitant drug 
therapy; blood flow and gastrointestinal motility; the activity of the intestinal 
drug-metabolising enzymes; vomiting and diarrhoea; disease states; and drug 
or food interactions (Thomson, 2000). Absorption is also influenced by bowel 
length, the permeability and maturation of the mucosal membrane, bile salt 
formation, intestinal microflora, and dietary composition (Berseth, 1992; Crom, 
1994).  
The acidity of the gastrointestinal system can influence both the stability 
and extent of ionisation of a drug. Invariably, this determines the proportion of 
drug available for absorption and its ability to traverse the cell membranes. In 
neonates, gastric pH, gastric motility, and intestinal motility are relatively 
increased (Crom, 1994; Dumont et al., 1994). The elevated gastric pH will 
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increase the absorption of acid-labile drugs, such as penicillin G, erythromycin, 
ampicillin, and amoxicillin, which results in a greater bioavailability in neonates 
than in infants, children, and adults (Benedetti et al., 2007; Brown et al., 1989; 
Huang et al., 1953). By contrast, weakly acidic drugs, such as phenobarbital and 
phenytoin, are readily absorbed in older children and adults, thereby suggesting 
a need for increased oral doses for younger children to achieve a therapeutic 
plasma concentration (Morselli et al., 1980; Wallin et al., 1974). Basic drugs, 
such as propranolol, are absorbed more rapidly in neonates, infants, and 
children than in adults (Bartelink et al., 2006). 
Gastric emptying and intestinal motility are important factors that 
influence the rate of drug contact and absorption across the intestinal mucosa. 
Compared to older children and adults, neonates and young infants experience 
reduced gastric emptying and intestinal motility (Kearns et al., 2003).  
Bile salt is required for the absorption of lipophilic drugs, such as 
diazepam (Serajuddin & Jarowski, 1985). Immature bile secretion and reduced 
activity of the bile salt and pancreatic juice contribute to the reduced absorption 
of fat soluble vitamins (i.e., vitamins D and E) in neonates and infants (Boehm 
et al., 1997; Heubi et al., 1982). The enzyme responsible for the conjugation of 
bile salt in neonates is immature and results in both reduced bile salt formation 
and decreased absorption of lipophilic drugs (Russell, 2003). 
Age-related changes in splanchnic blood flow during the early neonatal 
period may alter the drug concentration gradient across the bowel mucosa, thus 
influencing absorption rates (Kearns et al., 2003). The activity of the intestinal 
drug-metabolising enzyme, glutathione-S-transferase, is decreased from infancy 
through early adolescence. Busulfan, a substrate of glutathione-S-transferase, 
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has a reduced oral clearance in adolescents and adults due to decreased activity 
of the enzyme (Gibbs et al., 1999).  
The activity of gut microflora changes from infancy through childhood until 
adulthood. The gut microflora produces an enzyme that is responsible for the 
degradation of drugs such as digoxin. The activity of the enzyme is age 
dependent and higher in adults than in neonates, infants, and young children 
(Linday et al., 1987).  
Intramuscular or subcutaneous injections are often erratically absorbed 
due to variable chemical properties of drugs, differences in the absorptive 
capacity of the injection site, variability in muscle mass among children, and the 
hydration status of the patient, the latter of which may result in circulatory 
failure (Ballard, 1968). Reduced skeletal muscle mass, blood flow, and the 
inability of the muscle to contract efficiently are responsible for the reduced 
intramuscular absorption of drugs in neonates (Kearns et al., 2003).  
Enhanced transdermal absorption of drugs may occur in premature 
neonates and infants due to their thin outer skin layer (Rutter, 1987). 
Absorption can also be enhanced by their larger ratio of surface area to body 
weight (Amato et al., 1992; West et al., 1981), greater cutaneous perfusion, and 
increased epidermal hydration compared to adults (Fluhr et al., 2000; Okah et 
al., 1995). In children of any age, skin abrasions, dermatosis, and burns tend to 
increase percutaneous drug absorption. 
Transrectal drug administration is useful when oral and intravenous 
administrations of drugs are impossible. This route is also useful for emergency 
administration of drugs such as diazepam. The immature hepatic metabolism in 
neonates and young infants tends to enhance the bioavailability of the drug. 
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However, expulsion of the drug may be increased in young infants compared to 
adults, due to the IRUPHU¶V larger rectal contractions (Di Lorenzo et al., 1995).  
1.7.2. Drug distribution 
The absorbed drug is distributed into tissue reservoirs and bound to plasma 
proteins and receptors at the target sites, where it exists as a free or unbound 
drug in the systemic circulation (Baca & Golan, 2012). Only the bound fraction of 
the drug to the target site will produce a pharmacological effect. The process 
following drug absorption is dynamic and complex, because metabolism and 
excretion coincide with distribution.  
The volume of distribution (VD), otherwise called the apparent volume of 
distribution, of the drug is the hypothetical volume of fluid within which the total 
drug administered must be distributed to achieve the measured plasma 
concentration (Thomson, 2000). VD is the ratio of the drug administered (dose) 
to the plasma concentration (C) of the same drug; VD = dose (mg) / C (mg/L). 
A large VD influences the half-life (t½) of a drug, since its elimination depends on 
the amount of drug presented per unit of time to the organ of elimination or 
metabolism. A large VD suggests that a drug is distributed into the extravascular 
space and is thus unavailable to the excretory organs. Therefore, any condition 
that increases VD can result in an increase in the t½ and prolong the action of 
the drug (Thomson, 2000). An excessively large VD suggests that a large 
amount of the drug is sequestered in some tissues or compartments. 
The VD of drugs in children is age dependent (Friis±Hansen, 1983). Age-
related changes are associated with changing body fluid composition, body fat 
distribution, and plasma protein binding. The total body water (TBW) is higher in 
premature neonates (80%) and full-term neonates (70%) than in infants and 
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adults (60%) (Puig, 1996). This condition requires the use of higher doses 
(mg/kg body weight) of water-soluble drugs in young children. However, lower 
doses are required in older children in order to avert toxicity. Age-related 
changes in the VD of water-soluble drugs has accounted for a relatively higher 
VD of gentamicin (0.5±1.2 L/kg) in neonates and infants (0.2±0.3 L/kg) than in 
older children and adults (Kearns et al., 2003). The fat content in neonates and 
young infants is very low and up to 10% to 15% body weight. This condition 
accounts for the relatively low VD of diazepam in young children compared to 
adults (Bartelink et al., 2006). 
The extent to which a drug is distributed into tissues depends on the 
binding capacity of plasma proteins and WLVVXH ELQGLQJ $OEXPLQ Į1-acid 
glycoprotein, and lipoproteins constitute the plasma proteins that bind drugs and 
limit free drug distribution throughout the body. Acidic drugs bind extensively to 
DOEXPLQZKLOHEDVLFGUXJVELQGH[WHQVLYHO\WRĮ1-acid glycoprotein, lipoproteins, 
or both. Physiological hypoproteinaemia and hypoalbuminaemia occur in 
neonates and young infants, which results in an increased unbound fraction of 
drugs. Both the total plasma protein and albumin concentrations approach adult 
levels during late infancy (Ehrnebo et al., 1971). Foetal albumin may persist in 
neonates and reduce the binding capacity of albumin for weakly acidic drugs 
(Kearns et al., 2003). The plasma levels of endogenous substances, such as 
bilirubin and free fatty acids, are high in neonates and infants (Fredholm et al., 
1975). These substances compete with weakly acidic drugs for albumin binding 
sites, which results in increased plasma-free drug concentrations, prolonged 
pharmacological effects, and an increased potential for adverse effects. The 
bilirubin-displacing effect of highly protein-bound drugs, such as sulphisoxazole, 
has been responsible for the high incidence of kernicterus and mortality reported 
39 
 
in premature infants receiving prophylactic treatment with penicillin and 
sulphisoxazole (Silverman et al., 1956).  
1.7.3. Clearance 
Clearance (CL) is the volume of plasma completely cleared of a drug by an organ 
of elimination (kidneys, liver, bile duct, and others) per unit of time (Toutain & 
Bosquet±Mélou, 2004). Plasma CL, otherwise called total, systemic, or body CL, 
refers to the volume of plasma cleared of a drug per unit of time from all 
elimination systems. CL is dependent on the extraction ratio (E) and the rate of 
blood flow.  
 Extraction ratio describes the extent to which an organ contributes to drug 
clearance. It measures the relative efficiency with which an organ clears a drug 
from the systemic circulation over a single pass through the organ. E is thus the 
ratio of the difference in concentration of a drug immediately before entering 
(Cin) and just after leaving (Cout) the organ to the concentration entering the 
organ. Mathematically, E = (Cin-Cout) / Cin and generally it is in the range of 0 to 
1. An organ that contributes substantially to drug CL has an E close to 1, while E 
of an organ that has no substantial contribution is be close to zero. Changes in 
blood flow will produce corresponding changes in the CL of drugs with a high E. 
The rate of drug delivery to an organ of elimination is dependent on blood 
flow rate. Therefore, CL (volume/time) has the unit L/h or mL/min. The 
principles of CL are essential in designing dosage regimens in clinical practice as 
they relate drug input rate to the maintained level. A drug administered as an 
infusion at a constant rate will produce a gradual increase in plasma 
concentration until a steady state (constant plasma concentration) is achieved. 
At this stage, the rates of drug administration (infusion rate) and elimination are 
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equal, and the CL becomes the constant that relates the dosing rate to the 
target steady state concentration (Css). Therefore, dose rate (mg/hr) = target Css 
(mg/L) × CL (L/hr). Altering the dose changes the steady state concentration 
(Thomson, 2000).  
The above rules for infusion drug dosing also apply to other modes of drug 
administration. In the case of multiple oral doses, dosing rate is substituted for 
infusion rate, and Css average (i.e., the mean steady state concentration over 
the dosage interval) replaces Css. The steady state concentrations for other 
routes of administration will change in direct proportion to changes in dose rate. 
Once Css is achieved, subsequent doses are those required to replace only the 
amount of drug that is lost through metabolism and excretion. The maintenance 
dose rate of a drug is dependent on the drug CL, target Css average, and dosage 
interval. Therefore, maintenance dose = target Css average × CL (Thomson, 
2000). 
Many clinical and pharmacokinetic factors or concomitant medications can 
influence CL (Thomson, 2000). These factors may necessitate altering drug dose 
requirements and include weight of the patient in kilograms or body surface area 
(Holford, 1996). Other influential factors include hepatic or renal disease, altered 
protein binding capacity, co-administration of drugs that induce (rifampicin, 
carbamazepine, and phenobarbitone) or inhibit (cimetidine and ciprofloxacin) 
hepatic metabolising enzymes, and cardiac or respiratory disease (Thomson, 
2000).  
1.7.4. Elimination half-life 
The rate of drug elimination is proportional to the amount of the drug present in 
the body, which suggests that a fixed proportion of the drug is eliminated per 
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unit of time. The decline in concentration-time curve of the drug is exponential. 
The elimination rate constant (k) is dependent upon the volume of fluid cleared 
per unit of time (clearance) and the volume to be cleared (VD) (k = CL [L/hr] / 
volume [L]) (Thomson, 2000). 
The elimination half-life (t½) refers to the time required for a plasma 
concentration of a drug to decrease to one-half of its original value (Toutain & 
Bousquet±Mélou, 2004). The elimination t½ is dependent on the VD and CL. 
These parameters are related by the equation t½ = ln 2 × VD/CL, ln 2 = 0.693 
(natural log constant). Therefore, t½ = 0.693/k. 
The time taken to achieve Css with multiple-dosing regimens is also 
dependent on t½. The half-life can be used to determine the appropriate dosage 
interval required to achieve a target concentration time profile. 
1.7.5. Drug metabolism 
Many organs can metabolise drugs in humans, including the kidneys, liver, 
gastrointestinal tract, lungs, brain, and skin. The hepatic modification of drug 
molecules that renders them inactive or facilitates their elimination is referred to 
as biotransformation, the consequences of which are either (a) activation of an 
inactive precursor to a pharmacologically active drug (e.g., conversion of L-dopa 
to dopamine); (b) the further activation of a pharmacologically active drug to 
another active drug (e.g., conversion of diazepam to oxazepam); or (c) the 
conversion of a pharmacologically active drug to an inactive drug (e.g., 
phenobarbital to hydroxylated metabolites). The products of biotransformation 
are often more water soluble than the original drugs. The reactions involved in 
drug biotransformation are classified into either phase I (oxidation/reduction 
reactions) or phase II (conjugation reactions).  
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The cytochrome P-450 (CYP450) enzymes are involved in phase I 
reactions, while epoxide hydrolases, glutathione S-transferases, UDP-
glucuronosyltransferases, and N-acetyltransferases are involved in phase II 
reactions. All the enzymes are present in the liver, as well as the intestinal 
mucosa, kidneys, lungs, brain, and skin (Krishna et al., 1994). However, they 
are mainly concentrated in the liver, the principal site of drug metabolism. Both 
phase I and II metabolising enzymes constitute the mixed function oxidase and 
are primarily involved in the metabolism of several drugs in the liver. 
On the one hand, phase I reactions include oxidation, reduction, and 
hydrolysis, all of which may result in the increased, decreased, or unaltered 
pharmacological activity of a drug. In all phase I reactions a functional group on 
the drug is either introduced or unmasked to render them polar. On the other 
hand, phase II reactions consist of synthetic or conjugation processes during 
which endogenous substrates, such as glucuronic acid and glutathione, are 
combined with the functional groups derived from phase I reactions to produce a 
highly polar drug conjugate. Most phase II reactions result in decreased 
pharmacological activity.  
Many drugs first undergo the sequential process of phase I reactions and 
then the phase II reactions. However, the product of phase I reactions may be 
sufficiently polar to thus become directly eliminated without the need for phase 
II reactions. In some instances, however, phase II reactions may precede phase 
I reactions. Furthermore, a parent drug may be eliminated though unchanged 
and without having undergone any biotransformation. 
Both phase I and II processes involved in drug biotransformation undergo 
developmental maturation. Some of the metabolic pathways may therefore be 
more active in children than in adults. The developmental changes affecting the 
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isoforms of CYP1A; CYP2A, B, C, D, and E; CYP3A; flavin monooxygenase 
(FMO); and alcohol dehydrogenase (ADH) in phase I drug metabolism have been 
well documented (Hines & McCarver, 2002). CYP3A isoforms metabolise about 
50% of drugs and xenobiotics during phase I reactions, while conjugation via the 
glucuronic or sulphation pathway predominates during phase II reactions. The 
developmental changes in the activity of CYP3A, CYP2C, and CYP1A isoforms, as 
well as UGTs, affect phase I and II drug metabolism. 
1.7.5.1. Developmental changes in phase I drug metabolism 
Developmental changes in the activity of metabolising enzymes are complex and 
dynamic. The effect of age on drug metabolism varies throughout the 
developmental period that spans from birth to adolescence (De Wildt et al., 
2003). The total content of CYP450 enzymes in the foetal liver is 30% to 60% of 
the adult value, which is typically achieved at 10 years of age (Shimada et al., 
1996). +RZHYHUFKLOGUHQ¶V enzymatic activity exceeds adult values by the age of 
2 to 3 years (Morselli et al., 1980; Stewart & Hampton, 1987). Therefore, young 
children are more able than adults to metabolise drugs via CYP450 dependent 
metabolic pathways. By puberty, CYP450 enzymatic activity decreases to adult 
levels. 
Pharmacokinetic studies of drugs metabolised predominantly by different 
CYP450 enzymes, including CYP1A, CYP2C, and CYP3A, suggest an increase in 
the enzymeV¶ activity with age. The activity of CYP3A4, for instance, is very low 
at birth but increases with age and reaches adult levels during early infancy (De 
Wildt et al., 2003). The effect of developmental changes in the drug metabolism 
of CYP3A4 and CYP3A5 has been demonstrated in the CL of intravenous 
midazolam. Adequate sedation of critical care patients taking midazolam 
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requires higher infusion rates for older children (De Wildt, 2011) than for 
preterm neonates (Burtin et al., 1994). Another study has showed that children 
1 to 4 years old require a higher rate than the maximal recommended rate (0.3 
mg/kg/h) when compared to older children (de Gast±Bakker et al., 2007). These 
findings suggest faster CL in children than in neonates, which results in lower 
midazolam concentrations. 
Phenytoin is metabolised predominantly by hepatic CYP2C9 and CYP2C19 
enzymes to its major inactive metabolite, para-hydroxy-phenytoin (HPPH) 
(Bajpai et al., 1996). The mean maximal rate of metabolism (Vmax) of this drug 
is significantly higher in young children than in adults (Blain et al., 1981), 
progressively decreases during childhood, and reaches adult values after puberty 
(Anderson, 2000). 
CYP1A2 constitutes about 13% of the total CYP450 expression in adult 
human livers (Shimada et al., 1994). Caffeine is an acceptable probe substrate 
for the in vitro and in vivo study of CYP1A2 activity (Tucker et al., 2001). Some 
in vitro studies involving the use of specific immunological probes or a 
polymerase chain reaction have been unable to detect CYP1A2 expression in 
specimens of foetal livers at 11 to 24 weeks gestation (Shimada et al., 1996; 
Yang et al., 1995). This finding has been further corroborated by another study, 
which demonstrated the absence of CYP1A2 expression during foetal and 
neonatal periods (Sonnier & Cresteil, 1998). However, increased CYP1A2 
expression in infants 1 to 3 months old, as well as a further increase of up to 
50% of adult levels in older children, was documented in the same study by 
Sonnier & Cresteil (1998). 
Cazeneuve et al. (1994) have reported a significantly lower 1, 3, 7-N-
demethylation of caffeine in the liver microsomes of foetuses, neonates, and 
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infants than in those of adults. They also reported that the rate at which foetal 
microsomes generated the total caffeine metabolites (i.e., dimethylxanthine, 
paraxanthine, and theobromine) increased with gestational age. Since only 
CYP3A has been previously identified in human foetal livers, it has been 
concluded that caffeine metabolism depends on CYP3A during foetal 
development. 
In a study examining the maturation pathways of caffeine during infancy, 
it was reported that the total caffeine demethylation, as well as N3 and N7 
demethylation, increased exponentially with postnatal age and plateaued by 4 
months (Carrier et al., 1988). N-1-demethylation was not affected by postnatal 
age, which suggests a delay in its maturation until reaching 19 months of age. 
8-hydroxylation was observed in early and late infancy, which suggests that this 
pathway reaches maturity at an age as early as 1 month. Pharmacokinetic 
studies of caffeine disposition (Lee et al., 1997; Thomson et al., 1996) have 
shown more reduced CL in preterm neonates than in term neonates and infants 
(Pons et al., 1988a; Pons et al., 1988b). Caffeine CL was significantly influenced 
by the postnatal age and body weight of new-borns. Studies involving 
pharmacokinetics of caffeine and CYP1A2 phenotyping have demonstrated lower 
N-3-demethylation activity via CYP1A2 metabolic pathway (Pons et al., 1988a; 
Pons et al., 1988b) in neonates than in older children (El±Yazigi et al., 1999) and 
adults (Aranda et al., 1979). 
1.7.5.2. Developmental changes in phase II drug metabolism 
Phase II metabolism is considerably important, for it is concerned with the 
excretion of a number of drugs and other xenobiotics as conjugates. 
Developmental changes affecting the ERG\¶V ability to conjugate drugs may 
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therefore result in drug toxicity or an adverse effect. Similar to those of phase I 
metabolism, phase II metabolic pathways are poorly expressed during the foetal 
and neonatal periods (McCarver & Hines, 2002). The predominant phase II 
metabolism involves the conjugation reactions; the most studied pathway is 
glucuronidation.  
The ontogeny of hepatic glucuronidation may influence the CL of a number 
of drugs in children. The UDP-glucuronyltransferases (UGTs) are part of the 
important phase II metabolising enzymes that have been extensively studied in 
regards to developmental changes (Miyagi & Collier, 2011). Several drugs, 
including morphine, paracetamol, propofol, and chloramphenicol, undergo 
glucuronidation (De Wildt et al., 1999). These drugs are primarily metabolised 
via glucuronide conjugation pathways by one or different UGT isoforms, and 
some may undergo sulphate conjugation by sulphotransferases (SULT-1 and 
SULT-2 isoforms). The ontology of sulphate conjugation varies with different 
drugs, thus the effect of developmental changes on the metabolism of 
paracetamol, propofol, chloramphenicol, and other drugs metabolised via the 
same pathway may not be uniform. 
UGT1, UGT2, UGT3, and UGT8 are the four recognised UGT families 
capable of catalysing glucuronidation. The members of the UGT1 and UGT2 
families are mainly involved in compound detoxification. The UGT1A and UGT2B 
subfamilies have been the most extensively studied in regards to human 
glucuronidation reactions. 
Morphine is metabolised by the UGT2B7 enzyme to form two metabolites: 
morphine-3-glucuronide (M3G) and morphine-6-glucuronide (M6G). While the 
former is the major metabolite and an inactive compound, the latter has some 
analgesic properties. Sulphate conjugation of morphine has been documented as 
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a minor metabolic pathway, for it does not contribute to the overall CL of the 
drug (Choonara et al., 1990). Choonara et al. (1990) also documented 
significantly higher UGT2B7 activity in premature neonates than in children, 
according to measurements in terms of the ratio of morphine-3-sulphate to 
morphine in the plasma. This result suggests that morphine sulphation 
decreases after the neonatal period. However, other studies have documented 
contrasting results, in which morphine CL was lower in neonates than in young 
children (McRorie et al., 1992), older children, and adults (Hunt et al., 1999). 
UGT1A1 is the enzyme that predominantly metabolises bilirubin. Its 
expression in the foetal liver is triggered by processes associated with birth, and 
the levels of activity VLPLODUWRDGXOWV¶DUHDWWDLQHGDW to 6 months (Burchell et 
al., 1989). However, Burchell et al. (1989) detected UGT1A3 activity in both 
foetal and neonatal liver at levels 30% of those observed in adults. This result 
suggests developmental changes in the expression of UGT1A enzymes.  
Paracetamol is another drug metabolised by other UGT isoforms. Its major 
metabolism is achieved by conjugation via the UGT1A6 metabolic pathway, while 
metabolism via UGT1A9 and sulphation are its minor pathways (Miller et al., 
1976). UGT1A6 is absent in the foetus yet slightly increased in neonates and 
attains adult levels after 10 years of age (Alam et al., 1977; Rollins et al., 
1979). Data from few pharmacokinetic studies have also suggested a higher 
clearance of paracetamol in neonates, especially in preterm neonates (Allegaert 
et al., 2004; van Ligen et al., 1999) than in children and adolescents (Würthwein 
et al., 2005) who invariably have adult CL values. The ratio of glucuronidation to 
sulphation in the metabolism of paracetamol is significantly lower in children 
than in adults (Alam et al., 1977). This result suggests that sulphation possibly 
plays an important role in the metabolism of paracetamol, which contrasts its 
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minor role in morphine metabolism. Except in paracetamol metabolism, 
sulphation is typically low and may be unavailable as an alternative metabolic 
pathway in circumstances when glucuronidation is developmentally low. This is 
the basis for the development of adverse reactions to chloramphenicol therapy 
that manifest as gray baby syndrome in neonates. This condition has been 
attributed to the delayed onset of the UGT2B7 enzyme required for the 
glucuronidation of chloramphenicol (Becker & Leeder., 2010; Chen et al., 2010), 
as well as to the lack of alternative metabolic pathway. Consequently, the drug 
accumulates in the serum and tissue to exert adverse effects (Weiss et al., 
1960). 
1.7.5.2. Effects of pharmacogenetics on drug metabolism 
Pharmacogenetic studies suggest substantial inter-individual variation in the 
activity of many of the CYP450 enzymes, including CYP3A4, CYP2C9, and 
CYP1A2 (Lynch & Price, 2007), which may result in 2-to 3-fold variability in the 
CL of some drugs in children and adults, even when there are no confounding 
factors that might influence drug metabolism. Since metabolising enzymes are 
genetically determined and may be absent in some individuals, a defective 
metabolic pathway may result in individuals who are poor or intermediate 
metabolisers of numerous drugs (Relling et al., 1992). The two phenotypes 
appear in a considerable proportion of the human population and can result in 
significantly reduced CL and high drug concentrations in individuals who are 
deficient in the enzyme required for the drug metabolism. At the same time, 
normal therapeutic dosages in poor drug metabolisers can result in drug toxicity. 
Ultra-rapid metabolisers may mean that normal dosage produces insufficient 
therapeutic concentrations. 
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Carbamazepine, which is commonly used for children, is a substrate of the 
CYP3A5 enzyme. Among adults with epilepsy, three alleles of CYP3A5 have been 
identified and grouped as CYP3A5 expressers (CYP3A5*1/*1 and CYP3A5*1/*3) 
and CYP3A5 non-expressers (CYP3A5*3/*3). Oral CL of carbamazepine has been 
documented in adult Koreans with epilepsy; it was significantly higher in CYP3A5 
non-expressers than in CYP3A5 expressers (Park et al., 2009). CYP1A2 is 
substantially involved in the metabolism of drugs such as clozapine, imipramine, 
caffeine, theophylline, phenacetin, fluvoxamine, paracetamol, tactrine (Levien & 
Baker, 2003), artemisinin, and thiabendazole (Bapiro et al., 2005). Clinical 
studies of CYP1A2-dependent metabolism of caffeine have demonstrated 
polymorphic control of the enzyme activity (Basvi et al., 2007; Sachse et al., 
2003). Genetic polymorphisms that can cause changes in the enzymatic activity 
of the CYP1A2 enzyme have been identified in the wild-type allele (CYP1A2*1); 
they are the CYP1A2*1C allele, which results from a single point mutation (-
3860 G > A), and the CYP1A2*1F allele, which results from a single point 
mutation (-163C > A). Knowledge of genetic variations in CYP1A2 metabolising 
activity is therefore useful for identifying individuals who are at risk of adverse 
drug toxicity with conventional doses of drugs exclusively metabolised by the 
CYP1A2 enzyme. Individuals who express CYP1A2*1F or CYP1A2*1C variants 
may demonstrate different pharmacokinetics for different CYP1A2 substrates 
than normal individuals. Consequently, these individuals may require dose 
modifications of drugs that are exclusively metabolised by the hepatic CYP1A2 
enzyme. Conversely, alternative drugs metabolised independently of the CYP1A2 
enzyme may be preferred for patients with potentially impaired CYP1A2 
metabolic activity in order to avert adverse drug toxicity. 
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1.7.6. Drug excretion 
Water-soluble drugs are excreted primarily by the kidneys. Though the biliary 
system contributes to drug excretion, it does so to a lesser degree than the renal 
system. This finding ensures that the re-absorption of drugs in the 
gastrointestinal system does not occur. Drugs can also be excreted through 
breast milk and may affect breastfed infants (Wilson et al., 1980).  
Hepatic metabolism contributes to the CL and excretion of drugs by 
increasing the polarity and hydrophilicity of the drugs, which renders the 
resultant metabolites to be more readily excreted. Renal diseases and 
compromised or reduced hydration status can also cause reduced renal drug 
excretion. 
Renal excretion of drugs depends on glomerular filtration rate (GFR), as 
well as tubular secretion and reabsorption. GFR is influenced by renal blood flow 
(RBF), an age-dependent factor. RBF is 5% to 6% of the cardiac output at birth, 
increases from 15% to 25% in infancy, and attains adult values during early 
childhood (Alcorn & McNamara, 2002). The elimination of drugs, such as 
gentamicin and amikacin, which are exclusively excreted unchanged by the 
kidneys, depends on GFR efficiency. Neonates and young children are at risk of 
aminoglycoside toxicity due to their reduced GFR (Zarowitz et al., 1992). 
Ceftazidime and famotidine are excreted exclusively by the kidneys; their 
plasma CLs are known to correlate with appropriate maturational changes in 
renal function (James et al., 1998; van den Anker et al., 1995). 
Renal tubular secretion plays an important role in the excretion of drugs 
such as digoxin (Steiness, 1974). Renal tubular secretion capacity increases 
from birth through neonatal period and attains adult levels during late infancy 
(Linday et al., 1981). Amiodarone inhibits renal tubular secretion, thus 
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increasing the plasma concentration of digoxin in infants more than in 
adolescents and adults (Koren et al., 1984). 
Polar compounds, consisting mainly of drug metabolites, are not re-
absorbable. Drugs in their un-ionised forms are readily reabsorbed from the 
tubules. Urine pH (4.5±8.0) can influence drug reabsorption and excretion given 
their potential to ionise. Acidification of urine enhances reabsorption and 
diminishes the elimination of weakly acidic drugs, decreases reabsorption, and 
increases the elimination of weakly basic drugs. The opposite effects are 
produced by urine alkalinisation.  
 
1.8. EFFECTS OF MALNUTRITION ON DRUG DISPOSITION 
The nutritional status of individuals, dietary constituents, and many diseases 
associated with malnutrition (e.g., cancer and HIV) significantly influence the 
pharmacokinetics and pharmacodynamics of a drug (Kufe et al., 2003; Mukonzo 
et al., 2011; Walter±Sack & Klotz, 1996). Infectious diseases, such as malaria, 
often complicate severe malnutrition and significantly impact the disposition of 
drugs such as caffeine (Akinyinka et al., 2000) and quinine (Pussard et al., 
1999).  
Pathophysiological changes in malnutrition are enormous and complex and 
affect all organs concerned with drug disposition (Whitehead & Alleyne, 1972). 
Although some of these changes are adaptive, alterations in the 
pharmacokinetics and pharmacodynamics of drugs have also been reported 
(Mehta, 1983). This section thus discusses the impact of pathophysiological 
changes in malnutrition on the absorption, distribution, metabolism, and 
excretion of drugs in children.  
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1.8.1. Drug absorption 
Reduced gastric acid secretion, delayed gastric and bowel emptying time (Reddy 
et al., 1976; Shaaban et al., 2004), intestinal mucosa atrophy (Brewster, 2006a; 
Gilman et al., 1988; Schneider & Viteri, 1972), overgrowth of gut microflora, 
reduced peristalsis, and intestinal blood flow (Mata et al., 1972) have been 
reported in all types of severe malnutrition. All of these factors may affect the 
oral absorption of drugs in children with malnutrition. These factors have also 
been implicated in the reduced oral absorption of carbamazepine (Bano et al., 
1986), phenobarbitone (Syed et al., 1986), chloroquine (Walker et al., 1987), 
sulphadiazine (Mehta et al., 1980), and chloramphenicol (Eriksson et al., 1983a; 
Mehta et al., 1975; Samotra et al., 1986).  
Decreased muscle mass and body fat in malnourished children can impact 
the absorption of intramuscular drugs. Studies of the effects of malnutrition on 
the absorption of drugs administered intramuscularly have reported that the 
absorption rate of quinine (Treluyer et al., 1996) was significantly decreased in 
malnourished children who were undergoing treatment for malaria. By contrast, 
kwashiorkor had no effect on plasma concentrations of tobramycin following 
intramuscular injection (Buchanan & Eyberg, 1978). 
1.8.2. Drug distribution 
Alterations in plasma protein levels, body fluid composition, and tissue fat and 
protein occur in malnourished children, and these altered parameters can 
influence drug plasma CL and VD. Protein synthesis is decreased as indicated by 
decreased serum albumin, prealbumin, and lipoprotein levels (Treluyer et al., 
1996). By FRQWUDVW JOREXOLQ DQG Į-1-acid glycoprotein synthesis are increased 
(Pussard et al., 1999). Decreased plasma protein, particularly albumin, results in 
an increase in the unbound fraction of drugs. Changes in the plasma levels of an 
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unbound drug (fu) may increase its VD, and the unbound drug may distribute 
into the tissues, which leads to a decrease in the plasma concentration profile. 
For rapidly metabolised drugs, CL depends on the hepatic blood flow. However, 
changes in the fu of slowly metabolised drugs may directly change CL. 
Theoretically, acidic drugs, such as phenytoin, carbamazepine, and 
acetylsalicylate, which bind to plasma proteins, may exhibit potential toxicity in 
malnourished children when taken at the normal recommended dose. 
Total body water (TBW) increases proportionally to the degree of 
malnutrition (Buchanan & Eyberg, 1978) and is highest in marasmus (Rabinowitz 
et al., 2009). In addition to increased TBW, there is a proportionate increase in 
the extracellular fluid (ECF) in kwashiorkor due to oedema formation (Buchanan 
& Eyberg, 1978). 
Changes in body fluid may result in changes to the VD of hydrophilic 
drugs. Oedema, generalised dermatosis, and capillary leakage due to infection 
are common characteristics of kwashiorkor (Whitehead & Alleyne, 1972). These 
pathologies contribute to the increased ECF in kwashiorkor and account for the 
increased volume of distribution and decreased CL of aminoglycosides, such as 
gentamicin (Bravo et al., 1982; Buchanan et al., 1979a) and tobramycin 
(Buchanan & Eyberg, 1978).  
Earlier studies have suggested a decrease of adipose tissue in 
malnourished children (Garrow et al., 1965; Waterlow & Mendes, 1957). 
However, recent body composition studies have shown that malnourished 
children accumulate more body fat than lean body mass (das Neves et al., 2006; 
Martins et al., 2004). Theoretically, the VD of lipid-soluble drugs increases and 
can result in a decrease in the plasma levels of drugs. Clinically, normal 
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therapeutic doses of lipophilic drugs may not achieve the desired effects in 
malnourished children.  
1.8.3. Drug metabolism 
Biotransformation of drugs occurs mostly in the liver via the microsomal enzyme 
pathways. The activities of the enzymes for the metabolic pathways may be 
impaired in PEM. Although many animal studies have reported alterations in the 
activities of hepatic metabolising enzymes (Narang, 1987; Reen et al., 1999), 
few studies have reported findings regarding malnourished children.  
The activity of the bilirubin-uridyldiphosphate (UDP) enzyme, which is 
responsible for the hepatic metabolism of chloramphenicol, is significantly 
decreased in children with severe malnutrition (Mehta et al., 1975). The plasma 
level of paraxanthine, a metabolite of caffeine, was indirectly used to measure 
the activity of CYP1A2 after caffeine administration to children with kwashiorkor 
(Akinyinka et al., 2000). CYP1A2 activity, as well as the hepatic clearance of 
caffeine, was significantly decreased. 
A study of the activities of aminopyrine N-demethylase, which is 
responsible for the oxidation of drugs such as antipyrine, and bilirubin UDP-
glucuronyl transferase, which is responsible for conjugation of drugs such as 
chloramphenicol, showed severe impairment of the oxidative process and less 
impairment of the conjugation process in malnourished rats (Narang, 1987). 
Acetylsalicylic acid is metabolised by UDP-glucuronosyltransferase 1A6 
(UGT1A6) and cytochrome P450 2C9 (CYP2C9) (van Oijen et al., 2005). A study 
of acetylsalicylic acid in malnourished children with autoimmune disease 
suggests a decrease in the hydrolysis and oxidation of the drug (Lares±Asseff et 
al., 1999). These indicate that the hepatic metabolising activities of UGT1A6 and 
CYP2C9 are impaired by malnutrition. 
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The endocrine system may play a role in drug metabolism in children, 
since hormones mediate the dramatic physical changes of growth and 
development and also serve to coordinate metabolic events in diverse tissues 
(Redmond et al., 1980). Thyroid hormones often considerably affect drug 
metabolism in children (Saenger et al., 1976; Vesell et al., 1975). A decrease in 
serum triodothyronine (T3) level, a normal level of thyroxine (T4), and a free 
thyroxine index (FTI) have been reported in severely malnourished children 
(Onuora et al., 1983; Turkay et al., 1995). A study of antipyrine metabolism in 
malnourished children showed both a significant decrease in antipyrine 
metabolism and also an associated decrease in T3. It has been suggested that 
the decreased T3 concentration resulted in a decrease in antipyrine metabolism 
(Homeida et al., 1979). 
1.8.4. Drug excretion 
Glomerular filtration rate, renal blood flow, and tubular reabsorption are also 
impaired in severe malnutrition (Alleyne, 1967). The impact of malnutrition on 
the glomerular filtration rate is most relevant in children receiving drugs 
primarily excreted by the kidneys (e.g., penicillin and aminoglycosides). Studies 
in severely malnourished children have reported a significant decrease in renal 
CL of penicillin (Bolme et al., 1988; Buchanan et al., 1979a), cefoxitin 
(Buchanan et al., 1980b), and methotrexate (Mayhew & Christensen, 1993). 
Other studies have reported a decreased but not significantly changed renal CL 
of streptomycin (Bolme et al., 1988), amikacin (Hendricks et al., 1995), 
gentamicin (Bravo et al., 1982), and ethambutol (Graham et al., 2006). 
Considering the wide range of pathophysiological changes due to 
malnutrition that affect drug disposition, it was necessary to perform an 
extensive search of studies of drug disposition in children with malnutrition. This 
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search included a systematic review of studies of pharmacokinetics of drugs in 
malnourished children and aimed to identify new areas of research that will help 
improve drug safety in severely malnourished children. 
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CHAPTER TWO: 
SYSTEMATIC REVIEW OF STUDIES OF DRUG 
PHARMACOKINETICS IN PROTEIN-ENERGY 
MALNOURISHED CHILDREN 
2.1. INTRODUCTION 
Absorption, distribution, metabolism, and excretion (ADME) are the four major 
components of drug pharmacokinetics. Although drug metabolism is an integral 
part of pharmacokinetic studies, hepatic drug metabolism has not been 
specifically evaluated in malnourished children. Information regarding hepatic 
drug metabolism in malnourished children can therefore only be obtained 
indirectly from pharmacokinetic studies. A systematic review of studies of drug 
disposition in severely malnourished children is thus crucial in order to identify 
what work has been performed in this area. A systematic review is a type of 
literature review that focuses on a research question trying to identify, appraise, 
select, and synthesise all high quality research evidence relevant to the 
question. This review is necessary for a proper understanding of drug 
metabolism in malnourished children. 
This systematic review aimed to determine how different types of 
malnutrition affect absorption, distribution, metabolism, elimination, excretion, 
and the pharmacodynamics of drugs in children. It involved examining published 
articles for quantitative and qualitative evidence of the effects of malnutrition on 
drug disposition in children.  
 
 
58 
 
2.2. IDENTIFICATION OF RELEVANT LITERATURE 
Searches of the MEDLINE and EMBASE databases covered publications between 
January 1960 and December 2009. Articles describing drug absorption and 
disposition in malnourished children were sought using both databases and by 
reference tracking. The search strategies for both databases involved an initial 
search of all relevant abstracts using the medical subject heading (MeSH) 
GHVFULSWRUµGUXJDEVRUSWLRQ¶25µGUXJVDEVRUSWLRQ¶ OLPLWHGWRFKLOGUHQfrom 0 to 
17 years. Similar searches were performed for all drug pharmacokinetic 
parameters, which included distribution, metabolism, and clearance (CL). In 
RWKHU VHDUFKHV WKH WHUP µDEVRUSWLRQ¶ ZDV VXEVWLWXWHG ZLWK HDFK of the terms 
µGLVWULEXWLRQ¶ µSKDUPDFRNLQHWLFV¶ µSKDUPDFRG\QDPLFs¶ µPHWDEROLVP¶
µHOLPLQDWLRQ¶ DQG µFOHDUDQFH¶ UHVSHFWLYHO\ Another search was performed that 
involved the use of 0H6+ GHVFULSWRUV µPDOQXWULWLRQ¶ 25 µPDO-QXWULWLRQ¶ 25
µXQGHUQXWULWLRQ¶ 25 µXQGHU-QXWULWLRQ¶ 25 µXQGHUZHLJKW¶ 25 µXQGHU-ZHLJKW¶ 25
µSURWHLQHQHUJ\PDOQXWULWLRQ¶25µSURWHLQ-HQHUJ\PDOQXWULWLRQ¶25µSURWHLQFDORULH
PDOQXWULWLRQ¶ 25 µSURWHLQ-FDORULH PDOQXWULWLRQ¶ 25 µPDUDVPXV¶ 25 µPDUDVPLF-
NZDVKLRUNRU¶25µkwashiorkor¶7KHVHDUFKHs were later combined to produce the 
desired abstracts for the study. Duplicate abstracts were removed, and abstracts 
were scanned to determine whether they met the inclusion criteria.  
Inclusion criteria sought abstracts that assessed or discussed absorption, 
distribution, pharmacokinetics, pharmacodynamics, metabolism, elimination, or 
CL of drugs in children who were underweight and/or marasmic and who had 
marasmic-kwashiorkor and/or kwashiorkor. Abstracts that assessed or discussed 
disposition of micronutrients and orexigenic drugs in malnourished children were 
excluded. Full articles of the relevant abstracts were retrieved, and the 
references of the retrieved articles were scanned in order to identify additional 
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appropriate studies. The relevant additional articles meeting inclusion criteria 
were accessed.  
 
2.3. DATA EXTRACTION 
The desired studies were critically reviewed. Each study was independently 
reviewed by my lead supervisor, a paediatric clinical pharmacologist, and myself. 
A standard form was used to extract data on the number and year of studies, 
characteristics of the participants and controls, types of drug studied, and the 
number of blood samples collected. The pharmacokinetic parameters studied 
(absorption, distribution, metabolism, and CL were noted. We also extracted 
data on the methods of PEM classification in each of the studies.  
 
2.4. RESULTS OF THE SYSTEMATIC REVIEW 
Results were based on the specific parameters identified in the study.  
2.4.1. Publications 
The EMBASE search yielded 731 abstracts, while the MEDLINE search yielded 
546 abstracts, all of potential use. The results of the search strategy are 
presented schematically in Figure 2.1. Only 51 abstracts met the inclusion 
criteria. Most abstracts were excluded because they assessed serum macro-and 
micronutrients and serum proteins in malnourished children. One abstract 
written in French was excluded because the translator at the university was 
unable to assist.  
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Figure 2.1. Schematic representation of the literature search 
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The abstracts were mainly original research (41), review articles (4), and letters 
to the editor (6). Both original research articles and letters to the editor (47 
publications) were included in this review. Five publications (Akbani et al., 1977; 
Buchanan et al., 1976; Eriksson et al., 1988; Lares±Asseff et al., 1993; Seaton 
et al., 2007) were excluded because there were either insufficient details (no 
documentation of the mean value of the data or the control data) or the data 
were published in more detail in a subsequent paper, which was included in the 
final analysis. Altogether, 42 publications were analysed.  
The majority of studies were published in the 1970s (14) and 1980s (18); 
thereafter, the number progressively decreased over the subsequent two 
decades (Figure 2.2). Twenty-eight studies involved only one drug. A total of 34 
different drugs were studied. 
 
Figure 2.2: Frequency of publication of pharmacokinetic studies of drugs in children with protein-
energy malnutrition 
2.4.2. Methodology of trials 
The age range of the patients and control participants used for the studies was 3 
months to 16 years. The number of patients in individual studies varied from 5 
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to 41. Age-matched, healthy children were the control participants in 24 studies. 
Nutritionally rehabilitated children were used as additional control participants in 
four studies; they were also used as the only control participants in seven 
studies. Five studies had no control participants. 
PEM was classified in the participants according to the Wellcome Trust 
Working Party (WTWP) classification (22 studies) and Gómez classification 
(seven studies). Coexisting infections, including tuberculosis (4), bacterial sepsis 
(3), malaria (2), and HIV with tuberculosis (1), were reported in 10 studies. 
Most studies described in this review used traditional methods to study 
pharmacokinetics and involved a collection of one to 17 blood samples from the 
individual children. 
2.4.3. Effect of PEM on drug absorption  
Drug absorption is commonly described by rate (time dependent) and extent, 
otherwise called bioavailability (F), which is time independent. The extent of 
absorption was reported in only one study (Eriksson et al., 1983a). The effect of 
PEM on the absorption rate and area under curve concentration (AUC) of the 
drugs are presented in Table 2.1. The drug absorption rate (Ka) was reported for 
eight drugs, six of which showed no difference in the values of Ka for 
malnourished children and the control groups. These drugs were gentamicin 
(Samotra et al., 1995), metronidazole (Lares±Asseff et al., 1992), phenytoin 
(Bano et al., 1985), chloramphenicol (Samotra et al., 1986), paracetamol 
(Mehta et al., 1985), and sulphamethoxazole (Bravo et al., 1984). However, the 
p-values were not documented in the studies, except those involving gentamicin 
(p > 0.05) and chloramphenicol (p > 0.05). 
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Table 2.1: Effect of protein±energy malnutrition on absorption rate (Ka) and extent of absorption (AUC) of drugs  
Drug Route of 
administration 
Number 
of PEM 
children 
Age 
(years) 
Degree of 
malnutrition 
Mean± s.d  
absorption rate 
(Ka/h) 
Mean± s.d  
AUC (µg/ml/h) 
Controls P value Reference 
Controls PEM 
children 
Controls PEM children 
No statisticallly significant decrease in Ka and/or AUC 
Aspirin Oral 5 0±2 Undefined - - 154.9±59.3a 164.2±57.8a NH (n=6) - Treluyer et 
al., 1991  
Ethambutol Oral 15 1±12 U, M - - 23.1±9.8a 21.3±16.8a ± - Graham  et 
al., 2006  
Gentamicin IM 6 4±14 Undefined 0.2±0.0 0.1±0.0 22.4±2.3 22.3±2.2  H (n=4) - Samotra et 
al., 1985 
Metronidazole Oral 10 0±4 M-K, M 0.6±0.5 1.0±0.7 - - R (n=10) >0.05 Lares-Assef 
et al., 1992 
Penicillinb  
Oral 8 0±6 U 10.1±4.3   9.5±3.4 493.6±0.0c 476.7±0.0c NH (n=6) - Bolme et al., 
1995  Oral 6 0-6 M 10.1±4.3 8.4±1.5 - - NH (n=6) - 
Phenytoin Oral 5 7±14 Undefined 0.3±0.0 0.3±0.1 277.0±22.4 298.8±24.1 H (n=4) -  Bano et al., 
1985 
Pyrazinamide Oral 27 1±14 Undefined - - 496.0±407.0a  332.7±293.6a ± - Graham et 
al., 2006  
Quinine IM 8 0±5 M, M-K - - 97.5±31.4a 74.9±29.1a NH 
(n=10) 
- Treluyer et 
al., 1996  
Theophylline Oral 11 1±16 Undefined - - 52.8±6.7 42.0±5.8 ± >0.05 Kumar et 
al., 1989  
Tobramycin IM 4 0±2 K - -  0.4±0.2d  0.4±0.2d R (n=4) - Buchanan et 
al., 1978 
Chloramphenicol Oral 8 4±14 Undefined 1.1±0.6 1.0±0.4 - - H (n=4) >0.05 Samotra et 
al., 1986 
Paracetamol Oral 11 0±6 M, M-K, K 2.9±1.0 2.7±0.3 - - R (n=5) - Mehta et al., 
1985 
Sulphamethoxazole Oral 7 0±2 M 0.7±0.4 1.2±0.9 - - NH 
(n=10) 
- Bravo et al., 
1984  
Statistically significant decrease in Ka or AUC 
Carbamazepine Oral 6 6±13 Undefined - - 219.0±40.0 72.0±1.0 H (n=6) <0.05 Bano et al., 
1986 
Chloroquine 
Oral 5 2±4 K - - 9.2±3.1 3.3±2.1 NH (n=6) <0.001 Walker et 
al., 1987  
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 Table 2.1: Continued 
Drug Route of 
administration 
Number 
of PEM 
children 
Age 
(years) 
Degree of 
malnutrition 
Mean± s.d  
absorption rate 
(Ka/h) 
Mean± s.d  
AUC (µg/ml/h) 
Controls  Reference 
Penicillina Oral 6 0-6 K 
10.1±4.3 2.5±1.3 
- - NH(n=6) 
- Bolme et al., 
1995 
Sulphadiazine Oral 6 0±5 M, M-K  0.7±0.1 0.5±0.0 - - H (n=5) <0.01 Mehta et al., 
1980  
Chloramphenicol Oral   8 4±14 Undefined - - 252.0±45.0 128.0±45.0 H (n=4) <0.01 Samotra et 
al., 1986  
  Statistically significant increase in AUC 
Metronidazole Oral 10 0±4 M-K, M - - 140.0±47.0 191.7±101.7 R (n=10) <0.05 Lares-Assef 
et al., 1992 
Caffeine Oral 7 1±4 K - - 22.7±15.6 67.2±37.5 H (n=5) <0.05 Akinyinka et 
al., 2000 
Chloramphenicol Oral 10 0±3 U, M, K, M-K - - 222.0±0.0 375.0±0.0 H (n=4) - Mehta et al., 
1975 
Paracetamol Oral 11 0±6 M, M-K, K - - 30.0±5.4 66.1±20.9 R (n=5) <0.05 Mehta et al., 
1985 
Penicillinb  
  
Oral 6 0±6 M - - 493.6±0.0c 941.7±0.0c NH (n=6) - Bolme et al., 
1995 
Oral 6 0±6 K 
- - 
493.6±0.0c 975.2±0.0c NH (n=6) 
- Bolme et al., 
1995 
Phenobarbitone Oral 5 7±10 Undefined - - 454.0±45.1 607.1±49.9 H (n=5) <0.05 Syed et al., 
1986 
Quinine Oral 6 1±3 K - - 25.0±2.4 37.5±6.8 H (n=7) <0.001 Salako et 
al., 1989 
Sulphadiazine Oral 6 0±5 M, M-K - - 136.1±15.4 283.9±15.3 H (n=5) <0.01 Mehta et al., 
1980  
Sulphamethoxazole Oral 7 0±2 M - - 328.2±158.6 573.0±154.5 NH 
(n=10) 
<0.001 Bravo et al., 
1984  
IM = intramuscular; U= underweight; M = marasmus; K = kwashiorkor; M-K = marasmic-kwashiorkor; Undefined = PEM not classified; R- rehabilitated patients; H = healthy children with normal 
weight; NH = non-healthy children with normal weight; aValues in mg/L/h; bDrug administered to fasted patients; cValues in µg/ml/min; dUnit uncertain  
 
 
65 
 
In a study involving children with different categories of malnutrition, the 
absorption rate of penicillin showed no difference in underweight and marasmic 
children when compared to the control (Bolme et al., 1995) yet decreased in 
children with kwashiorkor. However, the p-values were again undocumented. 
Most drugs were administered either orally or intramuscularly, and their 
AUCs were reported in this review as AUCoral or AUCi.m. Although the p-values 
were undocumented, the AUC of seven drugs did not differ for malnourished 
children when compared to their control groups (Table 2.1). However, there was 
a statistically significant decrease in malnourished children regarding the AUC of 
two drugs: carbamazepine (p < 0.05) (Bano et al., 1986) and chloroquine (p < 
0.001) (Walker et al., 1987). By contrast, there was a statistically significant 
increase in the AUC of six drugs: metronidazole (p < 0.05) (Lares±Asseff et al., 
1992), caffeine (p < 0.05) (Akinyinka et al., 2000), paracetamol (p < 0.05) 
(Mehta et al., 1985), phenobarbitone (p < 0.05) (Syed et al., 1986), 
sulphadiazine (p < 0.01) (Mehta et al., 1980), and sulphamethoxazole (p < 
0.001) (Bravo et al., 1984). 
In a study of children with different categories of malnutrition, there was 
no change in the AUC of penicillin in underweight children. However, AUC was 
increased in children with marasmus and kwashiorkor when compared to the 
control group, though it is important to note that the p-values were not 
documented in the study (Bolme et al., 1995).  
In another study of children with different categories of malnutrition, 
Eriksson et al. (1983a) did not report the AUCs for chloramphenicol, though the 
bioavailability F (%) was reported. It was not affected in children with marasmus 
(57.0 ± 12.0), though there were statistically significant decreases in the values 
in children with marasmic-kwashiorkor (44.0 ± 6.0; p < 0.05) and kwashiorkor 
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(30.0 ± 9.0; p < 0.01) when compared to the control participants (85.0 ± 15.0). 
These results were similar to the statistically significant decrease (p < 0.01) in 
the AUC for children with undefined malnutrition reported by Samotra et al. 
(1986) but in contrast to the increased AUC for all forms of malnutrition reported 
by Mehta et al. (1975).  
In addition, contrasting results were also documented for quinine. There 
was a statistically significant increase (p < 0.001) in the AUC of oral quinine in 
malnourished children (Salako et al., 1989), though PEM had no effect on its 
intramuscular absorption (Treluyer et al., 1996).  
2.4.4. Effect of PEM on drug protein binding and volume of distribution  
The effects of PEM on plasma protein binding were identified in nine papers from 
the systematic review. Seven of these papers were published by Buchanan and 
his colleagues, who evaluated the plasma protein binding of 19 drugs in seven in 
vitro studies (Eyberg et al., 1974; Buchanan et al., 1976; Buchanan, 1977a; 
Buchanan & Van der Walt, 1977b; Buchanan & Van der Walt, 1977c; Buchanan 
& Van der Walt, 1977d; Buchanan & Van der Walt, 1977e). Only two studies 
(Treluyer et al., 1991; Treluyer et al., 1996) evaluated the in vivo binding of 
aspirin (salicylate) and quinine to serum protein. Serum or plasma of children 
with kwashiorkor was used for studies of protein binding of the drugs in the in 
vitro studies (Eyberg et al., 1974; Buchanan et al., 1976; Buchanan, 1977a; 
Buchanan & Van der Walt, 1977b; Buchanan & Van der Walt, 1977c; Buchanan 
& Van der Walt, 1977d; Buchanan & Van der Walt, 1977e). The number of 
patients studied and their ages were not provided, except for the studies that 
involved aspirin (Treluyer et al., 1991) and quinine (Treluyer et al., 1996). Fresh 
pooled adult serum and plasma were used as controls, except for the quinine 
study in which plasma from healthy children was used as a control. There was a 
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statistically significant decrease in the protein binding of 17 drugs in kwashiorkor 
when compared to healthy adults (p-values ranged from <0.0005 to <0.05) 
(Table 2.2). However, PEM had no statistically significant effect on the protein 
binding of two drugs: aspirin (p > 0.05) and quinine (p > 0.05).  
Table 2.2: Effect of kwashiorkor on drug protein binding or fraction unbound drug (fu)  
Drug Percentage 
free drug (%) 
Percentage change 
in free drug (%) 
P value 
Decreased protein binding (Increased fu )  and statistically significant percentage change in free 
drug  
Chloramphenicol (Buchanan, 1977a;  Buchanan & 
Van  der Walt, 1977b) 
80.0 5.9 <0.0005 
Cloxacillin (Buchanan, 1977a) 
25.1 65.1 <0.01 
Gentamicin (Buchanan, 1977a) 
96.0 4.7 <0.01 
Flucloxacillin (Buchanan, 1977a) 
28.9 83.7 <0.01 
Penicillin (Buchanan, 1977a) 
65.0 8.3 <0.01 
Streptomycin (Buchanan, 1977a; Buchanan & 
Van  der Walt, 1977c) 
67.6 28.3 <0.0005 
Sulphamethoxazole (Buchanan, 1977a) 
94.6 31.6 <0.0005 
Digoxin (Buchanan, 1977a; Buchanan et al., 
1976) 
89.2 8.3 <0.01 
Ethionamide (Buchanan, 1977a; Buchanan & Van  
der Walt, 1977c) 
78.5 13.6 <0.0005 
Para-amino salicylic acid (Buchanan & Van  der 
Walt, 1977c) 
96.2 14.4 <0.0005 
Rifampicin (Buchanan & Van  der Walt, 1977c) 
28.2 14.2 <0.0005 
Phenobarbitone (Buchanan, 1977a) 
84.7 11.4 <0.01 
Salicylate (Eyberg et al., 1974) 
71.3 54.7 <0.0005 
Thiopentone (Buchanan, 1977a; Buchanan & Van  
der Walt, 1977d) 
66.2 21.2 <0.0005 
Phenytoin (Buchanan, 1977a) 
12.0 27.7 <0.0005 
Chloroquine (Buchanan, 1977a; Buchanan & van 
der Walt; 1977e) 
60.3 16.0 <0.05 
Dicumarol (Buchanan, 1977a) 
9.8 22.5 <0.0005 
Unaffected protein binding (Unaffected fu ) and no statistically significant percentage change in free 
drug 
Ethambutol (Buchanan, 1977a) 93.8 0.0 - 
Isoniazid (Buchanan, 1977a) 100.0 0.0 - 
Quinine (Treluyer et al., 1996) 6.6 0.3 >0.05 
Aspirin (salicylate) (Treluyer et al., 1991) 9.6 1.3 >0.05 
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Five drugs (cloxacillin, flucloxacillin, rifampicin, phenytoin, and 
dicoumarol) were highly protein bound as suggested by their low percentage of 
the unbound fraction of drugs (Buchanan et al., 1976; Buchanan, 1977a; 
Buchanan & Van der Walt, 1977c). Of these drugs, cloxacillin and flucloxacillin 
showed an increase in percentage change of over 50% at the free drug level.  
The effects of PEM on the volume of distribution (VD) were evaluated for 
14 drugs in 19 papers. For most drugs, PEM had no statistically significant effect 
on VD (Table 2.3). There were contrasting results for four drugs: gentamicin 
(Bravo et al., 1982; Buchanan et al., 1979d), quinine (Pussard et al., 1999; 
Treluyer et al., 1996), streptomycin (Bolme et al., 1988) and theophylline 
(Eriksson et al., 1983b; Kumar et al., 1989). In the case of gentamicin, a study 
of children with kwashiorkor documented a statistically significant decrease (p < 
0.05) in VD (Buchanan et al., 1979d). By contrast, a study of children who were 
underweight, marasmic, or experiencing marasmic-kwashiorkor had a 
statistically significant increase (p < 0.05) in VD of gentamicin (Bravo et al., 
1982).  
In the case of theophylline, children with marasmus and kwashiorkor had 
a statistically significant increase in VD (p < 0.02 and p < 0.01, respectively) 
(Eriksson et al., 1983b), whereas children who were underweight presented no 
change in VD (Eriksson et al., 1983b). Another study in which the degree of 
malnutrition was undefined showed that PEM had no effect on the VD of 
theophylline (Kumar et al., 1989).  
In the case of streptomycin, children with kwashiorkor exhibited a 
statistically significant increase (p < 0.01) in VD, whereas children with 
marasmus or who were underweight had no change in VD (Bolme et al., 1988). 
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Table 2.3: Effect of protein energy malnutrition on drug distribution (Vd)  
Drug 
Number of PEM 
children 
Age (years) 
Degree of 
malnutrition 
Mean ±s.d  
 Vd (L/kg) 
P value 
 
Controls Reference 
Controls PEM children 
No statistically significant change in Vd values 
Acetanilide 5 0±2 K 6.3±0.6 5.3±0.3 - R (n=5) Buchanan et al.,1980 
Amikacin 10 1±4 K <1.0b 0.3±0.1 - 
H (controls, adults 
from another 
study) 
(Hendricks et al.,1995) 
Antipyrine 5 0±5 M, K 0.6±0.1 0.7±0.1 - R/H (n=5) Narang et al.,1977 
15 0±2 K 4.7±1.4 4.4±1.5 >0.25 R (n=15) Buchanan et al., 1979ª 
8 9±13 Undefined 25.0±3.1 21.7±2.7 - R (n=8) Homeida et al., 1979 
Aspirin 5 0±2 Undefined 0.3±0.1 0.3±0.1 >0.05 H (n=6) Treluyer et al., 1991 
Chloramphenicola 
8 0±6 M 1.9±0.2 2.1±0.5 - NH (n=8) Eriksson et al., 1983a 
9 0±6 M-K 1.9±0.2 1.5±0.2 - NH (n=8) Eriksson et al., 1983a 
8 0±6 K 1.9±0.2 1.3±0.2 - NH (n=8) Eriksson et al., 1983a 
Ethambutol 6 1±12 U, M 510.6±375.5c 300±156.1c >0.05 NH (n=7) Graham et al., 2006 
Isoniazid 7 0±3 K 14.2±8.0 9.7±3.9 - R (n=7) Buchanan  et al., 1979b 
Metronidazole 10 0±4 M-K, M 1.6±1.0 1.5±0.9 >0.05 R (n=10) Lares-Asseff et al., 1992 
Penicillina 
7 0±6 U 1.4±0.2 1.5±0.6 - NH (n=6) Bolme et al., 1995 
8 0±6 M 1.4±0.2 0.9±0.1 - NH (n=) Bolme et al., 1995 
8 0±6 M-K 1.4±0.2 0.9±0.1 - NH (n=6) Bolme et al., 1995 
8 0±6 K 1.4±0.2 1.2±0.2 - NH (n=6) Bolme et al., 1995 
8 0±2 K 13.1±7.4 12.8±3.9 -   R (n=9) Buchanan et al., 1979c 
Quinine 8 0±5 not K 1.7±0.4 2.0±0.8 >0.05 NH (n=7) Treluyer et al., 1996 
Sulphamethoxazole 7 0-2 M 0.6±0.3 0.5±0.1 - NH (10) Bravo et al., 1984 
Streptomycin 
11 0±12 U 0.3±0.0 0.3±0.1 >0.05 NH (n=4) Bolme et al., 1988 
12 0±12 M 0.3±0.0 0.3±0.1 >0.05 NH (n=4) Bolme et al., 1988 
Theophylline 11 1±16 Undefined 0.7±0.1 1.0±0.2 >0.05 H (n=10) Kumar et al., 1989 
6 1±s3 U 0.5±0.4 0.5±0.1 - H (n=12) Eriksson et al., 1983b 
Statistically significant increase in Vd  
Gentamicina 11 0±1 U, M, M-K 0.4±0.2 0.5±0.3 <0.05 H (n=7) Bravo et al., 1982 
Streptomycin 5 0-12 K 0.3±0.0 0.4±0.2 <0.01 H (n=4) Bolme et al., 1988 
Theophylline 8 1±8 M 0.5±0.4 0.7±0.1 <0.02 NH (n=12) Eriksson et al., 1983b 
5 1±8 K 0.5±0.4 0.7±0.1 <0.01 NH (n=12) Eriksson et al., 1983b 
Statistically significant decreased in Vd 
Quininea 
10 2±6 Undefined 1.6±1.1 0.6±0.3 <0.05 H (n=10) Pusasard et al., 1999 
Gentamicina 6 1±3 K 4.5±1.4c 3.9±0.5c <0.05 R (n=6) Buchanan et al., 1979d 
aDrug administered intravenously; bValues for adult reference;, cValues in litres; U= underweight; M = marasmus; K = kwashiorkor; M-K = marasmic-kwashiorkor; Undefined = PEM not classified; R- rehabilitated patients; H = 
healthy children with normal weight; NH = non-healthy children with normal weight 
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A statistically significant decrease (p < 0.05) in the VD of quinine in 
children with undefined PEM in one study (Pussard et al., 1999) was in contrast 
to another study involving children with marasmus and marasmic-kwashiorkor in 
which VD was unaffected (Treluyer et al., 1996). 
2.4.5. Effect of protein-energy malnutrition on drug CL and elimination 
half-life 
Table 2.4 shows the effect of PEM on the total CL and elimination half-life of nine 
drugs that are primarily metabolised in the liver. There was a statistically 
significant decrease in the total clearance of six drugs: acetanilide (p < 0.025) 
(Buchanan et al., 1980a); antipyrine (p < 0.05) (Narang et al., 1977), (p < 
0.0025) (Buchanan et al., 1979b), and (p < 0.05) (Homeida et al., 1979); 
caffeine (p < 0.01) (Akinyinka et al., 2000); sulphamethoxazole (Bravo et al., 
1984); isoniazid (p < 0.01) (Buchanan et al., 1979c); and metronidazole (p < 
0.01) (Lares±Asseff et al., 1992). There was a corresponding statistically 
significant increase in the plasma half-life. In two studies of malnourished 
children who were poorly categorised (Pussard et al., 1999) and experiencing 
kwashiorkor (Salako et al., 1989), there was a statistically significant decrease 
(p < 0.05 and p < 0.001, respectively) in the total clearance of quinine. 
However, a statistically significant increase (p < 0.05) in its total clearance was 
reported by another study of children with all categories of PEM except 
kwashiorkor (Treluyer et al., 1996). Similarly, one study reported a statistically 
significant decrease (p < 0.01) in the total CL of chloramphenicol in kwashiorkor 
or the total CL unaffected in marasmus and marasmic-kwashiorkor (Eriksson et 
al., 1983a).  
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Table 2.4: Effect of protein energy malnutrition on total clearance (CL) and half-life (t½) of drugs primarily metabolised by the liver 
Drug 
Number of 
PEM 
children 
Age 
(years) 
Degree of 
malnutriti
on 
Mean CL (ml/min/kg) Mean t½ (h, except where 
stated) 
P value Reference 
Controls PEM children Controls PEM children 
Statistically significant decrease in CL and increase in t½ 
Acetanilide 5 0±2 K 2.45±0.22b 0.92±0.19b 1.76±0.13 4.78±1.07 <0.025 for CL             
<0.0025 for t½ Buchanan  et al., 1980ª 
Antipyrine 10 0±5 M, M-K, K 70.10±7.20c 47.2±5.9c 6.30±0.50 10.40±0.80 <0.05 for CL     
<0.01 for t½ Narang et al., 1977 
15 0±2 K 15.50±8.70d 8.40±5.10d 4.30±2.30 7.90±5.00 <0.0025 for CL              
<0.0005 for t½ Buchanan et al., 1979b 
8 9±12 Undefined 32.00±5.1e 19.50±3.20e 9.90±1.30 14.80±2.10 <0.05 Homeida et al., 1979 
Caffeine 7 1±4 K 4.50±1.90 1.60±1.00 3.70±1.80 13.10±7.90 <0.01 for CL                   
<0.05 for t½ Akinyinka et al., 2000 
Chloramphenicole  8 0±6 K 7.53±1.09 4.16±0.73 2.85±0.26 3.76±0.36 <0.01 for CL               
<0.05 for t½ Eriksson et al., 1983ª 
Sulphamethoxazole 10 0-2 M 0.08±0.04 0.04±0.01 4.90±0.50 9.40±2.10 No P value for CL          
<0.001 for t½ 
Bravo et al., 1984 
Isoniazid 7 0±3 K 329.40±399.66d 114.0±75.38d 43.86±19.83 61.86±20.13 <0.01 for CL          
<0.0025 for t½ Buchanan et al., 1979c 
Metronidazole 10 0±4 M-K, M 0.17±0.98b, f 0.09±0.05b, f 5.68±1.97f 11.73±6.10f <0.01 for CL             
<0.05 for t½ Lares-Asseff et al., 1992 
Quinine 6 1±2 K 108.50±34.80g 31.50±8.50g 8.00±1.30 15.0±4.40 <0.001 Salako  et al., 1989 
Quininea  20 2±4 Undefined 4.00±2.10 1.70±1.50 5.10±2.60 7.20±5.90 <0.05 Pussard et al., 1999 
Statistically significant increase in CL and decrease in t½ 
Quinine 8 0±5 not K 2.30±1.40 4.40±3.60 10.10±3.40 6.30±1.80 <0.05 Treluyer et al., 1996 
 
 
 
72 
 
 
 
Table 2.4 
No statistically significant change in CL and t½ 
Chloramphenicole 17 0±6 M 7.53±1.09 8.16±2.29 2.85±0.26 2.88±0.52 - Eriksson et al., 1983a 
8 0±6 M-K 7.53±1.09 5.39±1.01 2.85±0.26 3.20±0.53 - Eriksson et al., 1983a 
Theophylline 11 1±16 Undefined 129.00±14.20c 170.70±20.70c 4.10±0.62 5.21±1.19 >0.05 Kumar et al., 1989 
6 1±8 U 1.22±0.20h 1.09±0.15h 4.93±0.59 5.25±0.55 - Eriksson et al., 1983b 
8 1±8 M 1.22±0.20h 1.45±0.17h 4.93±0.59 5.38±0.22 - Eriksson et al., 1983b 
5 1±8 K 1.22±0.20h 1.49±0.22h 4.93±0.59 5.61±0.31 - Eriksson et al., 1983b 
aDrug administered intravenously; bValue in L/h; cValue in kg/ml/h; dValue in ml/min; eUnit of the value was not given; fMedian value; gValue in mg/min; hValue in kg/ml/min; U= underweight; M = marasmus; 
K = kwashiorkor; M-K = marasmic-kwashiorkor; Undefined = PEM not classified 
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In a study involving poorly categorised children with malnutrition, there 
was no statistically significant change (p > 0.05) in the total CL of theophylline 
when compared to the controls (Kumar et al., 1999). Similar results were 
documented in another study of children who were underweight or experiencing 
either marasmus or kwashiorkor (Eriksson et al., 1983b).  
The effects of PEM on the total CL of six drugs primarily eliminated by the 
kidneys are presented in Table 2.5. In a study involving all categories of PEM, 
there was a statistically significant decrease in the total CL of penicillin in 
association with a statistically significant increase in elimination half-life for 
children with marasmus (p < 0.001), marasmic-kwashiorkor (p < 0.01), and 
kwashiorkor (p < 0.01) (Bolme et al., 1995). Another study involving children 
with kwashiorkor demonstrated a statistically significant decrease (p < 0.0005) 
in the CL of penicillin, as well as a statistically significant increase (p < 0.0025) 
in the GUXJ¶V elimination half-life (Buchanan et al., 1979d).  
There was a statistically significant decrease (p < 0.0005) in the CL of 
cefoxitin, though t½ was unaffected in children with kwashiorkor (Buchanan et 
al., 1980b). There was no influence of PEM on the total CL of the two 
aminoglycosides studied: gentamicin (Bravo et al., 1982; Buchanan et al., 
1980b) and amikacin (Hendricks et al., 1995). One study involving all categories 
of PEM documented a statistically significant decrease (p < 0.01) in the renal CL 
of streptomycin, as well as a statistically significant increase (p < 0.01) in the 
elimination half-life of the drug in children with kwashiorkor but no change in 
children who were underweight or had marasmus only (Bolme et al., 1988).  
Twelve studies calculated the plasma half-life without any CL values (Table 2.6).  
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Table 2.5: Effect of protein energy malnutrition on CL and t½ of drugs primarily eliminated by the kidneys 
Drug 
Number of 
PEM 
children 
Age (years) 
Degree of 
malnutrition 
Mean CL (ml/min/kg) Mean t½ (h) P value Reference 
Controls PEM children Controls PEM children 
Statistically significant decrease in CL and increase in t½ 
Penicillina 8 0±6 M 22.20±0.90 14.00±0.50 0.65±0.08 0.90±0.04 <0.001 Bolme et al., 1995 
8 0±6 M-K 22.20±0.90 16.90±1.0 0.65±0.08 0.92±0.08 <0.01 Bolme et al., 1995 
8 0±6 K 22.20±0.90 11.60±1.1 0.65±0.08 0.93±0.16 <0.01 Bolme et al., 1995 
8 0±2 K 271.69±75.94b 183.43±116.26b 0.65±0.08f 2.33±0.80f <0.0005 for CL        
<0.0025 for t½ 
Buchanan et al., 1979c 
Streptomycin 5 0±12 K 67.00±15.00 49.00±7.00 2.58±0.44f 9.69±2.56f <0.01 Bolme et al., 1988 
Statistically significant decrease in CL but t½ unaffected 
Penicillina 
7 0±6 U 22.20±0.90 15.10±0.90 0.65±0.08 0.68±0.13 <0.01  for CL     
No P-value for t½ 
Bolme et al., 1995 
Cefoxitin 6 1±4 K 70.60±16.6b 50.70±5.00b 0.47±0.07 0.49±0.06 <0.025 for CL    
No P-value for t½ 
Buchanan et al., 1980b 
No statistically significant change in CL and t½ 
Gentamicin 11 0±1 U, M, M-K 3.57±0.02 3.99±0.01 0.01±0.00 0.01±0.00 >0.05 Bravo  et al., 1982 
Gentamicina  6 1±3 K 28.70±21.30b 13.60±6.00b 2.98±1.66 3.82±1.58 - Buchanan et al., 1980b 
Amikacin 10 1±4 K <0.50±0.00c, d 6.19±2.51d <0.50±0.00e 2.56±1.00 - Hendricks et al., 1995 
Ethambutol 11 0±12 U 37.84±16.00 52.81±71.89 9.70±4.00 7.40±5.60 >0.05 Graham et al., 2006 
Streptomycin 
12 0±12 M 67.00±15.00 91.00±14.00 2.58±0.44 2.27±0.24 - Bolme et al., 1988  
11 0±12 U 67.00±15.00 74.00±8.00 2.58±0.44 2.14±0.26 - Bolme et al., 1988 
aDrugs administered intravenously; bValue in ml/min; cValues for adult reference; dValue in L//h/kg, eValue in L/h; fSignificant difference in t ½ values; U= underweight; M = marasmus; K = kwashiorkor; M-K = 
marasmic-kwashiorkor; Undefined = PEM not classified   
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Table 2.6: Effect of protein-energy malnutrition on half-life (t½)  
Drug 
Number of 
PEM children 
Age (years) 
Degree of 
malnutrition 
Mean t½ (h) P value Reference 
Controls PEM children 
Statistically significant increase in t½  
Chloramphenicol 8 0±5 Undefined 12.00±0.41  - Mehta et al., 1982 
Paracetamol 11 0±6 U, M, M-K, K 4.18±0.54 6.52±0.80 <0.05 Mehta et al., 1985 
Phenobarbitone 5 7±10 M-K, K 30.15±6.10 58.90±9.50 <0.05 Syed et al., 1986  
Sulphadiazine 6 0±5 Undefined 21.27±1.51 31.78±3.82 <0.02 Mehta et al., 1980 
Sulphamethoxazolea  7 0±2 M 4.90±0.50 9.40±2.10 <0.05 Mehta et al., 1980 
No statistically significant increase in t½ 
Chloramphenicol 8 4±14 Undefined 0.80±0.40 0.74±0.30 >0.05 Samotra et al., 1982 
Aspirin 5 0±2 Undefined 4.00±2.10 5.60±6.40 >0.05 Treluyer, et al., 1991 
Chloroquine 5 2±3 K 195.00±3.10 180.00±73.00 >0.05 Walker, et al., 1987 
Gentamicin 6 4±14 Undefined 3.31±0.30 6.21±1.21 >0.05  Samotra et al., 1985 
Isoniazid 13 0±7 U 1.82±0.21 1.78±0.28 >0.05 Seifart et al., 1995 
Phenytoin 5 7±13 Undefined 21.40±5.90 24.42±3.50 - Bano et al., 1985 
Tobramycin 4 0±2 K 1.12±0.32 0.84±0.16 0.2 Buchanan et al., 1978 
aClearance and half-life of the drug were provided in the study; clearance was apparently decreased in PEM children, but the level of significance was not provided when 
compared with normal control children; U= underweight; M = marasmus; K = kwashiorkor; M-K = marasmic-kwashiorkor; Undefined = PEM not classified 
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Four studies documented a statistically significant increase in the elimination 
half-life of four separate drugs: paracetamol (p < 0.05) (Mehta et al., 1985), 
phenobarbitone (p < 0.05) (Syed et al., 1986), sulphadiazine (p < 0.02) (Mehta 
et al., 1980), and sulphamethoxazole (p < 0.05) (Mehta et al., 1980), while 
others showed that PEM had no statistically significant effect on the elimination 
half-life of six of the remaining seven drugs (Bano et al., 1985; Samotra et al., 
1985; Seifart et al., 1995; Treluyer et al., 1991; Walker et al., 1987). One study 
documented an increased elimination half-life of chloramphenicol in children with 
poorly categorised malnutrition (Mehta et al., 1982), while another study 
documented no statistically significant effect (p > 0.05) (Samotra et al., 1982). 
 
2.5. DISCUSSION  
2.5.1. Number of publications and the methodology of the studies 
Between 1970 and 2009, only 42 publications had examined the disposition of 
drugs in malnourished children. These studies are relatively few when compared 
to the high proportion of children affected with malnutrition globally. 
Malnutrition, similar to the tropical diseases schistosomiasis, onchocerciasis, 
lymphatic filariasis, trachoma, hookworm, roundworm, and whipworm, causes 
severe morbidity and mortality in sub-Saharan Africa yet remains a neglected 
disease (WHO, 2012). To make matters worse, there has been inadequate 
international funding to fight malnutrition. At the World Food Summit in Rome in 
2009, the world leaders failed to commit to combating malnutrition (FAO, 2009). 
Also in 2009, the international assistance available to fight malnutrition was 
$350 million dollars, while the World Bank estimated $11.2 billion as the amount 
required to adequately fight the disease in the 36 most affected countries 
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(Médecins Sans Frontières, 2009). Since malnutrition is likely to remain a 
significant problem for many children, health professionals and scientists 
therefore have a duty to improve their understanding of how children with 
malnutrition handle medicines. 
To study pharmacokinetics, most studies described in this review used 
traditional methods, which involve taking multiple blood samples from each 
patient. However, the ethical issues surrounding multiple blood sampling from 
children currently necessitate the use of alternative approaches, such as 
population pharmacokinetics, in which a fewer number of blood samples are 
collected from a larger number of patients (Thomson, 2006), or non-invasive 
methods, such as the caffeine breath test (Parker et al., 1997a; Pons et al., 
1988a).  
In research a power calculation is necessary to determine the minimum 
sample size required to yield the desired or greater effect, if such an effect truly 
exists in a population (Raudys & Jain, 1991). Most studies evaluated in this 
systematic review did not, however, perform power calculations but often 
instead used sample sizes of fewer than 10 malnourished children. These studies 
may have therefore been underpowered and unable to detect any difference. 
Many studies also failed to report the p-values comparing the data for 
malnourished children and their control groups. Some of the p-values may have 
actually approached significance yet significant differences remained undetected 
because the study population was too small. These limitations recommend that 
some of their data be interpreted with caution. 
2.5.2. Effects of malnutrition on drug absorption 
All but three drugs (gentamicin, quinine, and tobramycin) evaluated for their 
absorption rate in malnourished children were administered orally. Although the 
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p-values were not documented, the systematic review showed that the 
absorption rate constant for the majority of the oral drugs was unaffected in 
malnourished children. However, this rate was significantly decreased for 
penicillin and sulphadiazine in children with kwashiorkor and marasmus or 
marasmic-kwashiorkor. Though the physiological changes in PEM have been 
known to alter the absorptive capacity of the gastrointestinal tract (Gómez et al., 
1956b; Schneider & Viteri, 1972), there appears to have been no significant 
change in the absorption rate of most oral drugs reported in this review. These 
results contrast the significantly decreased absorption rates of xylose and 
glucose in PEM reported in other studies (Das et al., 2004; James, 1971).  
Most drugs are absorbed by the intestine by either passive or facilitated 
diffusion and thus depend on the permeability of the mucosal membrane. 
Brewster et al. (1997b) assessed the intestinal permeability in malnourished 
children using a non-invasive lactulose±rhamnose (L±R) test. The geometric 
mean L±R ratios were significantly higher in malnourished children than in 
healthy control groups. A L±R ratio greater than 5 suggested a loss of integrity 
of the intestinal mucosa. The degree of abnormal permeability in PEM reflects 
the severity of the illness, and children with kwashiorkor are the most affected 
(Brewster et al., 1997b). This finding likely explains why the absorption rate of 
penicillin was unaffected in underweight and marasmic children but significantly 
decreased in children with kwashiorkor.  
Of the three intramuscular (i.m.) drugs evaluated, data on absorption 
rates were available for gentamicin only. Based on the limited data from a single 
study, it was not possible to draw a conclusion on 3(0¶V effect on the rate of 
absorption of i.m. drugs. 
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The extent of absorption (F = AUCoral/i.m / AUCi.v) represents bioavailability. 
This, however, was reported in only one study (Eriksson et al., 1983a). Based on 
the limited data available to this review, it was difficult to make conclusions 
regarding the effect of PEM on the extent of drug absorption.  
2.5.3. Effect of malnutrition on drug distribution 
2.5.3.1. Protein binding 
The majority of studies of protein binding presented no information about the 
number of patients studied and their ages, though patients were primarily 
children with kwashiorkor and controls were healthy adults. About 85% of the 
drugs demonstrated a significant decrease in their protein binding in children 
with kwashiorkor when compared to healthy adults. 
The lack of detailed information about the patients, the use of blood 
samples of adults as controls, and the exclusivity of the studies to only 
kwashiorkor patients recommend that the data on protein binding in PEM be 
interpreted with caution. Although information on drug protein binding in older 
children is lacking, a qualitative and quantitative decrease in plasma protein 
binding in new-borns compared to adults has been documented (Rylance, 1981). 
This finding emphasises the significance of age and the use of appropriate 
controls in studies of protein binding in PEM.  
About 70% of the drugs studied for plasma protein binding have low 
binding capacities (Table 2.2). The percentage change in the unbound fraction in 
PEM significantly increased for 17 drugs. Five of these drugs (cloxacillin, 
flucloxacillin, rifampicin, phenytoin, and dicoumarol) were highly protein bound. 
The efficiency of a drug may be affected by the degree to which it binds to 
plasma protein. Drugs that bind minimally to plasma protein traverse cell 
membranes and penetrate tissues better than their highly bound counterparts 
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(Scheife, 1989). Protein binding can also influence the elimination half-life of a 
drug, since as the bound fraction may act as a reservoir from which the drug is 
slowly released as the unbound fraction (Berezhkovskiy, 2010). Although the 
change in plasma binding was statistically significant, the clinical significance of 
these findings are likely relevant only to phenytoin and dicoumarol, since they 
were 80% to 90% protein bound. Slight changes in the binding of these drugs 
may influence the interpretation of their total concentrations. However, this may 
not result in significant changes in clinical response or toxicity unless their 
metabolism is altered. Previous studies have shown that the increased unbound 
fraction of drugs less than 80% protein bound are of slight clinical importance 
(Scheife, 1989).  
2.5.3.2. Volume of distribution 
The VDs of the majority of drugs identified in the systematic review were 
unaffected in malnourished children. However, malnutrition has varying effects 
on the VD of quinine, streptomycin, theophylline, and gentamicin (Table 2.3).  
According to Thomson (2000), VD is a constant of proportionality relating 
the quantity of drug in the body to its plasma concentration. Generally, VD is a 
theoretical, not a physiological, volume into which a drug distributes in order to 
achieve the measured plasma concentration. VD is dependent on drug 
lipophilicity, WKHGUXJ¶Vplasma protein binding capacity (Øie, 1986), and tissue 
components such as protein (Grover & Benet, 2009). The VD of drugs that 
distribute primarily in body water may be increased in conditions associated with 
fluid retention or decreased plasma protein binding (DiPiro et al., 2011). As 
expected, the VD for drugs of this type may be decreased during dehydration.  
Despite the oedema that characterise children with kwashiorkor and the 
dehydration that complicates severe malnutrition, the VDs for most drugs were 
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not significantly affected in PEM. It may be that the oedema had subsided in 
children with kwashiorkor or that other severely malnourished children were well 
hydrated during the study. However, detailed information about the treatments 
received remained undocumented in the studies. Since the majority of the drugs 
studied have low protein binding capacities as well as slight but nonetheless 
statistically significant changes in their unbound fractions (Table 2.2), their VDs 
were not likely affected. 
There were contrasting results on the effects of PEM on the VDs of quinine 
and gentamicin. The VD for quinine was unaffected in malnourished children 
without kwashiorkor (Treluyer et al., 1996). It decreased significantly in 
malnourished children who were not properly classified (Pussard et al., 1999) 
and was not reported in kwashiorkor children studied by Salako et al. (1989). 
While Treluyer et al. (1996) studied the pharmacokinetics of intramuscular 
quinine in malnourished and control children with malarial fever; Pussard et al. 
(1999) studied the pharmacokinetics of intravenous quinine in malnourished and 
healthy children without malaria. Additionally, Salako et al. (1989) studied the 
disposition of oral quinine in healthy children and children suffering from 
kwashiorkor, none of whom had malaria. The studies by Treluyer et al. (1996) 
and Pussard et al. (1999) documented a higher serum level oI Į1-acid 
glycoprotein (AGP) than in healthy afebrile children, while Salako et al. (1989) 
did not assess the AGP level and VD but nevertheless reported decreased total 
plasma protein and albumin levels. Irrespective of the cause, fever has been 
shown to modify the disposition of quinine (Shann et al., 1985; Trenholme et al., 
1976) and to increase the fixation of quinine to AGP (Silamut et al., 1991). 
Other studies have documented increased AGP plasma levels in children with 
bacterial infection (Treluyer et al., 1991) and malaria (Mansor et al., 1991). 
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Similar to many other basic drugs, quinine binds predominantly to albumin, 
though AGP level is the major determinant of the variation in quinine protein 
binding (Wanwimolruk & Denton, 1992). It can thus be concluded that variations 
in the methodologies of the studies involving quinine disposition have probably 
accounted for the varying effects of PEM on its VD. 
In two studies, it was documented that the VD for gentamicin significantly 
increased in a group of malnourished children who were underweight or 
experiencing marasmus or marasmic-kwashiorkor (Bravo et al., 1992), as well 
as those children with kwashiorkor only (Buchanan et al., 1979d). Both these 
above studies also documented that the clearance and elimination half-life of 
gentamicin were not significantly affected. Another study by Samotra et al. 
(1985) documented that the elimination half-life of gentamicin was not 
significantly affected in malnourished children who were poorly classified. A 
possible explanation for these findings is that oedema in marasmic-kwashiorkor 
and kwashiorkor tends to increase the body fluid within which water soluble 
gentamicin is distributed, given that its renal CL was unaffected. Increased VD 
has been reported for gentamicin in infantile sepsis (Thomson et al., 2003) and 
oliguric renal failure (DiPiro et al., 2011) as a result of fluid retention that 
complicated the conditions. 
Another study reported that the VD of amikacin was unaffected in children 
with kwashiorkor, as compared to healthy adult patients (Hendricks et al., 
1995). However, Motohiro et al. (1987) have documented a lower VD of 
amikacin in children than in adults. This discrepancy underscores the need for 
using well-nourished, healthy children as controls for pharmacokinetic studies of 
malnourished children. 
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Aminoglycosides are generally eliminated in unchanged forms by the 
kidneys. The unaffected renal elimination of aminoglycosides and the presence 
of oedema may explain the increased VD for streptomycin reported in children 
with kwashiorkor. It may also explain why the VD for streptomycin was 
unaffected in underweight and marasmic children (Bolme et al., 1998), since 
both conditions are not commonly associated with oedema. 
2.5.4. Effect of malnutrition on the plasma CL of drugs primarily 
metabolised by the liver  
Eight drugs (metronidazole, caffeine, chloramphenicol, paracetamol, 
phenobarbitone, quinine, sulphadiazine, and sulphamethoxazole) have 
significantly decreased plasma CLs (Table 2.4) or increased elimination half-lives 
(Table 2.5) in malnourished children. Most of these drugs were studied using a 
single-compartment model. About 80% of these drugs are converted by the liver 
to their metabolites during phase I and II reactions. The disappearance of the 
drugs from plasma has been used to compute the parameters of t½, VD, and CL, 
all of which provide an indirect estimate of hepatic function.  
CYP450 enzymes are involved in the phase I metabolism of most of these 
drugs (Badyal & Dadhich, 2001). These enzymes are part of the mixed function 
oxidase reported to be functioning less optimally in malnourished children 
(González±Hernández et al., 2008). A study using animal models has shown a 
50% reduction in the activity of total hepatic CYP450 enzyme in PEM and that 
individual CYP450 enzymes were affected differently (Cho et al., 1999). 
Similarly, Lee et al. (2004) have reported the suppression of hepatic CYP1A2 by 
60%, CYP 2C11 by 80%, CYP 2E1 by 40%, and CYP 3A1/2 by 50% in rats with 
PEM. Studies of animals with systems closer to those of humans have also 
documented a significant decrease during PEM in the total microsomal haeme, 
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phospholipid, and flavin adenine dinucleotide levels (Rumack et al., 1973), all of 
which are involved in microsomal drug metabolism. Malnourished monkeys have 
also been reported to have significantly lower quantities of microsomal protein 
as well as a lower activity of CYP450 reductase than healthy controls (Catz et al., 
1970). CYP450 reductase is an important component of mixed function oxidases 
in drug hydroxylation (Ortiz de Montellano & Correia, 1983).  
Two other studies documented a significantly decreased total CL of 
quinine in poorly categorised malnourished children (Pussard et al., 1999) and 
those experiencing kwashiorkor (Salako et al., 1989). However, a different result 
was reported by Treluyer et al. (1996), who documented a significantly 
increased total CL of quinine in children with all categories of PEM except 
kwashiorkor. Eriksson et al. (1983) reported a significantly decreased total CL of 
chloramphenicol in children with kwashiorkor. The CL was, however, unaffected 
in children with marasmus and marasmic-kwashiorkor. The metabolism of both 
quinine and chloramphenicol depends upon the activity of uridine diphosphate 
glucuronyltransferase (UDPGT) (Mirghani et al., 2003; Miyagi & Collier, 2007). 
Although data are lacking in regards to humans, there are reports of significantly 
reduced activities of phase II metabolising enzymes in malnourished rats. 
Among the enzymes affected are glutathione S-transferase (GST) and UDP-
glucuronosyltransferase (UDPGT) (Badary et al., 2003; Zhang et al., 1999). 
These above studies also documented that enzyme activities were reduced more 
in severely malnourished animals than in their moderately malnourished 
counterparts, which may explain the differential effects of marasmus and 
kwashiorkor on the CL of chloramphenicol reported by Eriksson et al. (1983a).  
A study of the ultrastructure of hepatic tissue of severely malnourished 
children has revealed decreased quantity and quality of phase II hepatic 
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metabolising enzymes (Brooks et al., 1994). Another study of the hepatic-tissue 
ultrastructure of children and adults with severe malnutrition also showed 
injuries to the organelles that are important to protein synthesis and hepatic 
drug metabolism (Tandon et al., 1974). Such damage included dilatation of the 
rough endoplasmic reticulum, causing it to form vesicles or fragments; 
abnormality of the mitochondrial content; variation in the shape and size of the 
rough endoplasmic reticula; and increased glycogen and collagen levels. 
However, these abnormalities were completely reversible after nutritional 
rehabilitation. 
All the drugs with decreased CLs in PEM have low extraction ratios (E < 
0.3) (Hoyumpa & Schenker, 1982). These drugs were not significantly bound to 
plasma protein, with the exception of quinine (Table 2.2). A hepatic blood-flow 
change that can occur in PEM is known to have insignificant effects on plasma 
levels of drugs with a low E. A decrease in the intrinsic ability of the liver to clear 
a low extraction drug significantly increases its plasma and tissue free levels.  
Based on both the decreased CYP450 enzyme activities in PEM and the 
decreased plasma CL or increased plasma half-life of all drugs primarily 
metabolised by the liver, it can be suggested that lower doses or, alternatively, 
less frequent administration of drugs should be observed in PEM. 
2.5.5. Effect of malnutrition on the clearance of drugs primarily 
eliminated unchanged by the kidneys  
The total CL of penicillin was significantly decreased in all of the four categories 
of malnutrition. However, there were varying effects of PEM on the elimination 
half-life of penicillin; it was unaffected in underweight children but significantly 
decreased in children experiencing marasmus, marasmic-kwashiorkor, or 
kwashiorkor. Penicillin is not metabolised by the liver, for it is eliminated 
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unchanged by the kidneys. Marasmus and kwashiorkor are two types of severe 
PEM known to be associated with diminished renal blood flow and glomerular 
filtration rate (GFR) (Alleyne, 1967). However, the altered renal functions are 
usually reversible after nutritional rehabilitation. The physiological changes in the 
renal system of severely malnourished children may have accounted for the 
observed differential results regarding the AUC (Table 2.1) and elimination half-
life (Table 2.5) of oral penicillin. 
PEM does not appear to affect the total CL of most drugs primarily 
eliminated by the kidneys, since their values remained almost unchanged in the 
participants and controls (Table 2.5). This was likely because most of these 
drugs are not usually metabolised before being eliminated unchanged by the 
kidneys (Faull & Lee, 2007). Decreased total CL was, however, demonstrated for 
streptomycin. In light of the six drugs studied, firm conclusions could not be 
made about the effect of PEM on renal drug elimination. Further studies are 
therefore required.  
2.5.6. Types of drugs evaluated for disposition in PEM 
This systematic review has identified pharmacokinetic studies of antimalarials, 
analgesics/antipyretics, antibiotics, and antitubercular drugs in PEM. Despite the 
strong association between malnutrition and HIV infection, the pharmacokinetics 
of antiretroviral drugs has not been studied in regards to PEM, which is likely due 
to the inaccessibility of these drugs in developing countries during the 1980s, 
the period when most pharmacokinetic studies were performed. Furthermore, 
antiretroviral drugs are rarely commenced in the acute phase of PEM 
management (Fergusson & Tomkins, 2009).  
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2.6. CONCLUSIONS 
Very few studies have evaluated drug disposition in malnourished children 
despite the high prevalence and burden of the disease worldwide. Some of the 
studies lacked clear definition of malnutrition, while other studies lumped 
children with different categories of malnutrition into one group. In fact, only a 
few studies have recognised malnutrition as a disease spectrum. These 
limitations likely contributed to some of the variations in the results. Further 
studies thus need to recognise PEM as a disease spectrum and examine the 
differential effects of kwashiorkor and marasmus.  
The total CL of most of the drugs primarily metabolised by the liver were 
significantly reduced in PEM, which may reflect decreased activity of the intrinsic 
hepatic metabolising enzymes and suggest a need to reduce drug dosage in 
PEM. More studies are therefore required to assess the activities of the hepatic 
metabolising enzymes in malnourished children.  
Previous studies involved the use of traditional pharmacokinetics that 
required taking multiple blood samples from each patient. Ethical concerns 
regarding multiple blood samplings in children currently urge the use of 
alternative and less invasive approaches.  
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CHAPTER THREE:  
PRINCIPLES OF THE CAFFEINE BREATH TEST AND 
PROTOCOL FOR USING THE METHOD TO STUDY DRUG 
METABOLISM IN CHILDREN WITH MALNUTRITION 
3.1. INTRODUCTION 
Despite the high proportion of children affected with PEM worldwide, there have 
been relatively few pharmacokinetic studies of drugs frequently used for the 
treatment of these children. Pharmacokinetic studies have since been considered 
invasive and have required multiple blood sampling. They also involved using 
both heterogeneous methods to classify PEM and small samples of participants 
and controls. Both by studying children experiencing coexisting diseases with the 
potential to influence the disposition of drugs being evaluated and by limiting the 
study to only one category of malnutrition, these studies were additionally 
limited (Oshikoya et al., 2010). There is thus a preferential need for alternative 
approaches that address these limitations, as well as examine the differential 
effects of marasmus and kwashiorkor on drug disposition. 
This chapter discusses the aims and objectives, as well as the 
methodology, of the present research. 
 
3.2. AIMS AND OBJECTIVES 
Although some information exists regarding the effects of malnutrition on drug 
disposition in children, only a few drugs have been investigated, and no previous 
study has specifically determined the effects of malnutrition on the hepatic 
metabolism of drugs in children. Furthermore, there are no published data on 
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the use of probe substrates in studies of the activity of individual cytochrome 
P450-enzymes in malnourished children. Similarly, non-invasive methods, such 
as the caffeine breath test, have not yet been explored for studies of drug 
metabolism in malnourished children. 
This study therefore aimed to use the caffeine breath test to determine 
the effects of different types of malnutrition on the metabolising activity of 
hepatic CYP450 enzymes, specifically CYP1A2. 
 
3.3. BACKGROUND OF THE CAFFEINE BREATH TEST  
Drug metabolism has been studied in adults using probe substrates for different 
types of CYP450 enzymes (Fontana et al., 1998; Kinirons et al., 1993). However, 
many tests are inapplicable in paediatric patients since they involve either the 
administration of radioactive substrates or intravenous drugs followed by 
multiple blood sampling, thus rendering their methods ethically unacceptable. 
$OWKRXJK WKH UDWLR RI XULQDU\ ǃ-hydroxycortisol:cortisol has been used to 
measure the activity of CYP3A4 in neonates (Nakamura et al., 1998) and adults 
(Kinirons et al., 1993; Watkins et al., 1992), the ratio does not always correlate 
with the disposition of CYP3A substrate drugs. This finding is due to intra- and 
inter-individual variability in the renal clearance (CL) of cortisol (Furuta et al., 
2003; Galteau & Shamsa, 2003). Furthermore, the test lacks validity for use 
with infants and older children (Johnson, 2002).  
The caffeine breath test (CBT) is a non-invasive method of studying drug 
metabolism, and many studies have validated its use in children (Parker et al., 
1994; Parker et al., 1997a; Parker et al., 1997b; Parker et al., 1998; Pons et al., 
1988a). 
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3.3.1. Caffeine metabolism 
Caffeine is a 1, 3, 7-trimethylxanthine compound with the structure presented in 
Figure 3.1.  
 
Figure 3.1: Structure of caffeine (1, 3, 7 trimethylxanthine) 
Structure adapted from Chem Spider website (Available on http://www.chemspider.com/Chemical-
Structure.2424.html; Accessed 25 April 2014) with kind permission of The Royal Society of Chemistry 2014  
Its metabolism in the liver is performed by 1-N, 3-N and 7-N demethylation, as 
well as C-8 hydroxylation to 1, 3, 7-trimethyluric acid (Figure 3.2) (Kalow & 
Tang, 1993).  
Caffeine (1, 3, 7 trimethylxanthine) 
               C-8 hydroxylation 
       N-1 demethylation   N- 3 demethylation N-7 demethylation   
1,3,7 trimethyluric acid 
 
3, 7 dimethylxanthine  1, 7 dimethylxanthine     1, 3 dimethylxanthine 
    (theobromine- 12%)     (paraxanthine- 84%)             (theophylline- 4%) 
Figure 3.2: The major pathways for caffeine metabolism 
 
Each of these metabolic pathways involves the CYP450 isoenzymes, and the 3-N 
and 7-N demethylation pathways account for 88% of caffeine metabolism in 
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humans (Notarianni et al., 1995). Since enzyme CYP1A2 is responsible for the 3-
N demethylation of caffeine (Kalow & Tang, 1993; Notarianni et al., 1995), 
caffeine as a probe substrate has been used to assess CYP1A2 activity in both 
adults (Blanchard & Sawers, 1983) and children (Akinyinka et al., 2000; 
Cazeneuve et al., 1994; Fontana et al., 1998; Nakamura et al., 1998; Parker et 
al., 1994; Parker et al., 1997a; Parker et al., 1997b; Parker et al., 1998). 
3.3.2. The caffeine breath test (CBT) 
The CBT involves the oral administration of a non-radioactive stable isotope of 
caffeine (13C replacing the carbon atom on the methyl group attached to N-3 on 
caffeine). The structure of labelled caffeine is presented in Figure 3.3.  
 
Figure 3.3: Structure of 13C-labelled caffeine 
Structure adapted from Chem Spider website (Available on http://www.chemspider.com/Chemical-
Structure.2424.html; Accessed 25 April 2014) with kind permission of The Royal Society of Chemistry 2014 
 A stable isotope includes a non-radioactive atom of the same chemical 
element, which differs only in the number of neutrons, as there was an extra 
neutron (Pons & Rey, 1999). Stable isotopes occur naturally, and approximately 
1% of carbon occurs in the 13C form instead of the more prevalent 12C. Caffeine 
undergoes 3-N-demethylation in the liver in a CYP450-dependent reaction. After 
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N-demethylation, the 13C methyl group enters the carbon pool as it is converted 
to formaldehyde, formate, and bicarbonate (Lambert et al., 1983). The 
bicarbonate is exhaled as carbon dioxide (CO2). The exhaled 13CO2 correlates 
with CYP1A2 activity (Parker et al., 1994; Parker et al., 1997a; Parker et al., 
1997b; Parker et al., 1998). The CBT is non-invasive and suitable for use in 
young children and has been used to study the effects of disease states, 
including cystic fibrosis, gastritis, and epilepsy (Parker et al., 1994; Parker et al., 
1997b; Parker et al., 1998), and drug interactions in children.  
Studies using the CBT were first performed by Schoeller et al. (1977) in 
the United States during the 1970s. Schoeller et al. (1977) showed that the 
precision of the CO2 breath test using 13C is limited by natural fluctuations in the 
ratio of 13C:12C in the expired CO2. These natural fluctuations increase if the 
participant had eaten anything either immediately before or during the test. 
Therefore, Schoeller et al. (1977) made the following recommendations: 
x The patient should fast overnight before and during the test. If fasting were 
impossible, the carbohydrate intake should at least be as low as possible. 
x The patient should be physically inactive during the test, since activity affects 
endogenous CO2 production. 
x Serial respiratory CO2 samples should be collected prior to substrate 
administration to determine the presence of 13C. 
x The collection of CO2 should be carefully standardised to avoid variation in 
isotope content due to fractionation effects. 
There is an optimal correlation between the plasma clearance of caffeine in 
infants, older children, and adults and the cumulative excretion of 13CO2 at 2 h (r 
= 0.84±0.90) (Pons et al., 1988b). Studies involving CBT and using three 
different doses of caffeine (1, 3, 5 mg/kg) have shown that increasing the 
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caffeine dose beyond 3 mg/kg has no effect on CO2 excretion during the first 2 
to 3 h of the test (Kotake et al., 1982). The optimal dose of caffeine has, 
therefore, been identified as 3mg/kg, and this dose has been used in various 
CBT studies in children with no adverse effects (Akinyinka et al., 2000; Parker et 
al., 1994; Parker et al., 1997a; Parker et al., 1997b; Parker et al., 1998). 
CYP1A2 activity may be influenced by the age, sex, and sexual maturation 
of the patient (Lambert et al., 1986). Such activity was high in prepubertal 
children and subsequently decreased in either early puberty in females or late 
puberty in males. In their study of caffeine N-demethylation maturation in 
infants, Pons et al. (1988) showed that CYP1A2 activity is minimal in infants 
during their first month of life. The CL of caffeine in children reaches adult rates 
by the age of 6 months (Pons et al., 1988b). The effect of age has been 
addressed in previous studies of the CBT by studying children aged at least 2 
years (Parker et al., 1994; Parker et al., 1997a; Parker et al., 1997b; Parker et 
al., 1998). CBT studies in adults (Kalow & Tang, 1993) and children (Webster et 
al., 2002) have shown a significant inter-individual variation in CYP1A2 activity; 
however, no studies have used the CBT to evaluate genetic differences in such 
activity. A review of the use of caffeine as a probe has confirmed the validity of 
the CBT as a method for studying CYP1A2 activity (Kalow & Tang, 1993). 
 
3.4. CAFFEINE METABOLISM IN MALNOURISHED CHILDREN  
Previous studies have reported alterations in the CL of multi-enzymatic CYP450 
substrates in malnourished animals (Adelusi & Salako, 1982; Cho et al., 2001); 
human adults (Buchanan, 1984; Krishnaswamy & Naidu, 1977); and children 
(Buchanan et al., 1980a; Salako et al., 1989); all of these results suggest that 
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malnutrition may alter the activity of the drug-metabolising enzymes. Among 
the drugs metabolised in the liver by the CYP1A2 enzyme, total CLs were either 
significantly decreased (i.e., for caffeine and isoniazid) or their elimination half-
lives significantly increased (i.e., for paracetamol and phenobarbitone) in 
malnourished children (Oshikoya et al., 2010). These results suggest an 
alteration in the CYP1A2 metabolic activity in children with malnutrition.  
The pharmacokinetics of caffeine has also been studied in children with 
malaria and kwashiorkor to show that its oral absorption rate, measured as Cmax 
and tmax, was not significantly affected in children with malaria and kwashiorkor, 
though hepatic CL significantly decreased (Akinyinka et al., 2000). Paraxanthine 
is a metabolite of caffeine; its plasma level has been used to measure the 
CYP1A2 activity after caffeine administration (Akinyinka et al., 2000). The 
significantly decreased plasma levels of paraxanthine in children with malaria or 
kwashiorkor suggest a significantly decreased CYP1A2 activity in these patients. 
Therefore, alternative methods that generate paraxanthine or quantifiable by-
products during caffeine metabolism can be used to measure CYP1A2 activity in 
children with malnutrition.  
The activity of CYP1A2 can also be measured by using the production rate 
of caffeine metabolites through 3-N-demethylation as catalysed by CYP1A2. This 
alternative method is the CBT.  
It is important for studies involving the use of a probe substrate to 
examine the effects of malnutrition on drug metabolism in order to address the 
differential effects of marasmus and kwashiorkor on drug metabolism. To 
address this question, the present research devised a method to use the CBT in 
order to measure CYP1A2 activity and to determine the effects of underweight 
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malnutrition, marasmus, marasmic-kwashiorkor, and kwashiorkor on caffeine 
metabolism. 
 
3.5. TRAINING ON BREATH SAMPLE COLLECTION 
I undertook observational training on breath sample collection at the 
pathology clinic of the Royal Derby Hospital in Derby, U.K. The steps 
involved in breath sample collection are (i) positioning the bottle in the 
hands, (ii) removing the cap of the exetainer bottle, (iii) placing a straw 
at the end of the exetainer bottle, (iv) taking a full breath and exhaling 
through the straw directly into the tube, (v) withdrawing the straw from 
the exetainer bottle before the exhalation is complete, and (vi) screwing 
WKH FDS ³ILQJHU- WLJKW´ LPPHGLDWHO\ DIWHU LWV UHPRYDO IURP WKH H[HWDLQHU
bottle. 
The breath sample is collected in a specialised container called an 
Exetainer® vial. Breath samples were collected at 11 time points: -20, -10, -1, 
15, 30, 45, 60, 75, 90, 105, and 120 min post caffeine ingestion for each 
SDWLHQW 7KH SDWLHQW¶V QDPH RU ,' QXPEHU DQG GDWH RI VDPSOH FROOHFWLRQZHUH
recorded on the vials. Each breath sample was collected in duplicate, thus 
requiring the use of 22 vials per patient. 
A straw was placed in the participant¶VPRXWKZLWKWKHExetainer® vial at 
the lower end. The participant was instructed to take a full breath and exhale 
through the straw directly into the vial. It was ensured that the breath was not 
forced. ,PPHGLDWHO\ SULRU WR WKH H[KDODWLRQ¶V EHLQJ FRPSOHWHG Whe vial was 
drawn away from the straw and the vial cap was immediately screwed onto the 
vial until finger-tight. Overtightening the cap can deform the seal in the cap, 
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which may cause air leakage.  
 
3.6. TRAINING ON BREATH SAMPLE ANALYSIS 
Eight sets of the breath samples collected at the outpatient clinic during my 
training at the outpatient clinic were analysed at the Pathology Laboratory of the 
Royal Derby Hospital. The data generated from this observational study were 
intended only for training and thus excluded from this study. 
The 13C enrichment of breath 13CO2 was determined by a continuous flow 
isotopic ratio mass spectrometer (Sercon Automated Breath Carbon Analyser 
[ABCA-MK5]; Europa Scientific Inc., Crewe, UK). An ABCA-MK5 is an elemental 
analyser, in which samples of breath nitrogen, oxygen, and CO2 are separated 
prior to analysis. Exetainer® vials containing breath samples were arranged in a 
tube rack with the capacity to hold four sets of samples, which was placed in a 
tray attached to the machine. A set of eight samples was separated by two 
reference samples (5%CO2) previously calibrated against a bicarbonate standard 
of known 13C enrichment. Breath samples contained within the Exetainer® vials 
were sampled in a sequential order through a needle attached to the machine. 
Autosampling involves the machine¶V automatic injection of 500 µl aliquots of 
breath sample into its analyser, in which the breath¶V CO2 is dried via a water 
trap and resolved from nitrogen and oxygen by gas chromatography. Using 
helium as a carrier, the purified CO2 was passed into an electron impact ion 
source of the isotope ratio mass spectrometer.  
Following ionisation, the ion beams were separated according to their 
mass/charge (m/z) ratio into masses 44, 45, and 46 m/z and collected by triple 
collector Faraday cups. For each mass detected, the machine recorded an area 
proportional to the number of ions contained in real time. The machine 
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automatically calculated the drift correction between the two sets of references, 
and the drift correction was applied to calculate the excess atom per cent (AP) of 
the unknown breath sample. The results were obtained as AP, which represented 
the absolute 13C enrichment present in the sample. AP was automatically 
calculated by the software using the formula: A (atom %) = (Ratiosample / (1 + 
Ratiosample) × 100. The difference between the enrichments of the breath 
samples taken at baseline and plateau were expressed as atom per cent excess 
(APE). 
 
3.7. PILOT STUDY ON A HEALTHY ADULT VOLUNTEER 
A pilot study was conducted and involved a breath sample collection from an 
adult volunteer. The healthy male volunteer (30 years old, 66kg) was advised to 
cease eating from 19:00 hours on the night before the study XQWLO WKH VWXG\¶V
completion. The weight was measured on the day of the study using a Seca 
Scale (model 707; Seca Limited, Birmingham, UK); a standiometer was used to 
measure the height (Holtain, Crymych, UK). After fasting overnight, the 
participant ingested labeled caffeine solution (4mg/kg, dissolved in distilled 
water). Prior to the test, the participant abstained from caffeinated products for 
a period from 48 to 72 h, approximately. The participant neither smokes nor 
drinks alcohol. 
The participant ingested labelled caffeine at 09:00 hours and thereafter 
blew air via a straw into Exetainer® vials. Three breath samples, in duplicate, 
were collected before caffeine administration (pre-dose) at -20, -10, and -1 min. 
Serial breath samples were further collected after caffeine ingestion, in 
duplicate, at 15 min intervals over a period of 2 h. 
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A set of the samples was analysed at the Pathology Laboratory of Royal 
Derby Hospital (A), while the other set was analysed at the Clinical Physiology 
Laboratory at the Medical School in Derby (B). The results were compared. 
The samples were analysed in duplicate 2 to 4 d after collection using a 
continuous flow isotope ratio mass spectrometry (CF-IRMS), Sercon-Automated 
Breath Carbon Analyser (ABCA-MK5), and an AP2003 Mass Spectrometer at the 
Laboratories A and B, respectively. Results were generated for the 13C-
enrichment in delta notation. The mean pre-dose (baseline) enrichment was 
calculated by determining the mean of the enrichments in delta unit at -20, -10, 
and -1 min (Table 3.1). The mean 13C-enrichment was expressed as atom 
percent (At%) excess (APE) of 13C concentration excess by subtracting the mean 
pre-dose enrichment from each of the post-dose enrichments. Medical tracer 
studies of human physiology are usually reported in units of APE, which indicates 
the level of isotopic abundance above baseline. The baseline reading in At% was 
subtracted from the experimental value to give APE. 
Table 3.1: Variation in the mean 13C- enrichment of exhaled CO2 over a 2 hour period 
Time (minute) Mean13C-enrichment of exhaled CO2 (At 
%) 
Hospital Lab (A) 
Mean13C-enrichment of exhaled CO2 (At %) 
Medical School Lab (B) 
Baseline -24.68 -25.73 
15 -22.45 -22.93 
30 -22.27 -22.73 
45 -21.90 -22.39 
60 -21.77 -22.42 
75 -21.41 -22.56 
90 -21.24 -22.40 
105 -21.24 -22.40 
120 -21.32 -22.44 
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Table 3.2: Variation in the mean atom percent of [13C] excess in the exhaled CO2 over a 2 hour period 
Time (minute) Mean13C-enrichment of exhaled CO2 as At % 
[13C] excess (A) × 10-3 (APE) 
Mean13C-enrichment of exhaled CO2 as At % [
13C] 
excess (B) × 10-3 (APE) 
15 2.45 3.08 
30 2.65 3.30 
45 3.06 3.67 
60 3.20 3.64 
75 3.60 3.49 
90 3.78 3.66 
105 3.78 3.66 
120 3.70 3.62 
Mean± S.D  3.28± 0.52*  3.52± 0.21* 
*There was no significant difference in the mean values, P=0.115, using 2-tailed student t-test  
The 13C-enrichment varies with the time of breath sample collection (Table 
3.2). Figure 3.4 shows the time course of the 13C-enrichment in APE for the 
participant based on data from the two laboratories. The 13C-enrichment in the 
exhaled CO2 appeared rapidly, increased gradually, and peaked after 90 min. 
The curves were similar for both laboratories and typical of the time course 
reported in previous studies involving a healthy adult (Park et al., 2003). This 
suggests a rapid hepatic metabolism of caffeine by CYP1A2 in the participant. 
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Figure 3.4: Time courses of 13C-enrichment for a healthy adult subject 
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Abnormal inter- and intra-laboratory variability has been reported in 
tracer studies when the same breath sample was analysed in the same or a 
different laboratory (Perri et al., 2003). This variability may, however, affect the 
CBT results and lead to inappropriate clinical decisions. Although there was an 
inter-laboratory variability in the results from the two laboratories (A and B), as 
indicated by the mean 13C-enrichments for the participant ([3.28 ± 0.52] × 10-3 
APE versus [3.52 ± 0.21] × 10-3 APE, respectively), there was no statistically 
significant difference in the 13C-enrichment values (p = 0.115) using a two-tailed 
Student¶V t-test.  
 
3.8. SETTING 
Malnourished children were recruited from Lagos and Kano, Nigeria. As for the 
first, Lagos is the smallest but most populous state in Nigeria and, according to 
the 2006 national census, has an estimated population of 17.5 million (Lagos 
State Government, 2010). It consists of five administrative divisions: Lagos 
Island, Ikorodu, Badagry, Ikeja, and Epe. Two teaching hospitals²the Lagos 
University Teaching Hospital (LUTH) and Lagos State University Teaching 
Hospital (LASUTH)²and many general hospitals serve the people of Lagos. 
Children were specifically recruited from four paediatric centres in Lagos: 
LASUTH; 0DVVH\ 6WUHHW &KLOGUHQ¶V +RVSLWDO; General Hospital, Ikorodu; and 
General Hospital, Gbagada. As for the second, Kano is one of the largest and 
most densely populated Nigerian states. It hosts several general hospitals and 
two tertiary hospitals: Aminu Kano Teaching Hospital (AKTH) and Murtala 
Mohammed Specialist Hospital. Malnutrition is rife in Northern Nigeria, 
particularly in Kano. In order to meet the sample size required for this study, 
additional patients were recruited from AKTH. 
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3.9. MANAGEMENT OF MALNUTRITION IN LAGOS AND KANO 
STATES IN NIGERIA  
Children with PEM were managed at all the paediatric centres used in this study 
according to the 10 steps recommended by the World Health Organization 
(WHO) (Ashworth et al., 2004). PEM was diagnosed on the basis of patient 
history, findings from physical examination, and laboratory investigations. 
Anthropometric measurements (weight and height) and the presence or absence 
of oedema were used to classify the patients into different categories of 
malnutrition according to the Wellcome Trust Working Party (WTWP) 
classification. 
Underweight children (i.e., with mild to moderate PEM) were recruited 
from the outpatient clinics among children who presented features of acute 
uncomplicated malaria. They were treated for malaria with artemisinin-based 
combination therapy and nutritionally managed at home by their parents, as well 
as followed up by their doctors at the outpatient clinic. The severely 
malnourished children (i.e., with kwashiorkor, marasmic-kwashiorkor, and 
marasmus) were admitted for specialised hospital ward management. 
3.9.1. Acute management  
Upon admission, severely malnourished children were routinely investigated for 
full blood count (FBC); genotype; random blood sugar (RBS); serum protein 
(total and albumin); electrolyte, urea, and creatinine (EUCr); blood culture; stool 
for ova and parasites; as well as by urinalysis, chest radiograph, and HIV 
screening. These investigations enabled the doctors to identify the clinical 
complications and diseases coexisting with PEM. The investigations were 
followed by empirical treatment with broad spectrum intravenous antibiotics 
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(amoxicillin/gentamicin, cefuroxime/gentamicin, or any of the third generation 
cephalosporins). The choice of antibiotics was informed by the clinical 
presentation of the patients and the high resistance to ampicillin and 
chloramphenicol currently experienced in Nigeria.  
 Due to the high prevalence of parasitic infestation in Nigeria, patients 
were frequently treated prophylactically with broad spectrum oral 
antihelminthics, specifically mebendazole.  
Patients with poor appetite were passed a nasogastric tube for small and 
frequent feeds, usually every 2 or 3 h. The diet was made by the hospital 
nutritionist from pap derived from locally processed maize or guinea corn. The 
pap was usually fortified with dairy milk, soybeans, dried fish, crayfish, 
groundnut and palm oil DGLHWUHIHUUHGWRDVµkwashi SDS¶ 
Potassium and micronutrient supplements (vitamin A and trace elements 
including copper, zinc, selenium, and manganese) were routinely administered 
orally to patients after feeds. All of these compounds were contained in the 
Astymin® supplement, which was routinely prescribed to the patients.  
3.9.2. Nutritional rehabilitation 
After becoming clinically stable, those patients on nasogastric (NG) tubes were 
initially weaned off of the NG tube and continued oral feeding with a kwashi pap. 
A week later, they were weaned on adult feeds. All patients were weighed twice 
weekly at regular intervals and their heights checked weekly in order to monitor 
their growth. Adult feeds were rich in high calories and protein and were offered 
daily in increasing amounts. As the clinical condition of the patients improved, 
their appetites increased and necessitated a further increase in protein and 
calorie intake, both of which enabled them to approach normal growth patterns. 
The duration of hospital admission varied with each patient and the 
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severity of malnutrition. Patients were hospitalised and rehabilitated nutritionally 
for an average of 1 month. Thereafter, they were discharged after: (i) exhibiting 
an excellent appetite; (ii) consistently gaining weight corresponding to height 
increases; and (iii) attaining a weight-for-age ±3 SD of the WHO child growth 
chart standards, for which the cut-off point for malnutrition is weight-for-age 
below -3 SD) (de Onis et al., 2007; WHO, 2006). 
Vulnerable patients whose parents were incapable of taking good care of 
them after discharge were referred by the attending doctor to a welfare home 
where they would receive support and care from the government. This group of 
patients were excluded from the study. 
3.9.3. Follow-up 
Nutritional rehabilitation continued at home after discharge and after the 
nutritionist had taught the FKLOGUHQ¶V mothers the most ideal and hygienic ways 
to prepare WKH FKLOG¶V GLHW $OO SDWLHQWV ZHUH IROORZHG XS DW KRPH DQG DW WKH
outpatient clinic by me. During this period, their heights, weights, and physical 
examinations were routinely checked as indicators of normal growth and well-
being. Any of the patients that took ill during follow-up were evaluated and 
treated accordingly by the attending doctors. 
 
3.10. PATIENT RECRUITMENT  
Malnutrition was defined in the patients according to the WTWP classification. 
Altogether, 60 patients between aged from 3 to12 years who were underweight 
and/or experiencing marasmus, kwashiorkor, or marasmic-kwashiorkor were 
recruited. There were 15 patients in each group of malnutrition. The study 
population was determined from a power calculation based on previous CBT 
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studies in children (see section 3.16 on statistical analysis). PEM children in the 
above age range were used for the study given their ability to follow the 
instructions for each step involved in breath sample collection. Moreover, a 
similar age group was studied in previous studies of CBT involving children 
(Parker et al., 1994; Parker et al., 1997a; Parker et al., 1997b; Parker et al., 
1998).  
Patients with severe PEM (marasmus, kwashiorkor, or marasmic-
kwashiorkor) were studied upon admission and during the first week of 
commencing treatments, so as to allow a recordable improvement in their 
conditions. Children with kwashiorkor were studied after oedema had subsided, 
since oedema may exaggerate the actual weight of the patients. The 
malnourished children also were re-studied after 4 to 8 weeks of nutritional 
rehabilitation. Underweight children were studied as outpatients.  
The clinical signs and laboratory findings of infection are usually masked 
in PEM; therefore, underweight patients were given oral amoxicillin while other 
patients with severe PEM received intravenous amoxicillin and gentamicin upon 
admission for 5 days. This is a standard empiric antibiotic therapy frequently 
used in Lagos and Kano for treating PEM. 
 
3.11. STUDY DESIGN 
Parents who consented to their child¶V participation in the study or older children 
who gave their assent were informed about the study procedure, which lasted 2 
to 3 h. Parents and older participants were additionally informed that the usual 
diet would be replaced with Casilan-90® during these hours. Parents were 
requested to keep their child in bed before and during the study in order to 
105 
 
minimise physical activity. Parents had the option of withdrawing their child at 
any stage of the procedure. 
The SDUWLFLSDQWV¶demographic and anthropometric parameters, including 
age, weight and height, were recorded during the first presentation for the study 
and during follow-up for restudy. All participants abstained from caffeinated 
products, including cola drinks, chocolate, and herbal medicines containing cola, 
for at least 20 h (overnight). Ideally, participants would fast for at least 4 h prior 
to the CBT procedure. This is, however, ethically unacceptable for children with 
PEM; therefore, all children received Casilan-90® 0.5 h prior to the study. 
Casilan-90® is a bland, high-quality protein powder derived from milk. It is very 
low in fat and carbohydrates (both less than 1%) (BNF for Children, 2006). It 
contains no added sugar, artificial sweeteners, colours, flavours, or 
preservatives, making it an ideal supplement to many drinks and foods to boost 
the protein content without altering the flavour. 
Underweight participants were studied as outpatients, but since severely 
malnourished participants required initial hospital admission for acute 
management, they were studied as inpatients when clinically stable. The stages 
of severe PEM management and the timing of CBT are presented in a flow chart 
in Figure 3.5.  
An appointment was given to each patient for 08:00 hours on different 
days between Mondays and Fridays. Participants fasted overnight (i.e., ate no 
additional food after a light protein diet for supper) and did not consume 
anything orally on the appointment day. On the day of the study, each 
participant was attended to in a private consulting room in the presence of the 
parents, if any. Body weight was measured (to 0.1kg) using a digital Seca scale 
(model 876, Seca Ltd., Birmingham, UK) as participants wore only underpants. 
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Height was measured (to within 1mm) using a Holtain stadiometer (Holtain, 
Crymych, UK) as the participants stood barefoot. Vital signs, including blood 
pressure, heart and respiratory rates, and temperature, were recorded and 
monitored throughout the study. 
Study stage              Time of study  
A child with PEM (3-12 years) who 
presented to any of the selected  
hospitals in Lagos or Kano      0 hours 
 
Resuscitation and early nutritional 
rehabilitation        24 hours 
 
 
Parents approached for consent 
 
 
CBT performed while malnourished     7 days 
 
 
Further nutritional rehabilitation 
 
 
Repeat CBT after a significant  
weight gain        6 weeks 
 
Figure 3.5: Flow chart for the stages of PEM management and time of study 
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Casilan-90® was administered to each participant 0.5 h prior to caffeine 
administration, according to the Recommended Dietary Allowance (RDA) 
(children 3 to 6 years old: [90 kcal × kg-1]; children 7 to 10 years old: [70 kcal 
× kg-1]) (National Research Council, 1989).  
 Participants sat quietly for 0.5 h before and throughout the CBT in order 
to minimise physical activity, which can influence endogenous CO2 production 
and affect CBT results. At 09:00 hours, participants ingested 3 mg/kg of [3-
methyl-13C] caffeine (99% 13C) obtained in powder form from Cambridge Isotope 
Laboratories (Cambridge, MA, USA). 
Caffeine quantity was determined using an electronic sensitive balance 
(Ohaus Pioneer Analytical and Precision balance; Ohaus Corporation, Pine brook, 
NJ, USA). Each sample of caffeine was dissolved in 10 mL of sterile water and 
mixed with sugar-free squash to mask its bitter taste and followed by a 20 mL 
water wash of the container. The quantity of caffeine consumed was 
approximately equivalent to the amount present in cola drinks.  
Paired breath samples were collected during normal expiration at -20, -
10, and -1 min prior to caffeine (pre-dose samples) and after caffeine ingestion 
(post-dose samples) at 15 min intervals over a period of 2 h. Breath samples 
were collected by having each participant blow via a straw into an Exetainer® 
vial. Participants were observed for signs of caffeine toxicity with a detailed 
symptom assessment, while blood pressure and respiratory and heart rates were 
monitored every 0.5 h during testing.  
Participants were restudied after nutritional rehabilitation and attainment 
of weight-for-age and weight-for-height Z-scores ±3 SD of the WHO child 
growth chart standards (de Onis et al., 2007; WHO Multicentre Growth 
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Reference Study Group, 2006). Caffeine administration and breath sample 
collection during the restudy phase adhered to the aforementioned protocol.  
Breath samples were couriered in batches to the Clinical Physiology 
Laboratory of the Medical School in Derby, University of Nottingham, for 
analysis. 
3.11.1. Inclusion criteria 
x Children aged from 3 to 12 years; 
x Expression of any of the 3 categories of PEM in a stable clinical condition; 
x Informed consent of the participant and/RUSDUWLFLSDQW¶VSDUHQWV 
3.11.2. Exclusion criteria 
x Clinical or investigational evidence of tachypnoea, heart failure, 
overwhelming sepsis, shock, prolonged diarrhoea, and/or vomiting (as 
recorded during routine medical examination or as documented in the case 
file of the patient); 
x HIV infection; 
x Underlying respiratory, cardiovascular, renal, gastrointestinal, or central 
nervous system disease; 
x Use of ventilation support; 
x Cerebral palsy, visual or hearing impairment, or other severe complications; 
x 7KH SDUWLFLSDQW¶V RU WKH SDUWLFLSDQW¶V SDUHQW¶V XQZLOOLQJQHVV WR SURYLGH
consent. 
3.11.3. Withdrawal criteria 
x Failure to gain weight-for-age of ±2 SD after 6 weeks of nutritional 
rehabilitation; 
x Deliberate withdrDZDO HLWKHU E\ WKH SDUWLFLSDQW RU WKH SDUWLFLSDQW¶V SDUHQW 
after WKHSDUWLFLSDQW¶Vbeing studied in the acute phase of PEM management.  
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3.12. ETHICAL CONSIDERATIONS 
The study protocol was approved by appropriate ethics committees at the Lagos 
State Health Service Commission (the body in charge of the management of all 
the General hospitals in Lagos), Lagos State University Teaching Hospital, and 
Aminu Kano Teaching Hospital (see Appendices I±III). All parents of the 
participants received both oral and written information about the study (see 
appendix IV) and were requested to give their written informed consent (see 
appendix V) before their child participated in the study. Older children were 
requested to give their assent (see appendix VI) in addition to the informed 
consent of their parents. 
 
3.13. ANALYTICAL PROCEDURE 
3.13.1. Validation of the stability and reliability of the breath samples 
A preliminary analysis of the breath samples from 10 underweight children was 
performed at the Clinical Physiology Laboratory by the laboratory manager. This 
analysis involved the use of analytical precision continuous flow isotopic ratio 
mass spectrometer (AP2003 CF-IRMS; Analytical Precision Products Ltd., 
Cambridge, UK). A detailed description of the machine is provided in section 
3.13.2.1. Data generated from the preliminary analysis were excluded from the 
final data analysis. The purpose of the preliminary analysis was to check for the 
stability and reliability of the breath samples. This analysis showed that four of 
the underweight children had taken either food or caffeinated products prior to 
the study. This was suggested by the excessively high AP dose of labelled 
caffeine determined by the breath samples. It was, however, confirmed from the 
four children affected that they had ingested something prior to the study. This 
therefore informed the decision to admit the underweight children to the hospital 
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24 h prior to the study, which enabled their intake to be monitored and ensured 
that they fasted overnight. 
3.13.2. Proper sample analysis 
All the samples for the study were analysed at the Clinical Physiology Laboratory 
at the Medical School in Derby by using the AP2003 CF-IRMS, which has both 
software and hardware components similar to those of the Sercon Automated 
Breath Carbon Analyser used to analyse the samples during the pilot study. 
Their modes of operation are also similar.  
3.13.2.1. The breath analyser 
The AP2003 CR-IRMS analysed the breath CO2 isotopically. Its main features are 
shown in Figure 3.6.  
 
Figure 3.6: The Breath analyser system 
It is composed of the mass spectrometer, in which ionisation occurs; the sample 
preparation module, in which CO2 is separated from the other constituents of 
whole breath; the autosampler, onto which the breath sample tubes are 
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positioned; and the data system, which controls the entire system. 
3.13.2.2. Tests prior to running samples 
Two important pre-programmed tests (i.e., peak centre and stability tests) were 
routinely performed before running the samples. These two tests ensured that 
the mass spectrometer was both working to specifications and stable. Running 
the peak centre scan yielded the curve shown in Figure 3.7.  
       
Figure 3.7: Peak centre scan recording 
A normal curve shows an approximately symmetrical peak and a flat portion 
occurring for at least 4 V. The height of the plateau should be approximately 2-
6E-11 A, and the vertical cursor should position itself close to the centre of the 
peak. If any of these conditions were not fulfilled, the help of the laboratory 
manager was sought. This check was performed at the start of every batch 
analysis and repeated after every 24 sample analyses during a batch analysis. 
The stability of the instrument was also tested after every 60 sample analyses. 
A stability test was initiated after a satisfactory peak centre scan test. Ten 
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pulses of reference gas were injected into the mass spectrometer, which later 
appeared as 10 rectangular peaks equally spaced across the acquisition window 
as shown in Figure 3.8. This test was performed at the start of every batch 
analysis. A normal result showed 10 pulses that were rectangular with flat tops, 
all of the same height, each approximately 5E-9 A. The SD of the ratio of the 
delta values for the two reference gases was automatically calculated by the 
software. A normal value is usually less than 1E-6. If either of these two 
conditions was not fully met, the help of the laboratory manager was sought. 
        
Figure 3.8: Stability test recording 
3.13.2.3. Quality control 
The machine runs predetermined peak centring and stability checks to optimise 
analytical parameters to allow large batches of samples to be run without any 
need for constant monitoring of the instrument. Any fault during an analysis is 
detected and, since the software either rectifies the fault if it is of a simple 
nature or aborts the analysis, any wastage of samples is prevented. There was 
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an additional complete check of the quality of the results throughout the analysis 
of a batch of samples, thus ensuring their validity. The quality control 
parameters were defined at the same time each batch was created and were 
saved with both all other details of each particular batch and the results for the 
analysis of samples. 
The full quality report was checked at the end of every batch analysis or 
at any necessary time. A sample was declared µEDG¶ if the height of the CO2 peak 
was below the threshold specified in the file for the integration of the peak. This 
height was normally set to 1E-9 A for the major ion beam. If this situation 
occurs, the software indicates such with the message µNo sample peak found¶. 
This can occur for a number of reasons, which may not necessarily be due to a 
system malfunction. Possible causes include no tube loaded in the particular 
autosampler hole, an improperly filled tube, an empty tube, and the repeated 
analysis of a tube sample. If three consecutive tubes were µbad¶, the 
malfunctioning instrument was suspected and the run was automatically 
aborted. 
3.13.2.4. End of batch summary 
The batch summary was printed automatically for every batch. It provided a 
sequential list of samples; their data file names, their names, their IDs, their 
positions, and results. The list was in the order that the samples were analysed. 
Results from the batch summary included the pre-dose (baseline) and post-dose 
13C enrichments in AP. 
3.13.2.5. Aliquot sampling of whole breath from an Exetainer® vial  
After the routine running tests, the needle was automatically driven down into 
the Exetainer® vial. The vial was exposed to the pressure set on the sample tube 
pressure regulator (PR), thus equilibrating with this pressure. After the 
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pressurisation period, the breath aliquot passed through a water removal device 
before entering the sample loop. The standard loop size fitted to the system in 
the sample preparation module has a volume of 120 Pl. Correct filling of the 
sample loop was essential; if partially filled, there may have been an error in the 
isotopic measurement. The sample loop was constructed of a semi-permeable 
membrane, which allowed water to pass from the wet gas stream inside the 
conduit to the outer surface of the membrane, from where it was carried by a 
dry stream of helium to another vent. The dry breath sample trapped within the 
volume of the sample loop flowed toward the short chromatography column 
(GC), which was maintained at room temperature. In the GC, CO2 was separated 
from O2 and N2, both of which eluted together before the CO2 gas peak. 
A small amount of pre-calibrated CO2 was delivered into the effluent of a 
column and moved downstream of the column. A pulse of reference gas was 
injected in this manner within each sample analysis a short time after the 
passage of the sample CO2. The delta value of the sample CO2 was calculated in 
comparison to the reference gas pulse. The amount of CO2 gas delivered to the 
column effluent depended on the pressure set at the pressure regulator. 
Breath samples were run in batches, initially in a single run, which allowed 
any saturated breath samples to be identified. Saturated breath samples refer to 
breath samples with excess CO2 saturating the detector and yielding incorrect 
isotopic ratios. These breath samples were de-saturated by withdrawing 1 mL to 
3 mL of air from the vial with a hypodermic needle connected to a syringe by a 
two-way valve. Batches of the unsaturated breath samples were then re-run in 
duplicate to improve data accuracy. 
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3.14. PRELIMINARY CHECK FOR STABILITY OF THE BREATH 
SAMPLES IN NIGERIA 
The high temperatures in Nigeria require that biological samples be stored by 
refrigerating, freezing, or using liquid nitrogen. Although previous studies of CBT 
have indicated that breath samples are stable at room temperature in developed 
countries (Webster et al., 2002), no such data is available for developing 
countries. It was therefore necessary to perform a preliminary analysis of the 
breath samples to check for their stability in Nigeria. 
Four underweight children, who were excluded from the main study, were 
studied on two occasions at 1 week intervals. Participants were studied 
according to the protocol of the main study (see section 3.11). Breath samples 
were collected from each participant in duplicate and kept on an open shelf for 6 
weeks before being transported to the U.K for preliminary analysis. Breath 
samples were analysed by the laboratory manager, a senior research fellow in 
clinical physiology, at the Clinical Physiology Laboratory at the Medical School in 
Derby within the University of Nottingham. The breath samples were analysed 
immediately upon arriving in the U.K., as per the analytical procedure outlined in 
section 3.13.  
CBT results for these four participants are presented in Table 3.2. There 
was no significance difference in the results of the CBT for each participant when 
compared to the samples collected at a 1 week interval (participant I: p = 
0.0030; participant II: p = 0.0002; participant III: p = 0.0078; and participant 
IV: p = 0.0009) using SWXGHQW¶Vt-test statistics. These results suggest that the 
breath samples for each participant were stable over the 6 weeks of open shelf 
storage in Nigeria. 
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Table 3.3: Variation in the mean 13C- enrichment of exhaled CO2 over a 2 hour period by 
underweight children 
Time 
(minute) 
Mean13C-enrichment of exhaled CO2 (At %) 
Subject I             
Age: 7.25 years        
weight: 20kg         
Height: 119 cm        
Subject II             
Age: 5 years           
weight: 18kg         
Height: 105 cm        
Subject III            
Age: 3.5 years         
weight: 11 kg           
Height: 99cm         
Subject IV           
Age: 4.2 years         
weight: 15kg         
Height: 108 cm        
A B A B A B A B 
Baseline -24.68 -24.73 -22.31 -22.52 -24.68 -23.74 -23.84 -23.42 
15 -22.45 -23.45 -22.43 -22.82 -20.49 -20.86 -19.76 -21.72 
30 -22.27 -22.73 -22.33 -22.14 -19.36 -19.75 -17.39 -21.13 
45 -21.90 -22.09 -19.15 -18.43 -19.12 -19.15 -18.86 -19.13 
60 -21.77 -21.42 -18.06 -19.06 -19.87 -18.39 -19.11 -17.47 
75 -21.41 -21.56 -18.44 -18.13 -19.64 -18.46 -17.47 -19.84 
90 -21.24 -21.04 -17.50 -18.35 -19.04  -20.21 -18.33 -19.24 
105 -21.24 -21.40 -17.37 -17.51 -20.13 -19.09 -19.29 -18.42 
120 -21.32 -21.08 -16.21 -17.17 -20.42 -20.51 -17.36 -19.13 
P- value 0.352 0.234 0.365 0.157 
A represents first breath test, B represents the second breath test conducted a week later; results of A and B 
ZHUHFRPSDUHGXVLQJVWXGHQW¶VSDLUHGt-test 
 
3.15. MATHEMATICAL CALCULATIONS AND ASSUMPTIONS 
The 13C enrichment of exhaled CO2 was expressed in AP. The results were 
expressed as 13C APE (i.e., each of the post-dose enrichments minus the mean 
pre-dose enrichment). A cumulative 13CO2 output was calculated from the 
measured 13C APE from the eight breath samples taken during the first 2 h 
following intake of 13C caffeine multiplied by the mean CO2 output over the 
period (assumed to be 300 mmol / body surface area [BSA] × time [h]) 
(Haycock et al., 1978; Shreeve et al., 1970). The value obtained was expressed 
as a percentage of the caffeine dose. 
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3.16. STATISTICAL ANALYSIS 
6WXGHQW¶VSDLUHGt-test at a significance level of p < 0.05 was used to compare 
data obtained from each participant group both when malnourished and after 
nutritional rehabilitation. The results of mean percentage of labelled caffeine 
exhaled as 13CO2 both before and after nutritional rehabilitation for children with 
marasmus, marasmic-kwashiorkor, and kwashiorkor were compared using 
repeated measures ANOVA at a significance level of p < 0.05. Post hoc 
comparisons, using Tukey¶V WHVW, were performed if the ANOVA test yielded no 
significant difference in the mean percentage of labelled-caffeine exhaled as 
13CO2 both before and after nutritional rehabilitation for all groups of 
malnutrition. A sample size of 15 patients per group of PEM has a power of 90%, 
assuming a difference of 2% in the mean ±SD score of the 2 h percentage of 
cumulative 13C from the baseline to 3 to 6 weeks after nutritional rehabilitation 
to be significant at the 5% level (Parker et al., 1997a). A 5% withdrawal 
assumption was made to calculate the population size. 
 
3.17. CONCLUSION 
This study aimed to determine the effects of different types of malnutrition on 
drug metabolism by conducting four CBT studies in underweight children and 
those with marasmus, marasmic-kwashiorkor, and kwashiorkor. The main 
outcomes measured were the mean percentage of labelled caffeine exhaled as 
13CO2 both before and after nutritional rehabilitation in each group of 
malnourished children. The level of significance differences between the mean 
values both before and after nutritional rehabilitation were compared using a 
Student¶V t-test and ANOVA and followed by 7XNH\¶V post hoc test.  
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CHAPTER FOUR:  
THE CHALLENGES OF CONDUCTING PAEDIATRIC 
CLINICAL PHARMACOLOGY RESEARCH IN NIGERIA 
4.1. INTRODUCTION 
Paediatric clinical pharmacology research in Nigeria has been infrequent due to 
the lack of formal training in this specialisation. The few publications in this 
specialisation emanating from Nigeria focus on clinical trials and the 
pharmacoepidemiology of antimalarial drugs (Ayede et al., 2010; Gbotosho et 
al., 2011; Salako et al., 1989; Walker et al., 1987).  
The primary goal of paediatric clinical pharmacology is to advance the 
clinical use of medicines in children (Hoppu & Kearns, 2013). To improve the use 
of medicines in children with malnutrition, I conducted a study of drug 
metabolism in malnourished children using the caffeine breath test (CBT). 
Previous studies involving the use of CBT to evaluate drug±drug interactions in 
children to determine the effect of disease on drug metabolism and to assess the 
developmental changes in CYP1A2 activity were conducted in high-income 
countries (Levitsky et al., 1989; Parker et al., 1994; Pons et al., 1988b). This 
trend derives from the high cost of the stable isotope (Webster et al., 2002). 
The literature on the challenges of conducting clinical pharmacology 
research in developing countries focuses mostly on the ethics of clinical trials. 
Such challenges include delays in obtaining ethical approval for studies 
(Mbuagbaw et al., 2011), difficulties in obtaining informed consent from 
participants (Chaisson et al., 2011), an inability to recruit the required number 
of participants (Alem & Kebede, 2003), a lack of human resources, and 
inadequate funding (Mbuagbaw et al., 2011). In the present research, many 
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challenges were encountered, most of which related to poverty and illiteracy. 
Despite the challenges, this non-invasive study was well received by parents and 
paediatricians. 
The challenges and benefits faced during the study are highlighted in 
Table 4.1 and followed by a brief discussion.  
Table 4.1: The challenges and prospects of conducting clinical paediatric pharmacology 
research in Nigeria 
Challenges 
Economy and political instability 
Delay in getting ethical approval from the institutional review board or ethics 
committee 
Gender dominance of fathers in consenting to child participating in a clinical research 
Lack of parental awareness of non-invasive studies involving the use of caffeine 
breath test in children 
Lack of nutritional rehabilitation centres in the local communities 
Inadequate manpower and infrastructures 
Poverty and financial incapacitation of the parents 
Non-compliance to the research protocol, especially feeding and fasting instructions 
Lateness in keeping appointments 
High cost of clinical research 
Prospects 
Acceptability of the caffeine breath test to the children and their parents 
Opportunity to collaborate and network with local researchers 
Safety of the breath samples collected without requiring a special storage system 
and/or electricity 
 
4.2. CHALLENGES 
Prior to commencing the study, I collaborated with paediatricians in the study 
centres to identify the challenges and to offer solutions in order to ensure the 
successful conduct of the research in Nigeria. Many of the challenges are 
characteristic of all resource-poor countries and include economic and political 
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instability, delays in obtaining research ethical approval, difficulties in obtaining 
LQIRUPHGFRQVHQWSDUWLFLSDQWV¶ODFNRINQRZOHGJHRIFOLQLFDOUHVHDUFKLQDGHTXDWH
manpower, poverty, difficulties in following research instructions, and the high 
cost of research. Other challenges, such as lack of centres for nutritional 
rehabilitation and tardiness in keeping appointments, are peculiar to Nigeria. 
4.2.1. Delays in obtaining ethical clearance 
The process of obtaining ethical clearance involved an initial submission of a 
research proposal to each of the hospitals in October 2010. Unfortunately, the 
study received ethical approval only five months later in Lagos and seven 
months later in Kano. Delays in obtaining ethical approval in Lagos mainly 
derived from bureaucratic slowness and elaborate procedures involved in the 
review processes. By contrast, the lack of an expert in clinical pharmacology at 
Aminu Kano University Teaching Hospital (AKTH) who could assess the proposal 
was responsible for a delay in obtaining ethical approval. It was implied by the 
secretary of the ethics committee that an expert of clinical pharmacology from 
another institution had been contacted to assess the proposal.  
Alem and Kebede (2002) identified bureaucratic slowness and delays in 
obtaining the approval of national and institutional research protocol review 
committees as a major challenge facing researchers in Ethiopia. Delays in 
obtaining ethical approval not only frustrate many local researchers but also 
discourage many foreign sponsors from supporting studies in resource-poor 
countries (Alem & Kebede, 2002; Olopade et al., 2012). In some developing 
countries, the structures and procedures for ethical review of a research 
proposal may be lacking or underdeveloped due to a lack of appropriately 
trained personnel and financial resources. This lack may complicate obtaining an 
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appropriate or valid ethical review of proposals for clinical research in some 
resource-poor countries (Nuffield Council on Bioethics, 1999).  
Lack of experts in clinical pharmacology at AKTH, therefore, underscores 
the need for training in paediatric clinical pharmacology in Nigeria and other 
African countries, which has long been advocated by the World Health 
Organization (WHO) and experts in paediatric clinical pharmacology in both 
North America and Europe (Hoppu, 2011). Training in this specialty will hopefully 
improve and hasten the assessment of future research proposals for paediatric 
clinical pharmacology for ethical consideration in Nigeria. 
4.2.2 Economic and political instability 
Rising poverty, decay in public utilities and infrastructures, social tensions, 
political turmoil, and ethnic conflicts and violence have resulted in economic and 
political instability in Nigeria (Fagbadebo, 2007). Collecting breath samples 
earmarked for September 2010 proved infeasible, due to the coincidence of a 
doctors' strike in public hospitals in Lagos. The doctors demanded improved 
healthcare facilities in all general hospitals in the state, as well as the full 
implementation of the new salary structure approved by the Nigerian 
government (Nigerian Tribune, 2011). Unfortunately, the strike lasted 6 months 
and ceased only by March 2011. The breath sample collections would have 
otherwise been completed during this period, had the General Hospitals in Lagos 
been in operation. However, the study was unavoidably extended by 1 year, 
which resulted in additional research costs. 
In January 2012, Nigeria experienced a national strike of all workforces 
due to an abrupt increase in the pump price of petrol by the Nigerian 
government in an effort to hasten the deregulation of the petroleum sector (BBC 
News Africa, 2012). The strike coincided with the finalisation of research in 
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Nigeria and the dispatch of the breath samples to the U.K by courier. The flight 
schedules were frequently changed due to the strike and affected my return 
date, as well as prevented the timely arrival of the samples in the U.K., which 
consequently delayed the analysis of the breath samples there. 
Although industrial strikes are common worldwide, they are more common 
in resource-poor countries, since general strikes are the only means by which 
workers express dissatisfaction with their working conditions in order to achieve 
their goals (Dhai et al., 2011). Similar factors, including civil unrest, incessant 
and protracted industrial strikes, and incessant power outages, have been 
recognised as a few of the key challenges affecting the successful conduct of 
foreign-sponsored clinical research in resource-poor countries (Olopade et al., 
2012) 
Considering these unforeseen circumstances, future clinical paediatric 
pharmacology research requiring collaboration between high- and low- or 
medium-income countries, particularly Nigeria, should allow for extra funding 
and time to accomplish their studies. 
4.2.3 Patriarchal dominance in granting consent 
Men in many parts of African countries exercise power over women. Men make 
decisions on behalf of women or revoke their decisions in matters that affect the 
family (Sen et al., 2007). Often, only the mothers were available to care for 
their children during hospital admissions. In the present research, the mothers 
initially signed 42 (70%) of the 60 informed consent forms. Of the 42 consent 
forms signed by the mothers, the fathers challenged (20; 48%) and revoked (5; 
12%) a significant number of the consent forms. Consequently, at the early 
stages of the study, five patients withdrew and were replaced by another five 
patients. The dates for sample collections repeatedly changed for eight children 
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due to a conflict of ideas between the parents. In two cases, a family feud 
ensued between the parents and resulted in their spousal separation, thus 
complicating follow-ups with the affected children during nutritional 
rehabilitation. It is therefore necessary for researchers to be aware of the 
tension that may arise in families in obtaining DSRVVLEOHSDUWLFLSDQW¶VSDUHQW¶V
consent to be included in clinical research studies. 
The autonomy of an individual to consent to participating in a clinical 
research study may not be present in some developing countries due to the 
cultural and social structures of their communities (Nuffield Council on Bioethics, 
1999). In such communities, an individual is seen as belonging to a family or a 
community and therefore must meet with the elders, their parents, or other 
children in the community before consenting to any clinical research or medical 
treatment (Frimpong±Mansoh, 2008; Nuffield Council on Bioethics, 1999). The 
present data are in agreement with the report of Marshall et al. (2006), who 
observed that women often obtain the consent of their husbands before they or 
their children participate in a clinical research study (Hyder et al., 2004). This 
stands in contrast to the practice of developed countries, where mothers are 
considered capable of providing consent for themselves and their children (Hyder 
& Wali, 2006).  
A strategy adopted to overcome the problem of informed consent was to 
LQIRUPERWKSDUHQWVRUWKHPRWKHUDQGDQ\RIWKHIDWKHU¶Vrelations, about the 
study, as well as to ensure that one of the parents signed the consent form. Of 
the 60 children involved in the study, the fathers (23, 38.3%), mothers (29, 
RUERWKSDUHQWVDQGWKHIDWKHU¶VUHODWLRQVLJQHGWKHFRQVHQW
form. 
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4.2.4. Lack of parental awareness of non-invasive studies  
The concept of CBT is new in Nigeria, and none of the parents approached for 
consent had either heard about CBT or seen it performed on adults or children. 
Therefore, parents were sceptical about the nature of the research, despite 
being provided with a detailed explanation of the procedure. The level of 
understanding of the study by sceptical parents was poor due to their low 
literacy levels. 
In sub-Saharan African countries, over 21 million adolescents had dropped 
out of school in 2007, and only 34% of the secondary school age group were 
enrolled; this was thus the lowest enrolment ratio in the world (Education for All 
Global Monitoring Report, 2010). It also has been reported that about 38% of 
the adult population in sub-Saharan Africa (i.e., 153 million adults) lack the 
basic literacy and numeracy skills required for everyday activities; over 60% of 
these illiterate adults were women (Education for All Global Monitoring Report, 
2010). Nigeria is among the top 10 countries in the world with the highest levels 
of adult illiteracy (Education for All Global Monitoring Report, 2010). 
Assessments of informed consent comprehension in previous clinical trials have 
shown that many participants were unaware of their being enrolled in the 
studies due to inaccurate or incomplete understanding of the consent forms 
(Chaisson et al., 2011; Hill et al., 2008). Factors contributing to the poor 
XQGHUVWDQGLQJLQFOXGHGWKHSDUWLFLSDQWV¶XQIDPLOLDULW\ZLWKFOLQLFDOUHVHDUFKSRRU
level of education, anticipation of the clinical benefits of the research, and the 
verboseness and complexity of the consent forms (Beardsley et al., 2007; 
Berger et al., 2008; Christopher et al., 2007; Paasche±Orlow et al., 2003). 
However, the confidence and maximum cooperation of the parents were 
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successfully gained by providing repeated explanations and demonstrations of 
the study procedures. 
4.2.5. Lack of nutritional rehabilitation centres 
Nutritional rehabilitation centres are necessary to the management of 
malnourished children and have been recommended as part of the management 
protocol by WHO (WHO, 1999). Unlike other African countries, where many 
nutritional rehabilitation centres exist to take care of the dietary needs of 
malnourished children (Brewster et al., 1997b; Giugliani et al., 2010), none are 
available in Lagos. Therefore, patients were recruited from four general hospitals 
and a teaching hospital in Lagos, as well as from another teaching hospital in 
Kano. The task, therefore, involved travelling between the hospitals, despite the 
distance between them. Given both the high poverty levels and high population 
of Nigeria, a relatively low proportion of severely malnourished children have 
presented for hospital care in Lagos, which has led to the erroneous belief of 
local paediatricians that severe malnutrition is becoming rare in Lagos. 
The few cases of severe malnutrition admitted to the study centres had no 
opportunity to enjoy complete nutritional rehabilitation before being discharged. 
This trend was due to inadequate bed space for children and the priority of 
treating children with other life-threatening, acute medical conditions. 
Admissions were provided only for emergency management of severely 
malnourished children. They were usually discharged when clinically stable and 
visited at home for follow-ups. A large proportion of the parents could not 
adequately feed their children after hospital discharge, thus again putting the 
children at risk of relapse of malnutrition. Many of the patients (25%) were 
initially lost to follow-up, though through the provision of incentives to the 
126 
 
parents, such as transport money, mobile phone Top-Up cards, and breakfast, 
their attitudes to keeping follow-up appointments improved over time. 
Inadequate infrastructure has also been identified as a major challenge for 
the conduct of good clinical research in resource-poor countries (Olopade et al., 
2012).  
4.2.6. Inadequate manpower 
The majority of malnourished children recruited for the present research lived in 
areas far from the hospitals, which are also poorly accessible. This inaccessibility 
likely contributed to the initial loss of 20% of patients for follow-up. It, 
therefore, became necessary to YLVLWWKHSDUWLFLSDQWV¶KRPHVIRU follow-ups and 
to monitor their feeding habits, weight gain, and well-being. The tasks of 
performing follow-up visits for the patients in their homes and recruiting new 
patients from the hospitals were too enormous for a single person to handle. 
Specific training in clinical research involving the use of CBT is not offered in 
postgraduate medical education in Nigeria. Furthermore, poor knowledge of 
clinical research and lack of infrastructure for highly technological research 
studies have been recognised as negative impacts on the quality of clinical 
research emanating from resource-poor countries (Olopade et al., 2012).  
Based on the lack of both researchers experienced in paediatric clinical 
pharmacology and SDHGLDWULFLDQV¶ specific interest in core paediatric research 
studies, a research nurse from Lagos assisted with breath sample collections.  
4.2.7. Poverty of the parents 
Poor social status of the parents of the children studied corroborated that 
malnutrition is a disease of poverty in developing countries (WHO, 2004). 
Procuring medicine for these children and for aiding their feeding was difficult 
due to the poor financial status of the parents. Food and money for medicines 
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were initially provided to the parents, though these aids were not judiciously 
utilised. The parents often distributed the medicines and foods to other children 
in the family, leaving the participants in the study with poor weight gain and 
delayed recovery from concurrent infections. In the present studies, feeding was 
later arranged for the participants twice daily in the hospital and feeding 
between meals at home was suggested to the parents. These practices helped 
the participants to attain the expected weight in 4 to 8 weeks, which was faster 
than the 3 to 4 months taken to attain the expected weight for malnourished 
children nutritionally rehabilitated in Karachi, Pakistan, with locally available 
foods (Akram et al., 2010). 
4.2.8. Noncompliance to feeding and fasting instructions 
Many of the children involved in the study lacked adequate supervision from 
their parents or guardians. A preliminary analysis of the breath samples in the 
U.K. showed that four of the underweight children had ingested either food or 
caffeinated products before the study. This was suggested by the excessively 
high values of per cent dose of caffeine determined in their breath samples. 
Subsequent interviews with the children revealed that they had ingested food 
prior to the studies, which partly explains why obtaining accurate data may be 
more difficult for research studies conducted in resource-poor settings than in 
high-income countries (Alem & Kebede, 2003).  
Through persuasion and repeated dissemination of information to the 
parents, the children were allowed to be admitted to the hospital for 24 h prior 
to the study, which enabled their intake to be monitored and ensured that they 
ingested nothing after their dinners and prior to the time of the study. 
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4.2.9. Tardiness in keeping appointments 
Eight parents refused the admission of their underweight child prior to the study 
and could not keep the early morning appointments during the study. Reasons 
alluded for the tardiness included lack of money for transportation, waking up 
late, lack of time to take care of other children, and uncooperative nature of the 
child on the day of the study. This resulted in frequent changes to the day of the 
CBT for individual children. These factors are among those previously identified 
by Olopade et al. (2011) as major setbacks in conducting clinical research in 
developing countries. However, the problem was overcome by arranging for a 
taxi to pick up the child and his or her parent on the day of the study, thus 
further increasing the research costs. 
4.2.10. Cost of research 
The cost of this study was nearly £20,000 (Table 4.2). The budget for the 
research was initially £9,000; additional costs (approximately £11,000) were, 
however, incurred due to the unforeseen circumstances resulting from the 
prolonged study period. 
Table 4.2: Cost of performing caffeine breath test in Nigeria 
Item Cost estimate in 
Great Britain 
Pounds (£) 
Economy flight to and from Nigeria on three occasions 1,642.88 
Labelled-caffeine procurement 4,401.50 
Exetainer® bottle procurement 814.68 
Weighing balance procurement 823.26 
Seca lightweight scale procurement 219.75 
DHL to courier breath samples from Nigeria, and to courier 
Exetainer® bottles and an official letter to Nigeria 
1,845.61 
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Table 4.2: continued 
Train ticket from Derby to London on three occasions and a 
return ticket from London to Derby on one occasion 
330.48 
Accommodation in Nigeria for 9 months 3,450.00 
Nutritional rehabilitation of underweight children 2,100.00 
Local flight and transportation in Nigeria, and Casilan® 
procurement 
3,848.30 
Total £19,476.46 
 
4.3. BENEFITS 
In developed countries, the CBT has been used in various disciplines, such as 
gastroenterology and clinical pharmacology, to assess the severity of hepatic 
diseases (Park et al., 2003) and to evaluate the activity of hepatic CYP1A2 in 
diseases such as cystic fibrosis (Parker et al., 1997a). The approach has been 
used in the present research to determine the effect of malnutrition on drug 
metabolism. As such, the present research is the first of its kind conducted in a 
resource-poor country. 
Despite the enormous challenges of conducting clinical research in 
Nigeria, the data generated in this study will contribute to advancing the 
knowledge of malnutrition and its therapeutic management. Other positive 
aspects of the CBT are: (i) its acceptability to children and their parents; (ii) its 
ability to foster collaboration and networking between a paediatric clinical 
pharmacologist and other clinical researchers in Nigeria; and (iii) the safety of its 
breath samples without refrigeration or the use of a special storage system. 
4.3.1. Acceptability of the caffeine breath test (CBT) 
The fact that the present studies were non-invasive and lasted only 2 h made it 
acceptable to both the participants and their parents. The approach was also 
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acceptable to the doctors involved in the management of the children. Similar 
acceptability has been reported among children and their parents involved in 
previous CBT studies (Parker et al., 1994; Parker et al., 1997b). The attitudes 
and knowledge of the parents of the malnourished children improved as the 
study progressed. Parents were able to discuss the details of the study with 
other parents whose children did not participate in the study. The parents were 
eager to learn the outcome of the study and they appreciated our extending the 
CBT to other childhood diseases. All parents were willing to allow their children 
to participate in future studies involving the use of the CBT. 
4.3.2. Collaboration and networking  
The nurses, pharmacists, and doctors involved in the care of the malnourished 
children in all centres involved with the study applauded the idea of using the 
CBT for the non-invasive study of drug metabolism in children. Though they 
found the procedure to be uncommon in Nigeria and other African countries, a 
considerable proportion of the healthcare professionals expressed a willingness 
to collaborate in this area of research. One of the doctors suggested that the 
CBT be extended to children with sickle cell anaemia, due to their nutritional 
deficiencies. Such collaboration should enhance the use of CBT for future clinical 
paediatric pharmacology research in Nigeria. 
4.3.3. Safety of breath samples 
The breath samples required storage over a period of 6 to 12 weeks preceding 
their transportation to the U.K. for analysis. Despite the fragility of the 
Exetainer® vials, none broke and no air leaked from the vials during 
transportation. A preliminary analysis of the breath samples (see section 3.13) 
yielded reliable data suggesting that the high temperatures in Nigeria did not 
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adversely affect the breath samples. This is an additional advantage of using the 
CBT in African countries for the research of paediatric clinical pharmacology. 
 
4.4. CONCLUSION 
In summary, though the challenges of effectively conducting paediatric clinical 
pharmacology research in Nigeria are many, they are surmountable. Studies 
involving the use of CBT are feasible in Nigeria and acceptable to both children 
and their parents. The use of the CBT promises to foster collaboration and 
networking between experts in clinical paediatric pharmacology and other 
healthcare professionals in paediatrics. There is additionally the prospect of 
using the CBT to study the effects of other tropical childhood diseases on drug 
metabolism. However, effective paediatric clinical pharmacology research 
requires economic and political stability, government commitment, the education 
of the parents, adequate funding, and collaboration with high-income countries. 
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CHAPTER FIVE:  
RESULTS 
5.1. EFFECTS OF UNDERWEIGHT ON CAFFEINE METABOLISM 
The demographics and anthropometric parameters of the 15 underweight 
children are presented in Table 5.1.  
Table 5.1: The demographics and anthropometric parameters of the underweight children 
Number of 
subject 
Gender Age 
(years) 
Pre-nutritional 
rehabilitation 
Duration of 
nutritional 
rehabilitation 
(weeks) 
 
Post-nutritional 
rehabilitation 
Weight 
(kg)  
Height 
(cm) 
Weight 
(kg) 
Height 
(cm) 
1 F 4.2 13.0 99.3  2 15.0 99.3 
2 M 4.3 11.0 92.0 2 13.6 93.5 
3 F 4.5 13.0 96.0  3 15.0 97.5 
4 F 5.0 14.0 107.0  3 15.0 109.0 
5 M 5.0 12.0 98.5 3 14.8 100.0 
6 M 5.5   13.0 106.5 3 16.0 107.8 
7 M 6.0 13.0 102.0 3 16.6 103.0 
8 F 7.5 18.0 119.0 2 20.0 120.0 
9 M  8.0 16.0 112.5  4 21.0 113.0 
10 M 10.0 22.0 129.5 6 26.4 131.0 
11 M 10.0 25.0 133.9  2 27.0 133.9 
12 M 10.0 25.0 130.0 4 28.0 130.5 
13 M 11.0 23.0 132.0 6 30.2 133.5 
14 M 11.5 26.0 137.2 6 31.0 139.0 
15 M 12.0 24.0 135.5 6 31.0 136.0 
Mean+ s.d 7.6± 0.9 17.9± 5.6 115.4± 6.3 3.7±1.6 21.4± 6.8* 116.5± 
6.2* 
*(P6WXGHQW¶VW-test) 
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Eleven male and four female children were studied. Their mean age was 
7.6 ± 2.9 years. Their mean weight significantly increased from 17.9 ± 5.6 kg 
(before nutritional rehabilitation) to 21.4 ± 6.8 kg (after nutritional 
rehabilitation) (p < 0.005). Similarly, their mean height significantly increased 
from 115.4 ± 16.3 cm (before nutritional rehabilitation) to 116.5 ± 16.2 cm 
(after nutritional rehabilitation) (p < 0.005). They were restudied after a mean 
period of 3.7 weeks following nutritional rehabilitation. 
The typical time courses of mean 13C-enrichments (substrate in atom per 
excess [APE]) for the underweight children investigated both before and after 
nutritional rehabilitation are shown in Figure 5.1. The curves were obtained by 
plotting the mean ±SD of the delta values at 15, 30, 45, 60, 75, 90, 105, and 
120 min for the 15 participants against time.  
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Fig. 5.1. Time courses of mean± SD 13C-enrichments of underweight children, before and 
after nutritional rehabilitation. APE represents 13C in atom per excess abundance (see 
Appendix VII for the raw data). 
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Both curves showed a gradual increase in the mean 13C-enrichments up to the 
peak values, which was followed by a gradual fall. The mean peak 13C-
enrichments were attained at 0.00740 ± 0.00350 APE before nutritional 
rehabilitation and 0.00694 ± 0.00345 APE after nutritional rehabilitation. There 
was no significant difference in the mean peak 13C-enrichments (p = 0.691). The 
peaks were attained at 61.00 ± 23.28 min and 76.00 ± 26.87 min before and 
after nutritional rehabilitation, respectively. The difference between the two 
periods in attaining the mean peaks of 13C-enrichments was not statistically 
significant (p = 0.060). 
The mean areas under the enrichment-time curve before and after 
nutritional rehabilitation were 0.539 ± 0.320 APE min and 0.620 ± 0.322 APE 
min, respectively. The difference between the two values was not statistically 
significant (p = 0.528).  
The average cumulative per cent 13C-doses recovered (CPDR) in the 
exhaled CO2 over the period of 2 h of the underweight children are shown below 
in Table 5.2. The mean cumulative per cent 13C-dose recovered was 7.56 ± 
4.01% and 7.95 ± 3.68% before and after nutritional rehabilitation, 
respectively, and there was no significant difference in the mean values (p = 
0.603). The individual cumulative per cent labelled caffeine dose exhaled as CO2 
in the period of 2 h by each underweight child both before and after nutritional 
rehabilitation is presented in Figure 5.2.  
 
 
 
135 
 
Table 5.2: Average cumulative percent 13C-dose in the exhaled 2-hour CO2 of underweight children, before and after nutritional rehabilitation 
Number of subject 
 
 
Pre-nutritional rehabilitation Time interval 
between study I 
and II (weeks) 
 
Post-nutritional rehabilitation Change after nutritional 
rehabilitation (B-A) (%) 
Labelled CO2 output 
over the 2hr study 
period (mmol/hr) 
 
Average percent 
13CO2 exhaled 
(studyI) 
Cumulative percent 13C-
dose (Caffeine) recovered 
in the 2 hr CO2 exhaled 
(%)      (A) 
Labelled CO2 output 
over the 2hr study 
period (mmol/hr) 
 
Average percent 
13CO2 exhaled 
(studyII) 
Cumulative percent 13C-
dose (Caffeine) recovered 
in the 2 hr CO2 exhaled 
(%)                      (B) 
1 251.44 0.04230 10.64 2 232.82 0.05708 13.29 2.65 (24.9) 
2 283.53 0.01391 3.94 2 251.34 0.02519 6.33 2.39 (60.7) 
3 254.84 0.04083 10.41 3 234.51 0.05352 12.55 2.14 (20.6) 
4 234.57 0.03194 7.49 3 224.37 0.05611 11.34 3.85 (51.4) 
5 263.35 0.04455 11.73 3 233.85 0.05029 11.76 0.03 (0.3) 
6 244.56 0.00332 0.81 3 217.67 0.00910 1.98 1.17 (14.4) 
7 248.78 0.00557 1.39 3 217.29 0.00893 1.94 0.55 (39.6) 
8 196.46 0.03276 6.44 2 185.02 0.02886 5.34 -1.10 (-17.1) 
9 214.02 0.01971 4.22 4 184.58 0.02714 5.01 0.79 (18.7) 
10 170.55 0.05025 8.57 6 153.92 0.03742 5.76 -2.81 (-32.9) 
11 157.12 0.10210 16.04 2 150.75 0.05645 8.51 -7.53 (-46.9) 
12 158.98 0.05382 8.56 4 149.35 0.06501 9.71 1.15 (13.4) 
13 165.26 0.05325 8.80 6 142.11 0.05397 7.67 -1.13 (-12.8) 
14 152.37 0.03678 5.60 6 137.90 0.04880 6.73 1.13 (20.2) 
15 159.86 0.05460 8.73 6 139.10 0.07268 10.11 1.38 (15.8) 
Mean+ s.d 7.56±4.01 3.7±1.6  7.95±3.68  
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The cumulative per cent labeled caffeine dose exhaled as CO2 showed an 
increase in 10 children, a decrease in four children, and remained relatively 
unchanged in one child after nutritional rehabilitation (Table 5.2 and Figure 5.2). 
There was greater inter-individual variation before nutritional rehabilitation than 
after such rehabilitation. 
 
A= Pre-nutritional rehabilitation
  B= Post-nutritional rehabilitation
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Fig. 5.2. Individual cumulative percent 13C-dose recovery (CPDR) in 2-hours for each 
underweight child, both before and after nutritional rehabilitation, expressed as a 
percentage of the oral caffeine dose administered 
There was no significant correlation between the changes in CPDR during 
the period of 2 h for underweight children and their age or changes in their 
weight or height when comparing figures from before and after nutritional 
rehabilitation (Figure 5.3). The correlation between the change in CPDR and age 
was r = -0.473 (p = 0.075), while the correlation between the change in CPDR 
and change in height was 0.341 (p = 0.213). However, there was no clear 
correlation between change in CPDR and change in weight. 
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Fig. 5.3. Correlation between changes in cumulative percent 13C-dose recovered (CPDR) 
in 2-hours for underweight children and (a) their age, (b) changes in their weight or (c) 
height 
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5.2. EFFECTS OF MARASMUS ON CAFFEINE METABOLISM 
The demographics and anthropometric parameters of the 15 marasmic children 
are presented in Table 5.3.  
Table 5.3: The demographics and anthropometric parameters of the marasmic children 
Number of 
subject 
Gender Age 
(years) 
Pre-nutritional 
rehabilitation 
Duration of 
nutritional 
rehabilitation 
(weeks) 
Post-nutritional 
rehabilitation 
Weight 
(kg)  
Height 
(cm) 
Weight 
(kg) 
Height (cm) 
1 F 3.0 7.5 82.0 5 12.0 84.5 
2 M 3.0 7.6   79.5 4 11.0 82.0 
3 F 3.5   8.7 90.5 4 12.0 91.0 
4 F 3.5 8.7 96.0 4 11.8 97.0 
5 F 3.5 9.0 92.0 3 12.0 93.4 
6 M 3.8 9.3 94.5 5 13.0  95.8 
7 M 4.0 9.2 98.0 6 13.0 99.5 
8 F 4.3 9.6 94.0 4 11.5 95.5 
9 F  4.5 9.6 102.0  6 13.5 103.5 
10 M 4.5 10.0 95.0 6 14.1 95.5 
11 F 4.5 10.0 96.0 3 13.0 97.0 
12 F 4.5 10.5 100.0 5 14.0 102.0 
13 F 5.5 11.3 115.0 5 15.0 116.0 
14 M 6.0 11.5 105.0 6 16.0 106.0 
15 F 6.5 12.6 114.0 5 16.5 116.0 
Mean+ s.d 4.3± 1.0 9.7± 1.4 96.9± 9.8 4.7±1.0 13.2± 1.6* 98.3± 9.6* 
* (P6WXGHQW¶VW-test) 
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Ten female and five male children were studied. Their mean age was 4.3 
± 1.0 year. Their mean weight significantly increased from 9.7 ± 1.4 kg (before 
nutritional rehabilitation) to 13.2 ± 1.6 kg (after nutritional rehabilitation) (p < 
0.005). Similarly, their mean height significantly increased from 96.9 ± 9.8 cm 
(before nutritional rehabilitation) to 98.3 ± 9.6 cm (after nutritional 
rehabilitation) (p < 0.005). The marasmic children were restudied after a mean 
period of 4.7 weeks following nutritional rehabilitation. 
The time courses of mean ±SD of the 13C-enrichments for marasmic 
children studied before and after nutritional rehabilitation are shown in Figure 
5.4.  
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Fig. 5.4. Time courses of mean± SD 13C-enrichments of marasmic children, before and 
after nutritional rehabilitation. APE represents 13C in atom per excess abundance (see 
Appendix VIII for the raw data) 
In both curves, there was a sudden rise in the mean 13C-enrichments in the first 
45 min, followed by a gradual increase until peak values were attained. 
Thereafter, the mean 13C-enrichments stabilised until the study ended after 
lasting 120 min. The mean peak enrichment was significantly higher after 
nutritional rehabilitation (0.00603 ± 0.00250 APE) than before such 
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rehabilitation (0.00499 ± 0.00221 APE) (p = 0.003). The mean peak 13C-
enrichments were attained at 91.00 ± 30.50 min and 90.00 ± 34.49 min before 
and after nutritional rehabilitation, respectively. There was no significant 
difference in the mean peak times (p = 0.898). The mean area under the 
enrichment-time curve was significantly higher after nutritional rehabilitation 
(0.498 ± 0.186 APE min) than before nutritional rehabilitation (0.419 ± 0.182 
APE min) (p = 0.002). 
The mean cumulative per cent 13C-dose exhaled as CO2 during the period 
of 2 h by the marasmic children is shown in Table 5.4. The mean cumulative per 
cent 13C-dose significantly increased from 6.80 ± 3.00% (before nutritional 
rehabilitation) to 7.67 ± 2.81% (after nutritional rehabilitation) (p < 0.001). 
The individual cumulative per cent labelled caffeine dose exhaled as CO2 
over a period of 2 h for each marasmic child both before and after nutritional 
rehabilitation is presented in Figure 5.5. The cumulative per cent labelled 
caffeine dose exhaled as CO2 showed an increase in 13 children, a decrease in 
one child, and remained relatively unchanged in another child after nutritional 
rehabilitation (Table 5.4 and Figure 5.5). The inter-individual variations before 
and after nutritional rehabilitation were similar. 
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Table 5.4: Average cumulative percent 13C-dose recovered in the exhaled 2-hours CO2 of marasmic children, before and after nutritional rehabilitation 
Number of 
subject 
 
 
Pre-nutritional rehabilitation Time interval 
between study I 
and II (weeks) 
 
Post-nutritional rehabilitation Change after nutritional 
rehabilitation (B-A) (%) 
Labelled CO2 
output over the 
2hr study period 
(mmol/hr) 
 
Average percent 
13CO2 exhaled      
(study I) 
Cumulative percent 
13C-dose (Caffeine) 
recovered in the 2 hrs 
CO2 exhaled (%)           
(A) 
Labelled CO2 output 
over the 2hr study 
period (mmol/hr) 
 
Average percent 
13CO2 exhaled    
(study II) 
Cumulative percent 
13C-dose (Caffeine) 
recovered in the 2 hrs 
CO2 exhaled (%)          
(B) 
1 364.64 0.02444 8.91 5 279.85 0.03187 8.92 0.01 (0.1) 
2 366.53 0.01724 6.32 4 296.77 0.02335 6.93 0.61 (9.7) 
3 323.76 0.01946 6.30 4 271.75 0.03109 8.45 2.15 (34.1) 
4 316.28 0.03535 11.18 4 267.36 0.04346 11.62 0.44 (39.4) 
5 315.84 0.01681 5.31 3 268.96 0.02090 5.62 0.31 (5.8) 
6 307.04 0.02886 8.86 5 255.05 0.03972 10.13 1.27 (14.3) 
7 304.41 0.01895 5.77 6 251.24 0.02937 7.38 1.61 (27.9) 
8 302.48 0.02893 8.75 4 272.77 0.03465 9.45 0.70 (8.0) 
9 292.84 0.02298 6.73 6 242.38 0.03358 8.14 1.41 (21.0) 
10 294.67 0.00825 2.43 6 244.45 0.01030 2.54 0.11 (4.5) 
11 293.56 0.01516 4.45 3 253.79 0.02581 6.55 2.1 (47.2) 
12 281.27 0.04874 13.71 5 239.06 0.05643 13.49 -0.22 (-1.6) 
13 255.80 0.01927 4.93 5 218.91 0.02439 5.34 0.41 (8.3) 
14 262.70 0.01881 4.94 6 219.96 0.02328 5.12 0.18 (36.4) 
15 242.09 0.01413 3.42 5 207.97 0.02577 5.36 1.94 (56.7) 
Mean+ s.d 6.80±3.00* 4.7±1.0  7.67±2.81*    
* Significant difference in the mean values (P 6WXGHQW¶VW-test) 
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A= Pre-nutritional rehabilitation
  B= Post-nutritional rehabilitation
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Fig.5.5. Individual cumulative percent 13C-dose recovery (CPDR) in 2-hours for each 
marasmic child, both before and after nutritional rehabilitation, expressed as a 
percentage of the oral caffeine dose administered 
There was no significant correlation between the changes in either the CPDR 
during the 2 h period for marasmic children and their age or in their changes in 
weight or height when comparing data before and after nutritional rehabilitation 
(Figure 5.6). The correlation between the changes in CPDR and age was r = 
0.121 (p = 0.667). There was a negative correlation between the changes in 
CPDR and both changes in weight (r = -0.200, p = 0.476) and changes in height 
(r = -0.395, p = 0.145).  
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(c) 
Fig. 5.6. Correlation between changes in cumulative percent 13C-dose recovered (CPDR) 
in 2-hours for marasmic children and (a) their age, (b) changes in their weight or (c) 
height 
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5.3. EFFECTS OF MARASMIC-KWASHIORKOR ON CAFFEINE 
METABOLISM 
The demographics and anthropometric parameters of the 15 marasmic-
kwashiorkor children are presented in Table 5.5.  
Table 5.5: The demographics and anthropometric parameters of the marasmic-kwashiorkor children 
Number of 
subject 
Gender Age 
(years) 
Pre-nutritional 
rehabilitation 
Duration of 
nutritional 
rehabilitation 
(weeks) 
 
Post-nutritional 
rehabilitation 
Weight 
(kg)  
Height 
(cm) 
Weight 
(kg) 
Height 
(cm) 
1 M 3.00 8.2 90.0 5 11.2 92.2 
2 F 3.50 8.2 90 4 12.3 92.3 
3 F 3.50 8.8 91.2 4 12.0 92.7 
4 F 3.50 9.0 92.3 4 12.5 95.0 
5 M 3.75 9.4 96.5 3 12.5 98.0 
6 F 4.00 9.2 97.5 5 13.1 99.3 
7 M  4.00 9.5 99.2 6 13.5 101.4 
8 F 4.50 9.8 98.0  4 13.8 99.50 
9 F 4.50 10.1 97.0 6 14.5 98.6 
10 F 4.75 10.0 98.0 6 14.2 100.2 
11 M 5.00 10.4 110.4 3 14.7 112.3 
12 M 5.50 11.0 116.0 5 16.5 118.0 
13 F 5.50 11.4 114.5  5 15.5 115.8 
14 M 6.00 11.3 105.0 6 16.0 107.6 
15 F 6.50 12.5 109.0 5 16.5 116.0 
Mean+ s.d 4.5± 1.0 9.9± 1.2 100.3± 
8.7 
4.7±1.0 13.9± 1.7* 102.6± 
9.0* 
* (P6WXGHQW¶VW-test) 
Nine female and six male children were studied. Their mean age was 4.5 
± 1.0 years, which was similar to the age group affected by marasmus. The 
mean weight of the marasmic-kwashiorkor children significantly increased from 
9.9 ± 1.2 kg (before nutritional rehabilitation) to 13.9 ± 1.7 kg (after nutritional 
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rehabilitation) (p < 0.005). Similarly, their mean height significantly increased 
from 100.3 ± 8.67 cm (before nutritional rehabilitation) to 102.6 ± 9.04 cm 
(after nutritional rehabilitation) (p < 0.005). The children were restudied after a 
mean of 4.7 weeks following nutritional rehabilitation.  
The time courses of mean 13C-enrichments of children with marasmic-
kwashiorkor studied before and after nutritional rehabilitation are shown in 
Figure 5.7. Both curves demonstrated a gradual rise in the 13C-enrichments with 
time.  
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Fig. 5.7. Time courses of mean ± SD 13C-enrichments of children with marasmic-
kwashiorkor, before and after nutritional rehabilitation. APE represents 13C in atom per 
excess abundance (see Appendix IX for the raw data). 
The mean peak 13C-enrichments, before (0.00511 ± 0.00178 APE) and 
after nutritional rehabilitation (0.00577 ± 0.00207 APE), were attained at 87.00 
± 19.80 min and 84.00 ± 33.45 min, respectively, after caffeine administration. 
There was no significant difference in the mean peak 13C-enrichments in the 
13CO2 exhaled before and after nutritional rehabilitation (p = 0.102). Similarly, 
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there was no significant difference in the time to the mean peak 13C-enrichments 
before and after nutritional rehabilitation (p = 0.783).  
The mean areas under the enrichment-time curve before and after 
nutritional rehabilitation were 0.431 ± 0.144 APE min and 0.480 ± 0.198 APE 
min, respectively. The difference between the two values was not statistically 
significant (p = 0.140). 
The mean CPDR in the exhaled CO2 over the 2 h period of the marasmic-
kwashiorkor children are shown in Table 5.6. The mean cumulative per cent 13C-
dose significantly increased from 6.61 ± 2.26% (before nutritional rehabilitation) 
to 7.56 ± 2.46% (after nutritional rehabilitation) (p < 0.041).  
The cumulative 13C-dose exhaled CO2 over a period of 2 h for each 
marasmic-kwashiorkor child before and after nutritional rehabilitation is 
presented in Figure 5.8. It showed an increase in 13 children and a decrease in 
two children after nutritional rehabilitation (Table 5.6 and Figure 5.8). The inter-
individual variations before and after nutritional rehabilitation were similar. 
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Table 5.6: Average cumulative percent 13C-dose in the exhaled 2-hour CO2 of marasmic ±kwashiorkor children, before and   after nutritional rehabilitation 
Number of 
subject 
 
 
Pre-nutritional rehabilitation Time interval 
between study 
I and II 
(weeks) 
 
Post-nutritional rehabilitation Change after nutritional 
rehabilitation          (B-A) 
(%) Labelled CO2 output 
over the 2hr study 
period (mmol/hr) 
 
Average 
percent 13CO2 
exhaled (study 
I) 
Cumulative percent 
13C-dose (Caffeine) 
recovered in the 2 hrs 
CO2 exhaled (%)          
(A) 
Labelled CO2 output 
over the 2hr study 
period (mmol/hr) 
 
Average percent 
13CO2 exhaled 
post- rehab      
(study II) 
Cumulative percent 
13C-dose (Caffeine) 
recovered in the 2 hrs 
CO2 exhaled (%)          
(B) 
1 336.78 0.01808 6.09 5 280.56 0.02784 7.81 1.72 (28.2) 
2 336.78 0.03317 11.17 4 266.66 0.04238 11.30 0.13 (1.2) 
3 320.79 0.01300 4.17 4 269.76 0.02117 5.71 1.54 (36.9) 
4 315.44 0.01633 5.15 4 261.35 0.042097 5.48 0.33 (6.4) 
5 302.76 0.01691 5.12 3 258.15 0.02487 6.42 1.30 (21.4) 
6 305.03 0.02262 6.90 5 250.41 0.02987 7.48 0.58 (8.4) 
7 297.41 0.02354 7.00 6 244.36 0.03851 9.41 2.41 (34.4) 
8 294.24 0.01410 4.15 4 243.30 0.03153 7.67 3.52 (84.8) 
9 290.69 0.02167 6.30 6 237.77 0.02730 6.49 0.19 (3.0) 
10 291.06 0.03673 10.69 6 238.93 0.05261 12.57 1.88 (17.6) 
11 271.84 0.01229 3.34 3 224.16 0.01847 4.14 0.80 (24.0) 
12 258.64 0.02099 5.43 5 206.56 0.03321 6.86 1.43 (26.3) 
13 255.03 0.03223 8.22 5 215.23 0.02718 5.85 -2.37 (-28.8) 
14 265.20 0.02990 7.93 6 217.83 0.05031 10.96 3.03 (38.3) 
15 247.49 0.03022 7.48 5 218.66 0.02433 5.32 -2.16 (28.9) 
Mean+ s.d 6.61±2.26* 4.7±1.0  7.56±2.46*    
* Significant difference in the mean values (P 6WXGHQW¶VW-test) 
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A= Pre-nutritional rehabilitation
  B= Post-nutritional rehabilitation
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Fig.5.8. Individual cumulative percent 13C-dose recovery (CPDR) in 2-hours for each 
marasmic-kwashiorkor child, both before and after nutritional rehabilitation, expressed 
as a percentage of the oral caffeine dose administered 
There was no significant correlation between either the changes in CPDR 
during the 2 h period for children with marasmic-kwashiorkor and their age or 
the changes in their weight or height when comparing the data before and after 
nutritional rehabilitation (Figure 5.9). Change in the CPDR did not significantly 
correlate with age (r = -0.291, p = 0.293), changes in weight (r = 0.0264, p = 
0.926), or changes in height (r = -0.426, p = 0.113). 
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Fig.5.9. Correlation between changes in cumulative percent 13C-dose recovered (CPDR) 
in 2-hours for marasmic-kwashiorkor children and (a) their age, (b) changes in their 
weight or (c) height 
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5.4. EFFECTS OF KWASHIORKOR ON CAFFEINE METABOLISM 
The demographics and anthropometric parameters of the 15 kwashiorkor 
children are presented in Table 5.7.  
Table 5.7: The demographics and anthropometric parameters of the kwashiorkor children 
Number of 
subject 
Gender Age (years) Pre-nutritional 
rehabilitation 
Duration of 
nutritional 
rehabilitation 
(weeks) 
 
Post-nutritional 
rehabilitation 
Weight 
(kg)  
Height 
(cm) 
Weight (kg) Height 
(cm) 
1 M 3.5 9.8 97.8 6 11.9 98.2 
2 M 5.8 13.9 116.8 5 15.4 118.3 
3 F 4.5 11.2 101.0 6 13.5 102.2 
4 F 5.0 10.8 108.5 8 14.5 110.0 
5 F 3.0 9.4 97.5 4 11.0 98.0 
6 M 4.0 9.9 99.0 7 13.1 99.3 
7 F  6.5 12.6 118.4 8 17.2 119.0 
8 F 3.2 10.1 95.0  4 11.4 96.5 
9 M 5.5 12.2 116.2 5 14.9 117.6 
10 M 4.5 10.7 100.1 6 13.5 101.2 
11 M 4.8 10.6 110.4 7 14.0 112.3 
12 M 6.0 13.0 116.0 5 16.5 118.0 
13 F 3.5 9.5 94.2  5 11.9 95.8 
14 M 4.5 11.3 102.0 6 13.8 103.2 
15 F 3.8 9.6 96.8 5 12.4 98.3 
Mean+ s.d  4.5± 1.1 11.0± 1.4 104.7± 8.9 5.8±1.3 13.7± 1.8* 105.8± 
8.9* 
* (P6WXGHQW¶VW-test) 
Eight male and seven female children were studied. Their mean age was 
4.5 ± 1.1 years, which was similar to the age of groups affected by marasmus 
and marasmic-kwashiorkor alike. The mean weight of the children with 
kwashiorkor significantly increased from 11.0 ± 1.4 kg (before nutritional 
rehabilitation) to 13.7 ± 1.8 kg (after nutritional rehabilitation) (p < 0.005). 
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Similarly, their mean height significantly increased from 104.7 ± 8.9 cm (before 
nutritional rehabilitation) to 105.8 ± 8.9 cm (after nutritional rehabilitation) (p < 
0.005). The children were restudied after a mean period of 5.8 weeks following 
nutritional rehabilitation.  
The time courses of mean ±SD 13C-enrichments of the kwashiorkor 
children studied before and after nutritional rehabilitation are shown in Figure 
5.10. 
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Fig. 5.10. Time courses of mean± SD 13C-enrichments of children with kwashiorkor, 
before and after nutritional rehabilitation. APE represents 13C in atom per excess 
abundance (see Appendix X for the raw data). 
Both curves showed a rapid rise in the 13C-enrichments during the first 30 
min. There was a gradual rise until 45 min, followed by minor changes until the 
mean peak 13C-enrichment was attained. Thereafter, the curve for post-
nutritional rehabilitation gradually fell. By contrast, the curve for pre-nutritional 
rehabilitation gradually rose after 45 min to the mean peak 13C-enrichment at 
the end of the study. 
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The mean peak 13C-enrichments were 0.00544 ± 0.00156 APE and 
0.00647 ± 0.00163 APE before and after nutritional rehabilitation, respectively. 
There was no significant difference between these mean values (p = 0.104). The 
mean peak 13C-enrichments were attained at 110.00 ± 29.17 min and 84.00 ± 
37.09 min before and after nutritional rehabilitation, respectively. The difference 
between these mean time periods was statistically significant (p = 0.049). 
The mean area under the enrichment-time curve was significantly higher 
after nutritional rehabilitation (0.538 ± 0.160 APE min) than before nutritional 
rehabilitation (0.433 ± 0.118 APE min) (p = 0.0001).  
The mean cumulative per cent 13C-doses exhaled by the kwashiorkor 
children and labelled CO2 over a period of 2 h are shown in Table 5.8. The CPDR 
in the exhaled caffeine labelled CO2 of the 2 h period significantly increased from 
6.29 ± 1.06% (before nutritional rehabilitation) to 7.13 ± 1.72% (after 
nutritional rehabilitation) (p < 0.002) (Figure 5.11).  
The mean cumulative per cent 13C-dose exhaled over the period of 2 h by 
each kwashiorkor child both before and after nutritional rehabilitation is 
presented in Figure 5.11. The cumulative per cent 13C-dose showed an increase 
in 13 children, a decrease in one child, and remained relatively unchanged in 
another child after nutritional rehabilitation. There was greater inter-individual 
variation after nutritional rehabilitation. 
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Table 5.8: Average cumulative percent 13C-dose exhaled in 2-hours CO2 of kwashiorkor children, before and after nutritional rehabilitation 
Number of 
subject 
 
 
Pre-nutritional rehabilitation Time interval 
between study I 
and II (weeks) 
 
Post-nutritional rehabilitation Change after nutritional 
rehabilitation (B-A) (%) 
Labelled CO2 output 
over the 2hr study 
period (mmol/hr) 
 
Average percent 
13CO2 exhaled    
(study I) 
Cumulative percent 13C-
dose (Caffeine) 
recovered in the 2 hr 
CO2 exhaled (%)  (A) 
Labelled CO2 output 
over the 2hr study 
period (mmol/hr) 
 
Average percent 
13CO2 exhaled     
(study II) 
Cumulative percent 13C-
dose (Caffeine) 
recovered in the 2 hr 
CO2 exhaled (%)           
(B) 
1 294.48 0.02289 6.74 6 264.86 0.03243 8.59 1.85(27.5) 
2 227.44 0.02014 4.58 5 214.16 0.02330 4.99 0.41(9.0) 
3 270.60 0.02095 5.67 6 243.60 0.02701 6.58 0.91(16.0) 
4 268.22 0.02647 7.10 8 227.68 0.03176 7.23 0.13(1.8) 
5 301.52 0.02096 6.32 4 276.52 0.02300 6.36 0.04(0.6) 
6 291.47 0.01942 5.66 7 250.41 0.03027 7.58 1.92(33.9) 
7 238.00 0.02744 6.53 8 201.73 0.03495 7.05 0.52(8.0) 
8 293.10 0.02167 6.35 4 272.92 0.02635 7.19 0.84(13.2) 
9 244.47 0.02679 6.55 5 218.51 0.03373 7.37 0.82(11.1) 
10 278.32 0.02641 7.35 6 244.55 0.03378 8.26 0.91(12.4) 
11 269.07 0.02631 7.08 7 230.12 0.03707 8.53 1.45(20.5) 
12 236.42 0.02631 6.22 5 206.56 0.03331 6.88 0.66(10.6) 
13 303.93 0.02323 7.06 5 267.47 0.03204 8.57 1.51(21.4) 
14 268.26 0.02788 7.48 6 239.81 0.03945 9.46 1.98(26.5) 
15 298.98 0.01205 3.60 5 258.95 0.00904 2.34 -1.26(35.0) 
Mean+ s.d 6.29±1.06* 5.8±1.3  7.20±1.80*    
7KHUHZDVDVLJQLILFDQWGLIIHUHQWLQWKHPHDQYDOXHV6WXGHQW¶V t-test, P=0.002) 
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A= Pre-nutritional rehabilitation
  B= Post-nutritional rehabilitation
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Fig.5.11. Individual cumulative percent 13C-dose recovery (CPDR) in 2-hours for each 
kwashiorkor child, both before and after nutritional rehabilitation, expressed as a 
percentage of the oral caffeine dose administered. 
There was no significant correlation between either the changes in CPDR 
over the period of 2 h for children with kwashiorkor and their age or changes in 
weight or height when comparing data before and after nutritional rehabilitation 
(Figure 5.12). The correlation between the changes in CPDR and age was r = -
0.0953 (p = 0.735). The correlation was r = -0.0235 (p = 0.934) with changes 
in height and r = -0.2533 (p = 0.362) with changes in weight. 
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Fig.5.12. Correlation between changes in cumulative percent 13C-dose recovered (CPDR) 
in 2-hours for children with kwashiorkor and (a) their age, (b) changes in their weight 
or (c) height 
 
5.5. SUMMARY OF RESULTS 
The present studies assessed the activity of CYP1A2 in underweight and severely 
malnourished children both during acute malnutrition and after nutritional 
rehabilitation by using the CBT. The activity of CYP1A2 was determined for each 
group of malnutrition, both before and after nutritional rehabilitation, by the 
cumulative CO2 exhaled over a period of 2 h. The time courses of mean ±SD 13C-
enrichments of all four categories of malnourished children studied before and 
after nutritional rehabilitation are shown in Figure 5.13 for comparison. 
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Fig. 5.13. The time courses of mean ±SD 13C-enrichments of all four categories of malnourished children studied before and after 
nutritional rehabilitation. APE represents 13C in atom per excess abundance. 
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The patterns of the curves were dissimilar for underweight malnourished 
children and the other three categories of malnutrition before and after 
nutritional rehabilitation. The curves for underweight malnourished children 
before and after nutritional rehabilitation, however, were characterised by a 
steady rise to a peak point and, subsequently, a gradual fall. The pre- and post-
nutritional rehabilitation curves for underweight children were consistently 
higher than those for children with marasmus, marasmic-kwashiorkor, and 
kwashiorkor. When the three severe forms of protein-energy malnutrition (PEM) 
were compared, the post-nutritional rehabilitation curves were consistently 
higher than those for pre-nutritional rehabilitation. However, the curves for 
marasmus, marasmic-kwashiorkor, and kwashiorkor both before and after 
nutritional rehabilitation plateaued after reaching the peak levels, and there 
were no clear differences between them. 
The CBT parameters derived from the enrichment-time curves for all the 
four groups of PEM before and after nutritional rehabilitation are summarised in 
Table 5.9. When each CBT parameter was compared for the four groups of 
malnourished children, the mean AUCs did not differ significantly before (p = 
$129$7XNH\¶VSRVWKRFWHVWQRWVWDWLVWLFDOO\VLJQLILFDQWRUDIWHUp = 
 $129$ 7XNH\¶V SRVW KRF WHVW QRW VWDWLVWLFDOO\ VLJQLILFDQW QXWUitional 
rehabilitation. However, there were significant differences in the mean peak 13C-
enrichments (Cmax) before nutritional rehabilitation (p = 0.0474, ANOVA; 
7XNH\¶V SRVW KRF WHVW QRW VWDWLVWLFDOO\ VLJQLILFDQW EXW VKRZHG QR VLJQLILFDQW
difference after nutritional rehabilitation (p  $129$7XNH\¶VSRVWKRF
test, not statistically significant). The mean time (Tmax) to attain the mean peak 
enrichments did not significantly differ for all categories of malnutrition before (p 
= 0.675, ANOVA; Tukey¶VSRVWKRFWHVWQRWVWDWLVWLFDOO\VLJQLILFDQWRUDIWHUp = 
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 $129$ 7XNH\¶V SRVW KRF WHVW QRW VWDWLVWLFDOO\ VLJQLILFDQW QXWULWLRQDO
rehabilitation. 
 
Table 5.9: Comparison of the CBT parameters from the enrichment-time curves for different types of malnutrition, before 
and after nutritional rehabilitation  
CBT parameters Type of malnutrition  
Underweight Marasmus Marasmic-
kwashiorkor 
Kwashiorkor 
AUC                                          
Pre-nutritional rehabilitation        
Post-nutritional rehabilitation 
                  
0.539±0.320 
0.620±0.322        
(P= 0.528)          
Post hoc power= 
10.2% 
                  
0.419±0.182 
0.498±0.186        
(P= 0.002)* 
               
0.431±0.144 
0.480±0.198        
(P= 0.140)          
Post hoc power= 
11.8% 
                  
0.433±0.118 
0.538±0.160        
(P= 0.0001)* 
Cmax                                         
Pre-nutritional rehabilitation        
Post-nutritional rehabilitation 
           
0.00740±0.00350 
0.00694±0.00345     
(P= 0.691)          
Post hoc power= 
5.5%           
             
0.00499±0.00221 
0.00603±0.00250     
(P= 0.003)* 
               
0.00511±0.00178  
0.00577±0.00207   
(P= 0.102)          
Post hoc power= 
15.3% 
              
0.00544±0.00156 
0.00647±0.00163    
(P= 0.104)          
Post hoc power= 
42.4% 
Tmax                                         
Pre-nutritional rehabilitation        
Post-nutritional rehabilitation 
                  
61.00±23.28 
76.00±26.87        
(P= 0.060)          
Post hoc power= 
37.2% 
                  
91.00±30.50 
90.00±34.49        
(P= 0.898)          
Post hoc power= 
3.0% 
                
87.00±19.80 
84.00±33.45        
(P= 0.783)          
Post hoc power= 
4.8% 
                  
110.00± 29.17 
74.00±29.17        
(P= 0.049)*         
7KHUHZDVDVLJQLILFDQWGLIIHUHQFHLQWKHPHDQYDOXHV6WXGHQW¶V t-test, P <0.05); CBT represents caffeine breath test; AUC 
represents area under the enrichment-time curve; Cmax is the mean peak 13C-enrichment; Tmax is the mean time to attain 
the mean peak 13C-enrichment   
The mean percentage labelled caffeine in the CO2 exhaled over a period of 
2 h before and after nutritional rehabilitation was compared for underweight 
children and/or children experiencing marasmus, marasmic-kwashiorkor, and 
kwashiorkor in Table 5.10.  
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Table 5.10: Comparison of the mean percentage of labelled caffeine in CO2 exhaled over a two hour period, before and 
after nutritional rehabilitation, for different types of malnutrition 
Type of malnutrition Mean percentage labelled caffeine in CO2 
exhaled over a two hour period (%) 
P YDOXH6WXGHQW¶Vt-
test) 
Post hoc 
power 
Pre-nutritional 
rehabilitation 
Post-snutritional 
rehabilitation 
Underweight 7.56±4.02 7.95±3.68 0.603 4.6% 
Marasmus 6.80±3.00 7.67±2.81 0.001 - 
Marasmic-kwashiorkor 6.61±2.26 7.56±2.46 0.041 - 
Kwashiorkor 6.29±1.06 7.20±1.80 0.002 - 
 
Among the four groups of malnourished children, there was no significant 
difference in the mean CPDR either before (p = $129$7XNH\¶VSRVW hoc 
test, not statistically significant) or after (p = $129$7XNH\¶VSRVW hoc 
test, not statistically significant) nutritional rehabilitation. However, for the 
individual group of underweight children, there was no significant change in the 
mean percentage labelled caffeine in the exhaled CO2 following nutritional 
rehabilitation, but there were significant changes in marasmus, marasmic-
kwashiorkor, and kwashiorkor following nutritional rehabilitation.  
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CHAPTER SIX:  
DISCUSSION 
6.1. INTRODUCTION 
This section compares the caffeine breath test (CBT) results for each type of 
malnutrition with those of previous studies that evaluated the hepatic 
metabolism of drugs in malnourished adults, children, and animals. It also 
provides insights into the possible mechanisms for the altered drug metabolism 
in malnourished children, as well as discusses the clinical implications of the 
findings of the studies. Furthermore, the results of the four groups of 
malnutrition are related to one another in order to compare their similarities and 
differences. Lastly, the limitations of the methodology of the studies are also 
discussed. 
 
6.2. UNDERWEIGHT AND CAFFEINE METABOLISM  
Only a few studies have evaluated drug disposition in underweight children. 
Limited pharmacokinetic data emanating from a systematic review suggest 
impaired drug metabolism in underweight children (Oshikoya et al., 2010).  
In the present study underweight children were studied before and after 
nutritional rehabilitation. Nutritional rehabilitation for 2 to 6 weeks enabled the 
underweight children to attain the expected weight-for-height of well-nourished 
children before they were restudied, thus serving as normal weight controls. The 
13C-enrichment curves for the underweight children before and after nutritional 
rehabilitation were similar. The rates (as indicated by the Cmax and Tmax values) 
of labelled caffeine recovered in the 13CO2 exhaled in the 2 h period by the 
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underweight children before and after nutritional rehabilitation also were similar. 
There was also a similarity in the extents of recovery of labelled caffeine (as 
indicated by the AUC values) in the 13CO2 exhaled in the 2 h period by 
underweight children both before and after nutritional rehabilitation. The results 
suggest that the metabolism of labelled caffeine was not significantly affected in 
children when they were underweight compared to when they had attained 
normal weight after nutritional rehabilitation. 
The similarities observed in the 13C-enrichment curves for the underweight 
children before and after nutritional rehabilitation are comparable to results of 
similar studies. Park et al. (2003) used the CBT to compare the metabolising 
activities of CYP1A2 in healthy adult controls and adults with hepatitis. They 
observed that the time to peak 13C-enrichment, as well as the peak enrichment 
level, both after oral labelled-caffeine administration, was not significantly 
different between the two groups. A study comparing the disposition of labelled 
caffeine in healthy adult controls and those with liver cirrhosis has also 
documented no significant difference in the absorption rates (Desmond et al., 
1980). Similarly, the absorption rates of labelled caffeine did not differ 
significantly when its disposition in healthy controls was compared to children 
suffering from malaria (Akinyinka et al., 2000). It may thus be concluded that 
disease states, as well as underweight malnutrition, appear to not significantly 
affect the oral absorption of caffeine.  
The CBT was first used by Lambert et al. (1986) to determine the activity 
of CYP1A2 in children. They reported that the time to peak rate of 13CO2 
exhalation occurred in the first 2 h after labelled caffeine administration. In the 
present study the mean peak 13C-enrichment values were attained for 
underweight children before and after nutritional rehabilitation in less than 2 h. 
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These results were quite similar to the 60 min generally taken to attain the peak 
13C-enrichments in healthy adult controls and adults with chronic hepatitis (Park 
et al., 2003). A pharmacokinetic study also has documented a time of 50 to 60 
min to attain the peak plasma concentration of caffeine in healthy children and 
children suffering from malaria in Nigeria (Akinyinka et al., 2000).  
Previous studies involving the use of CBT in children (Lambert et al., 
1986; Parker et al., 1994) and adults (Butler et al., 1989; Kalow and Tang, 
1993) have shown that the cumulative 13CO2 exhaled in the 2 h period reflects a 
3-N-demethylation of caffeine, which is a CYP1A2-dependent reaction. Two 
different studies have established the 2 h SHULRG¶Vcumulative exhalation of 13CO2 
as a standard for determining CYP1A2 activity (Kotake et al., 1982; Park et al., 
2003), which was based on the observation that a maximal correlation (r = 
0.90) between the cumulative percent 13C-caffeine doses recovered (CPDR) in 
the breath samples and its plasma clearance (CL) occurred at 2 h after the oral 
intake of labelled caffeine. The present study has established that the mean 
CPDR in the breath samples collected during the 2 h period before and after 
nutritional rehabilitation were similar. This result suggests that the metabolising 
activity of CYP1A2 was unaffected by underweight malnutrition.  
Considering the small number of underweight children evaluated before 
and after nutritional rehabilitation, the present study may not have been 
powered enough to detect a statistically significant difference in the results. 
Such a difference would have been the basis for validating the results in a larger 
population of underweight children. However, a previous study involving the use 
of CBT has shown that a smaller sample size of 11 children with gastritis was 
adequately powered to demonstrate a lack of inhibitory effect of cimetidine on 
caffeine metabolism (Parker et al., 1997b). In another study involving 12 
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healthy and six underweight children, the lack of significant change between 
plasma CLs of oral theophylline was documented (Eriksson et al., 1983). Both 
caffeine and theophylline are methylxanthines predominantly metabolised by the 
CYP1A2 enzyme via the same pathway. Therefore, it may be concluded that the 
N-demethylation pathway was not significantly affected in underweight children.  
The unaffected CYP1A2 activity observed in the underweight children is 
also comparable to the findings of Tranvouez et al. (1985), who determined that 
the plasma CL of antipyrine (a drug that is partially metabolised by CYP1A2) in 
underweight adults showed significant change after WKH DGXOWV¶ nutritional 
rehabilitation. However, three other studies have shown decreased CL of 
different drugs in underweight patients. Specifically, antipyrine CL was 
decreased in underweight adults (Krishnaswamy & Naidu, 1977), while the CLs 
of acetylsalicylic acid and penicillin decreased in underweight children (Bolme et 
al., 1995; Lares±Asseff et al., 1999). Different types of CYP450 enzymes are 
responsible for the metabolism of caffeine and acetylsalicylic acid, while penicillin 
is usually eliminated without undergoing hepatic metabolism. Acetylsalicylic acid 
is metabolised by CYP3A4, while caffeine is predominantly metabolised by 
CYP1A2. Variation in the activity of the metabolising enzymes may account for 
the differences in the disposition of caffeine and other drugs in underweight 
children. 
 
6.3. MARASMUS AND CAFFEINE METABOLISM 
The mean CPDR exhaled as CO2 which measures the activity of CY1A2 in the 2 h 
period was significantly lower in marasmic states than after nutritional recovery. 
Caffeine is a probe substrate of CYP1A2 enzyme activity which has been 
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previously used to predict the pharmacokinetics of tactrine in patients with 
$O]KHLPHU¶VGLVHDVH)RQWDQDet al., 1998). Since the CBT directly assesses the 
metabolic activity of CYP1A2 enzyme, it may be appropriate to compare the 
results with those of the plasma CLs of drugs in malnourished children. The 
decreased metabolism of labelled caffeine observed in marasmic children is 
consistent with the decreased plasma clearance of sulphamethoxazole and 
quinine previously reported in a similar group of children (Bravo et al., 1984; 
Pussard et al., 1999).  
Other studies have similarly documented decreased plasma CLs of 
antipyrine (Homeida et al., 1979; Narang et al., 1977) and metronidazole 
(Lares±Asseff et al., 1992) in marasmic children. Like caffeine, antipyrine and 
metronidazole are metabolised by oxidation. Although all three drugs are 
metabolised by CYP1A2, other hepatic cytochrome P450 enzymes (CYP2B6, 
CYP2C8, CYP2C9, CYP2C18, and CYP3A4) are involved in the metabolism of 
antipyrine and metronidazole (Engel et al., 1996; Loft, 1991). Both CYP1A2 and 
all other cytochrome P450 enzymes constitute the hepatic mixed-function 
oxidase system (Watkins, 1990). Limited data have indicated that the 
metabolising activities of the mixed-function oxidase system are affected by 
malnutrition (Cho et al., 1999; González±Hernández et al., 2008; Krishnaswamy 
& Naidu, 1977; Narang, 1977).  
My findings regarding marasmic children also agree with those of 
Tranvouez et al. (1985), who investigated the total CL of antipyrine in 49 global 
protein-calorie malnourished adults, 25 well-nourished control groups, and 27 
malnourished adults who had been rehabilitated nutritionally with artificial 
nutrition for a month. The metabolic CL rate was significantly lower in the 
control and nutritionally rehabilitated groups. However, the lack of a significant 
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difference between the metabolic CL rates of the control and nutritionally 
rehabilitated groups suggested that the activity of the metabolising enzymes 
reverted to normal after nutritional recovery. Pantuck et al. (1985) also found 
that parenteral nutritional replenishment in adult patients with protein-calorie 
malnutrition for a week resulted in the increased CL of antipyrine by 87%. A 
similar result was obtained after changing to oral diets rich in both 
carbohydrates and proteins.  
Unlike the present CBT results, another study has indicated no significant 
difference in the plasma CL of theophylline in marasmic children compared to 
their healthy controls (Eriksson et al., 1983b). This study was conducted in eight 
children only and estimated the plasma CL of theophylline instead of the 
metabolic CL by CYP1A2. Moreover, the marasmic children were not restudied as 
their own controls after nutritional rehabilitation. The results of the theophylline 
study may, therefore, be prone to bias from a wide inter-participant variation in 
CYP1A2 activity. Plus, the small sample size may have underpowered the study¶V
capacity to detect a significant difference in the results.  
Eriksson et al. (1983a) also studied the total plasma CL of 
chloramphenicol in eight children with marasmus and eight healthy control 
groups to show no significant difference in the results. Chloramphenicol is 
metabolised predominantly by glucuronidation via a conjugation process. This 
metabolic pathway is quite different from the oxidative process evaluated in the 
present studies. The enzymes involved in both metabolic processes may have 
been affected differently by marasmus. However, another study that examined 
the metabolism of chloramphenicol in seven marasmic children before and after 
4 to 6 weeks of nutritional rehabilitation demonstrated a significantly decreased 
plasma CL in patients with malnutrition compared to these patients after they 
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had received nutritional rehabilitation (Mehta et al., 1975). Liver biopsies from 
two of these marasmic children demonstrated a reduction of the glucuronyl 
transferase enzyme to one-half and one-third, respectively, of the normal value. 
The mechanism involved in the altered CYP1A2 activity and decreased 
caffeine metabolism in marasmic children remains poorly understood. However, 
it has been suggested that marasmus, as an adaptation to insufficient energy 
intake, results in reduced total microsomal haeme, phospholipids, and flavin 
adenine dinucleotide levels, normal levels of which are all necessary for 
microsomal drug metabolism (Rumack et al., 1973).  
In the present studies the patterns of 13C-enrichment curves for marasmic 
children before and after nutritional rehabilitation were similar. However, the 
curves were clearly different from those for adults with or without hepatic 
disease studied by Park et al. (2003). They also differed from those reported in 
adult smokers and non-smokers (Kotake et al., 1982), and sham-operated rat 
controls (Schaad et al., 1995). A typical 13C-enrichment curve is characterised 
by a gradual rise to a peak level and then a steady fall over the study period 
(Park et al., 2003; Kotake et al., 1982; Schaad et al., 1995). By contrast, after 
attaining the peak levels in the present studies, the 13C-enrichment curves 
remained relatively constant in marasmic children before and after nutritional 
rehabilitation. These patterns are similar to the CBT curves observed in rats that 
underwent a two-third resection of the liver, bile duct ligation, or portocaval 
anastomosis (Schaad et al., 1995). The hepatic injuries in the animal study were 
associated with a significantly decreased liver mass and reduced CYP1A2 
activity, as indicated by 50% to 60% reduction in the fraction of labelled caffeine 
dose recovered over the study period. The study of animal models also indicated 
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that the 3-N-demethylation of caffeine was saturated faster when CYP1A2 
activity was reduced.  
The present UHVHDUFK¶V CBT curves for marasmic children also were similar 
to those described by Kotake et al. (1982) for adult non-smokers administered 
5mg/kg labelled caffeine. After attaining the peak 13C-enrichment level in the 
first hour, the enrichment levels remained relatively constant, since the 
saturation of CYP1A2 enzyme occurred at a lower dose of 3mg/kg.  
The quantity and quality of metabolising enzymes are known to decrease 
in severe malnutrition (Mehta et al., 1975; Narang, 1977). It is therefore 
postulated that the 3-N-demethylation of caffeine by CYP1A2 enzyme is 
saturated faster in marasmic children than in well-nourished children. This 
suggestion may explain the current pattern of CBT curves for children in 
marasmic and nutritional recovery states. This hypothesis is supported by the 
following points: (i) decreased oxidative phosphorylation in the liver 
homogenates of malnourished infants, which was less pronounced in marasmus 
than in kwashiorkor (Waterlow, 1970); (ii) reduced activities of the enzymes 
involved in amino acid metabolism in the liver of marasmic infants (Stephen & 
Waterlow, 1968); and (iii) decreased capacity and affinity of CYP1A2 enzyme in 
the liver homogenates of juvenile and adult rats that were malnourished (Mao et 
al. , 2006). Moreover, the biochemical and physiological normalities had been 
reported to lag behind nutritional recovery in malnourished children, which may 
not be regained until several weeks later (Golden, 2009). Despite the rapid 
weight gain and early attainment of normal weight-for-height, malnourished 
children are deficient in functional tissue during the early stages of nutritional 
recovery (Cheek et al., 1970).  
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The rate and extent of labelled caffeine recovery in the exhaled 13CO2 
were significantly lower in the marasmic state than after nutritional recovery. 
The percentage decrease in these parameters was much lower than those 
reported in partially hepatectomised rats and their control groups (Schaad et al., 
1995).  
 
6.4. MARASMIC-KWASHIORKOR AND CAFFEINE METABOLISM 
In the present studies caffeine metabolism, as determined by the mean CPDR in 
the CO2 exhaled in 2 h, significantly decreased in children with marasmic-
kwashiorkor compared to the amount exhaled after their nutritional 
rehabilitation. This finding suggests a decreased CYP1A2 activity in children with 
marasmic-kwashiorkor. The mechanism involved in the altered CYP1A2 activity 
and decreased caffeine metabolism in these children is not yet fully understood. 
As an intermediate severe malnutrition, marasmic-kwashiorkor is characterised 
by some of the clinical features of marasmus and kwashiorkor. The 
pathophysiological changes affecting drug metabolism are therefore likely to be 
less severe in marasmic-kwashiorkor than in marasmus and kwashiorkor. The 
metabolic alteration in marasmic-kwashiorkor has been attributed mainly to 
changes in the levels of microsomal membrane proteins, especially that of 
cytochrome P450 (Hayes et al, 1978; Thabrew, 1983) and decreased fluidity of 
the phospholipid bilayer of the endoplasmic reticulum membrane, which impairs 
the interactions among NADPH-cytochrome P450 reductase, cytochrome P450, 
cytochrome b, and other specific drug metabolising enzymes (Suzuki et al., 
1980; Thabrew, 1983). 
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Few data are available on the hepatic CL of drugs in children with 
marasmic-kwashiorkor (Eriksson et al., 1983a; Lares±Asseff et al., 1992; 
Narang et al., 1977). The findings of the present research are consistent with 
the reports of reduced plasma CL of antipyrine and metronidazole in children 
with marasmic-kwashiorkor compared to healthy control children (Lares±Asseff 
et al., 1992; Narang et al., 1977). Although the CBT assessed caffeine 
metabolism by CYP1A2 enzyme, other studies have assessed antipyrine and 
metronidazole metabolism by other cytochrome P450 enzymes, including 
CYP2B6, CYP2C8, CYP2C9, CYP2C18, and CYP3A4. 
The findings of the present research, however, contrast the lack of 
significant difference between the total CL of chloramphenicol in nine children 
with marasmic-kwashiorkor and eight healthy controls (Eriksson et al., 1983a). 
This difference may derive from the separate pathways involved in the 
metabolism of chloramphenicol and caffeine. Caffeine is metabolised by an 
oxidation process, via an N-demethylation pathway, while chloramphenicol is 
metabolised in young children predominantly by conjugation to the production of 
glucuronic acid (Glazko, 1966). The oxidation of chloramphenicol thus concerns 
a minor pathway. Bolme et al. (1995) reported a significantly decreased plasma 
CL of penicillin in eight children with marasmic-kwashiorkor compared to six 
healthy controls. Penicillin rarely undergoes hepatic metabolism, for it is 
eliminated unchanged by the kidneys primarily, while caffeine is predominantly 
metabolised in the liver by CYP1A2 enzymes. The variations in the metabolic 
pathways of both penicillin and caffeine may explain the differences in the 
results of the two studies. 
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6.5. KWASHIORKOR AND CAFFEINE METABOLISM 
In the present research the mean cumulative per cent 13C-doses exhaled as 
labelled CO2 over a 2 h period significantly decreased in children with 
kwashiorkor compared to data following their nutritional rehabilitation. Since the 
labelled caffeine recovered in the 2 h breath samples measures CYP1A2 activity, 
it can be concluded that the enzyme activity was reduced in children with 
kwashiorkor.  
Of the four categories of malnutrition, pharmacokinetic studies have been 
most often conducted in children with kwashiorkor (Oshikoya et al., 2010). 
However, the majority of the medicines evaluated were metabolised through 
pathways other than those catalysed by CYP1A2.  
When CYP1A2 activity from the present CBT data was compared to the 
activities of other CYP450 enzymes previously assessed by drug plasma CLs in 
children with kwashiorkor, some similarities and discrepancies were observed. 
The findings of the present research agree with the significantly reduced plasma 
CL of caffeine reported in children with kwashiorkor (Akinyinka et al., 2000). 
Another study of adults with or without liver cirrhosis also documented a 
significantly decreased plasma CL of caffeine in patients with decompensated 
liver cirrhosis compared to the healthy controls (Scott et al., 1988). This study 
also reported that patients with compensated liver cirrhosis and the healthy 
controls metabolised caffeine similarly. Both Akinyinka et al. (2000) and Scott et 
al. (1988) involved six to 10 participants and five to eight controls compared to 
the 15 participants or controls evaluated in the four present studies. However, 
contrasting results have been reported regarding the metabolism of theophylline 
in children with kwashiorkor. Its plasma CL was significantly reduced in 
kwashiorkor compared to the healthy controls (Eriksson et al., 1983b). Only five 
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participants and 12 controls were studied, which is less than the number of 
participants or controls evaluated in the present studies¶ CBT. The small sample 
size may have underpowered the study¶V FDSDFLW\ to detect a significant 
difference in the plasma CLs of theophylline, which may have contributed to the 
varied effects of kwashiorkor on different drugs metabolised by the CYP1A2 
enzyme.  
The findings of this study are also similar to the effects of kwashiorkor on 
the plasma CLs of isoniazid, antipyrine, quinine, and chloramphenicol (Buchanan 
et al., 1979; Buchanan et al., 1980; Eriksson et al., 1983b; Salako et al., 1989). 
The plasma CLs of these four drugs were significantly reduced in kwashiorkor. As 
aforementioned, caffeine is metabolised predominantly by CYP1A2 enzyme, yet 
other drugs are metabolised by different metabolising enzymes. Isoniazid is 
metabolised by N-acetyltransferase-2 (NAT2), CYP2E1, and glutathione S-
transferase (GST) (Sotsuka et al., 2011); antipyrine is metabolised by CYP1A2, 
CYP2B6, CYP2C8, CYP2C9, CYP2C18, and CYP3A4 (Engel et al., 1996); the 
metabolism of quinine is catalysed predominantly by CYP3A4 (Zhao et al., 
1996); and chloramphenicol is metabolised predominantly via glucuronidation by 
the UDP-glucuronyl transferase enzyme (Park et al., 2003). These findings could 
suggest that multiple metabolising enzymes are impaired in children with 
kwashiorkor.  
Penicillin, streptomycin, and cefoxitin, all of which are primarily eliminated 
unchanged by the kidneys without undergoing hepatic metabolism, have shown 
decreased plasma CLs in children with kwashiorkor (Bolme et al., 1988; Bolme 
et al., 1995; Buchanan et al., 1979c; Buchanan et al., 1980b). The findings of 
the present research concur regarding children with kwashiorkor. Contrasting 
reports have, however, been documented on the plasma CLs of gentamicin and 
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amikacin (Buchanan et al., 1980b; Hendricks et al., 1995). Both drugs 
demonstrated no significant changes in their plasma CLs in children with 
kwashiorkor. These varying effects of kwashiorkor on the hepatic metabolism 
and renal elimination of drugs may derive from the pathophysiological changes 
that affect all organs of drug disposition (Krishnaswamy, 1983).  
A number of potential mechanisms have been documented to explain the 
altered drug metabolism in children with kwashiorkor. The activity of the 
metabolising enzymes may be suppressed or reduced (Eriksson et al., 1983a; 
Narang, 1987). The quantity of the metabolising enzymes may also be 
decreased (Mehta et al., 1975) or their quality decreased (Chatterjee & 
Mukherjee, 1968; Rumack et al., 1973). Kwashiorkor has been linked to 
diminished kinetics of microsomal enzymes (Mgbodile et al., 1973). 
Micronutrient deficiencies are constituent features of children with kwashiorkor 
(Krishnaswamy, 1983; Sauerwein et al., 1997), and the absences of these 
deficiencies are necessary cofactors to the metabolising enzymes¶ optimal 
performance. The growth hormone required for the modulation of the 
metabolising enzymes (Wilson, 1973) is known to be significantly increased in 
kwashiorkor (Laditan, 1983; Van Der Westhuysen et al., 1975). 
Limited data have also indicated that impairment of drug metabolism in 
children with kwashiorkor may be related, at least in part, to maladaptation and 
nutritional deprivation (Franco et al., 1999). Hepatomegaly is a common feature 
of kwashiorkor, though liver function tests have shown normal results in at least 
two studies (Porta & Hartroft, 1970; Tandon et al., 1974). However, 
ultrastructural studies of liver biopsies of patients with kwashiorkor have shown 
fatty changes, abnormal rough endoplasmic reticula and mitochondria, and 
decreased peroxisomes (Brooks et al., 1992; Brooks et al., 1994; Tandon et al., 
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1974), all of which were completely reversible after nutritional rehabilitation 
(Buchanan et al., 1979a).  
 
6.6. DIFFERENTIAL EFFECTS OF ALL CATEGORIES OF 
MALNUTRITION ON CAFFEINE METABOLISM 
This section aims to compare the similarities and differences among the effects 
of each category of malnutrition on caffeine metabolism. 
The enrichment curves for the underweight children before and after 
nutritional rehabilitation were similar and comparable to those of healthy adults 
(Park et al., 2003), adult non-smokers (Kotake et al., 1982), and sham-operated 
rat controls (Schaad et al., 1995). These results suggest that the activity of the 
enzyme involved in the metabolism of labelled caffeine was not significantly 
affected in underweight children compared to results after they had attained 
normal weight following nutritional rehabilitation. 
The 13C-enrichment curves for children with marasmus, marasmic-
kwashiorkor, and kwashiorkor differed from those of the underweight children 
and were characterised by plateaus after attaining peak levels. These are similar 
to the shape of the CBT curves described for rats that had undergone a partial 
hepatectomy, bile duct ligation, or portocaval anastomosis (Schaad et al., 1995). 
The rats of the experimental group lost approximately 30% of their liver mass in 
association with a reduction of approximately 60% in their CYP1A2 activity. The 
significance of the altered curves remains uncertain. 
The mean cumulative per cent labelled-caffeine in the CO2 exhaled over a 
period of 2 h showed no significant difference between the four groups of 
malnutrition before and after nutritional rehabilitation. This result would suggest 
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that the activity of CYP1A2 enzymes were similar in underweight children and 
those experiencing marasmus, marasmic-kwashiorkor, or kwashiorkor. The 
studies were not, however, powered well enough to detect a significant 
difference in CYP1A2 activities between the four groups of malnutrition. 
Therefore, caution is recommended in interpreting the results. A larger study is 
needed to validate the results presented in this study.  
 
6.7. COMPARISON WITH OTHER STUDIES  
When the results of the present CBT are compared to those of pharmacokinetic 
studies in healthy controls and those patients experiencing marasmus, 
marasmic-kwashiorkor, or kwashiorkor, there were some similarities and 
differences (Bolme et al., 1995; Bolme et al., 1988; Eriksson et al., 1983a; 
Eriksson et al., 1983b). The data from the three groups of severely 
malnourished children stood in contrast to the lack of significant difference in the 
plasma CLs of streptomycin and theophylline reported in similar groups of 
patients (Bolme et al., 1988; Eriksson et al., 1983b). However, other studies 
have documented a significant decrease in the plasma CLs of penicillin and 
chloramphenicol in children with marasmus, marasmic-kwashiorkor, and 
kwashiorkor compared to their respective healthy control groups (Bolme et al., 
1995; Eriksson et al., 1983a). 
The variation in the present CBT results and those of these previous 
pharmacokinetic studies may be explained by methodological differences, the 
involvement of other hepatic cytochrome P450 enzymes in the metabolism of 
drugs other than caffeine, and the elimination pathways of some of the drugs. 
The present research evaluated malnourished children who also served as their 
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own controls after nutritional rehabilitation. Their nutritional statuses were 
determined from anthropometric parameters only. Furthermore, they were 
treated empirically for infections prior to the study, and the CBT was used to 
assess the activity of their CYP1A2 enzyme. By contrast, participants in the 
previous pharmacokinetic studies were either children or adults; malnutrition 
ZDVVHFRQGDU\WRFRH[LVWLQJJDVWURLQWHVWLQDOGLVHDVHVVXFKDV&URKQ¶VGLVHDVH
ulcerative colitis, and bowel cancer; diagnosis of malnutrition was based on 
weight loss of 10% and reduced serum albumin concentration; participants 
either served as their own controls or age, sex-matched control groups were 
used for comparison; plasma CLs of the drugs were determined; and the drugs 
studied were metabolised by cytochrome P450 enzymes other than CYP1A2 
(Krishnaswamy & Naidu, 1977; Tranvouez et al., 1985). Previous studies have 
shown that coexisting diseases, such as malaria, can influence the disposition of 
caffeine and quinine in children (Akinyinka et al., 2000; Pussard et al., 1999).  
The percentage decrease in CYP1A2 activity, as indicated by the mean 
cumulative per cent labelled caffeine in the CO2 exhaled in 2 h was 4.9% in 
underweight children. This contrasted the 11.3%, 12.5%, and 12.6% observed 
in marasmus, marasmic-kwashiorkor and kwashiorkor, respectively. These 
percentage changes in CYP1A2 activity for the three groups of severely 
malnourished children were relatively similar but much lower than the 55.5% 
decrease by ciprofloxacin in children with cystic fibrosis (Parker et al., 1994). It 
is believed that variation in the pathophysiology of malnutrition and cystic 
fibrosis and the potential interaction of ciprofloxacin with caffeine may have 
caused the differences in the results. On its own, cystic fibrosis has been 
reported to enhance xanthine oxidase activity required in caffeine metabolism 
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(Hamelin et al., 1994), while ciprofloxacin is a known CYP1A2 inhibitor (Levien & 
Baker, 2003). 
6.7.1. Appropriateness of the sample size  
The sample size of 15 participants per group of malnutrition type is substantially 
larger than any of those involved in the previous studies that evaluated total 
plasma CLs of drugs exclusively metabolised in the liver of malnourished children 
(Oshikoya et al., 2010).  
Only 5 to 10 malnourished children were studied for the clearances of 
caffeine (Akinyinka et al., 2000), theophylline (Eriksson et al., 1983b), 
chloramphenicol (Eriksson et al., 1983a), acetanilide (Buchanan et al., 1980a), 
quinine (Salako et al., 1989), antipyrine (Narang et al., 1977), and 
metronidazole (Lares±Asseff et al., 1992). Based on a power calculation, it was 
determined that the 15 patients who participated in each CBT study were 
adequate to minimising bias caused by the small sample size characterising 
previous pharmacokinetic studies of malnourished children. However, post hoc 
analysis of the results that yielded no significant difference between the 
malnourished and nutritionally restored states showed that a sample size of 15 
may not be adequately powered to detect any significant difference in the 
results. Therefore, a sample size greater than 15 may be necessary to validate 
some of the results presented in this study. 
6.7.2. Age group and gender of the patients 
Previous studies have shown low 3-N-demethylation of caffeine in infants 
younger than 6 months (Pons, et al., 1988). The CBT is therefore appropriate to 
use in children older than 6 months as a method to study the effect of diseases 
on drug metabolism (Parker et al., 1994). Malnutrition affects infants and young 
children (6 to 60 months old) more frequently than older age groups (Nnakwe, 
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1995; WHO, 2000). The severely malnourished children evaluated in the present 
CBT study were between 3 and 6.5 years old²ages which are in keeping with 
the age group most affected by malnutrition. However, children younger than 3 
years were excluded, because they may not have been able to follow the 
instructions required for reliable breath sample collection. Similar exclusion 
criteria have been used in previous CBT studies of children (Parker et al, 1994; 
Parker et al, 1997a; Parker et al, 1997b). All the previous CBT studies involved 
children who were 6 to 17 years old. The children tolerated the test for 2 h and 
cooperated with the investigators throughout its duration.   
The participants for the present studies were not balanced by gender. No 
balance was considered necessary, because the participants served as their own 
controls. In addition, the gender effect of CYP1A2 on caffeine metabolism has 
not been determined in children, though there have been inconsistent reports in 
adults (Horn et al., 1995; Ou±Yang et al., 2000). In one study the activity of 
CYP1A2, as indicated by the metabolic CL of caffeine, was reported to be higher 
in men than in women (Ou±Yang et al., 2000). In another study, which used 
CBT to assess the activity of CYP1A2 enzyme, there was no statistically 
significant difference between the enzyme activity in men and women (Horn et 
al., 1995).  
6.7.3. Focusing on CYP1A2 enzymes only 
CYP1A2 accounts for about 13% of the total human hepatic cytochrome P450 
enzymes (Shimada et al., 1994) and metabolises a variety of clinically important 
drugs. Nevertheless, only the dispositions of caffeine, theophylline, antipyrine, 
aminopyrine, metronidazole, and propranolol have been studied in malnourished 
children. The present studies focused on the metabolising activity of CYP1A2 
enzymes only, thus precluding the use of CBT to evaluate the metabolism of 
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other clinically relevant drugs that operate independently of CYP1A2 enzymes in 
malnourished children. 
Given the spectrum of medicines used for treating malnourished children 
that are not metabolised by the N-demethylation pathway only, there is a need 
to develop or explore other methods for studying drug metabolism in this sect of 
the population. Such methods include a population pharmacokinetic study 
involving a larger paediatric sample size with a few blood samples (Thomson, 
2006). Salivary samples or dried blood spot tests may replace the venous blood 
to render the procedure as non-invasive as possible.  
 
6.8. SUMMARY   
Four studies involving the use of CBT were conducted to evaluate the effect of 
underweight malnutrition, marasmus, marasmic-kwashiorkor, and kwashiorkor 
on 13C-caffeine metabolism and CYP1A2 activity. Altogether, 60 malnourished 
children²15 participants per group of malnutrition²were studied, both in their 
acute malnourished states and after their nutritional rehabilitation.  
The 13C-enrichment curves for underweight children before and after 
nutritional rehabilitation were similar to those previously reported in the 
literature regarding healthy adults. The curves showed both the same pattern 
and similarities in the rates and extents of recovery of labelled caffeine in the 
13CO2 exhaled in 2 h before and after nutritional rehabilitation. Furthermore, the 
mean CPDR in the expired CO2 in 2 h by underweight children both before and 
after nutritional rehabilitation did not differ significantly. These results suggest 
that the metabolism of labelled caffeine, as well as the activity of CYP1A2 
enzyme, was not significantly affected in underweight children compared to 
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findings when they had attained normal weight after their nutritional 
rehabilitation. The findings were, however, based on a small number of 
underweight children, which may not be powered enough to detect any 
significant difference in the results before and after nutritional rehabilitation. 
Severely malnourished children (i.e., experiencing marasmus, marasmic-
kwashiorkor, and kwashiorkor) also demonstrated significantly decreased 
CYP1A2 metabolising activities compared to findings when they had recovered 
nutritionally. This was made clear by the decreased mean CPDR in their expired 
CO2 in 2 h during acute malnutrition.  
Upon comparing the four groups of malnutrition both before and after nutritional 
rehabilitation, there was no significant difference in their mean CPDRs. This 
result suggests that the activity of CYP1A2 enzymes is similar in underweight 
children and those experiencing marasmus, marasmic-kwashiorkor, or 
kwashiorkor. The four studies, however, were not powered enough to detect a 
significant difference in CYP1A2 activities between the four groups of 
malnutrition.
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CHAPTER SEVEN:  
CONCLUSION 
7.1. INTRODUCTION 
This research initially involved performing a systematic review of 
pharmacokinetic studies in children with protein-energy malnutrition (PEM), 
followed by the caffeine breath test (CBT) to assess the activity of CYP1A2 
enzyme in four study samples of child participants. The major findings from the 
systematic review and the CBT are summarised below. 
7.2. THE SYSTEMATIC REVIEW 
The systematic review identified that different groups of malnutrition affect drug 
disposition differently. The absorption of oral drugs was generally not 
significantly impaired in malnourished children compared to the control groups. 
However, in a study involving children with different categories of malnutrition, 
there were variations in the oral absorption of penicillin. Its absorption rates 
were similar for underweight and marasmic children when compared to the 
controls (Bolme et al., 1995) but decreased in kwashiorkor. There were 
insufficient data on the absorption rate of intramuscular (i.m.) drugs, thus 
precluding any firm conclusion regarding the effects of PEM on the absorption 
rate of i.m. drugs. Similarly, there was a scarcity of data on the extent of 
absorption (i.e., bioavailability) of drugs in PEM. It is, therefore, difficult to 
conclude on this topic. 
Malnutrition appeared to not affect the volume of distribution (VD) of oral 
and i.m drugs identified in the systematic review, likely since the majority of the 
drugs have low protein-binding capacities and slight but statistically significant 
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changes in their unbound fractions. However, while malnutrition showed varying 
effects on the VD of quinine, streptomycin, theophylline, and gentamicin, the 
values remained unaffected or decreased and/or increased. 
About a half of the drugs identified in the systematic review had 
significantly decreased plasma clearances (CL) or increased elimination half-lives 
in malnourished children. However, two drugs (chloramphenicol and quinine) 
demonstrated variations in their plasma CLs in different groups of malnutrition. 
For chloramphenicol, total CL was significantly decreased in children with 
kwashiorkor but unaffected in children with marasmus and marasmic-
kwashiorkor (Eriksson et al., 1983a). Similarly, the total CL of quinine was 
significantly decreased in children with kwashiorkor (Salako et al., 1989) but 
increased in those who had marasmus or marasmic-kwashiorkor (Treluyer et al., 
1996). The pathophysiological changes affecting different types of malnutrition 
appeared to have contributed to the variations in the results. 
7.3. THE CAFFEINE BREATH TEST (CBT) 
Caffeine metabolism was not significantly impaired in underweight children as 
suggested by the similarity in their mean cumulative per cent 13C-dose 
recovered in the 2 h CO2 exhaled, both before and after nutritional rehabilitation. 
Overall, this finding suggests that underweight malnutrition did not significantly 
influence CYP1A2¶V metabolising activity. However, post hoc power analysis 
showed that the study was inadequately powered to detect a statistically 
significant difference in the activity of CYP1A2 in underweight children and when 
they had been nutritionally rehabilitated. Further studies with larger sample 
sizes are therefore required to validate the present results. 
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There were contrasting results for underweight children regarding the 
effects of the three types of severe malnutrition (marasmus, marasmic-
kwashiorkor, and kwashiorkor) on caffeine metabolism. The mean cumulative 
per cent 13C-dose recovered in the exhaled CO2 over the period of 2 h 
significantly decreased in children with marasmus, marasmic-kwashiorkor, and 
kwashiorkor, compared to when they were nutritionally rehabilitated. It is 
uncertain why there was plateauing of the 13C-enrichment curves for each group 
of severe malnutrition after attaining peak levels before and after nutritional 
rehabilitation. However, it is possible that the N-demethylation pathway was 
saturated early in the three forms of severe malnutrition.  
The decreasing trend in the mean cumulative per cent 13C in the CO2 
exhaled over the period of 2 h observed from underweight to kwashiorkor 
children, before and after nutritional rehabilitation, would suggest that different 
groups of malnutrition affect drug metabolism differently. However, the lack of a 
significant difference in the mean cumulative per cent 13C recovered in the 
exhaled CO2 of the underweight and severely malnourished children, before and 
after nutritional rehabilitation, was not powered enough to enable a firm 
conclusion regarding the differential effects of malnutrition on caffeine 
metabolism.  
7.4. CLINICAL IMPLICATIONS 
Data emanating from the systematic review have indicated a significantly 
reduced total CL of drugs predominantly metabolised in the liver of children with 
marasmus, marasmic-kwashiorkor, or kwashiorkor. Data from the present CBT 
have demonstrated a decreased metabolising activity of the CYP1A2 enzyme in 
severely malnourished children. Clinicians may need to consider reducing the 
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dose of clinically relevant drugs such as paracetamol, theophylline, diazepam, 
naproxen, propranolol, ondansetron, amiodarone, cimetidine, omeprazole, 
ciprofloxacin, clarithromycin, erythromycin, nalidixic acid, ketoconazole, 
arthemether/lumefantrine, thiabendazole, carbamazepine, phenobarbital, 
phenytoin, isoniazid, rifampicin, and ritonavir (Levien & Baker, , 2003), all of 
which are metabolised via the N-demethylation pathway. However, population 
pharmacokinetic studies are required to determine the therapeutically safe doses 
of these drugs in severely malnourished children.  
The altered hepatic drug metabolism in all groups of severely 
malnourished children is reversible after nutritional rehabilitation, therefore drug 
dosages and dosing regimens should be revised for patients continuing drug 
therapy after nutritional recovery.  
Both using the CBT to further study caffeine metabolism in large 
populations of severely malnourished children and validating those results with 
population pharmacokinetic and pharmacodynamic studies are necessary to 
inform future international guideline recommendations. 
7.5. FUTURE WORK 
This research recognises that even more research needs to be done in the area 
of malnutrition and drug metabolism. There is a particular need for more 
population pharmacokinetic studies to define drug dosages and dosing regimens 
of clinically relevant drugs yet unstudied in malnourished children. The CBT can 
be extended to study the effects of concomitant diseases in malnourished 
children on CYP1A2 activity.  
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7.5.1. Additional pharmacokinetic studies 
A significant limitation of traditional pharmacokinetic studies is the need for 
multiple blood samples. This need poses ethical and practical challenges for 
obtaining pharmacokinetic data in malnourished children. Antitubercular drugs 
(isoniazid, rifampicin, pyrazinamide, and ethambutol), and antiretroviral drugs 
(nevirapine, efavirenz, stavudine, lamivudine, zidovudine, abacavir, didanosine, 
and lopinavir/ritonavir) are other therapeutically relevant drugs for malnourished 
children. Many of these drugs may not be metabolised by the CYP1A2 enzyme, 
and their metabolism could not be studied with the CBT. An alternative approach 
that involves the use of population pharmacokinetics in which a few blood 
samples are collected from a large number of patients (Thomson, 2006) may be 
necessary. The dried blood spot (DBS) technique that involves the collection of a 
few drops of blood onto a filter paper and is used in combination with 
pharmacokinetic modelling techniques (Patel et al., 2010) is another useful 
approach. Salivary samples have been compared with venous and capillary blood 
samples in the investigation of pharmacokinetics of paracetamol (Rittau & 
McLachlan, 2012). The results were promising and may be useful for future 
pharmacokinetic studies in malnourished children, especially if there were an 
associated mild-to-moderate anaemia.   
7.5.2. Using the CBT to study the effects of concurrent infections with 
malnutrition on caffeine metabolism 
It may be possible to use the CBT to evaluate the combined effects of 
malnutrition and concurrent diseases, such as malaria, tuberculosis, and HIV 
infection, on caffeine metabolism. Previous pharmacokinetic studies have 
indicated decreased plasma CLs of caffeine and quinine in children with malaria 
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(Akinyinka et al., 2000; Pussard et al., 1999). HIV infection or stage of infection 
in adults has been reported to alter the activities of phase I and II drug 
metabolising enzymes (Jones et al., 2010). HIV infection has also been 
associated with an increased variability of CYP1A2, CYP2D6, N-acetyltransferase 
2 (NAT2), and xanthine oxidase (XO) compared to uninfected control groups.  
Malnutrition is also frequently associated with HIV infection. Concomitant 
malnutrition causes significant increases in mortality rate and diminished 
response to therapies, including antiretroviral therapy (ART) (Fergusson & 
Tomkins, 2009). The feasibility of using the CBT to determine the combined 
effects of malnutrition and HIV infection on drug metabolism in children should 
be explored in the future. 
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Appendix I 
 
Participant Information Sheet 
 
7KLVLVDGRFXPHQWFRQWDLQLQJDVXPPDU\RIWKHVWXG\³USING THE BREATH 
TEST TO STUDY CAFFEINE METABOLISM IN PROTEIN-ENERGY 
MALNOURISHED CHILDREN´ 
 
1. Children suffering from protein-energy malnutrition (PEM) are at risk of other 
health problems that may require multiple drug therapies. The body of these 
children handles drug differently from that of other children. Only a few 
studies have looked at drug metabolism in PEM children, they all involved 
collection of multiple blood samples. 
2. We plan to study drug metabolism in your child without taking any blood 
sample. The study hopes to improve the safety and dosing of medicines for 
children with the same illness as your child. 
3. The study will last 2-3 hours, commencing at 9a.m. During the study, the 
usual diet of your child will be replaced with Casilan®.  
4. Your child will abstain from caffeinated products for at least 20 hours and 
remain in bed, before and during the study, so as to minimise physical 
activities. 
5. We plan to administer, in a small quantity, a substance called caffeine to your 
child a few days after hospital admission and between 4-6 weeks after an 
appreciable recovery. 
6. Caffeine is harmless to children and is abundant in many of their daily foods 
and drinks such as candies, cookies, chocolate bars and drinks, coffee drink, 
soda drinks, and diary drinks. 3 mg/kg dose have been used in previous 
studies involving children without any adverse effects. The caffeine will be 
dissolved in a small quantity of water with a little squash added for your child 
to drink. 
7. We will request your child to blow through a straw into a special bottle. This 
will be done at 20, 10 and 1 minute before taking the caffeine drink and at 
every 15 minutes after taking the caffeine drink over a 2 hour period. 
8. We will continue to monitor your child to be sure that everything is fine 
during and after the procedure. 
9. There is no monetary reward for participating in the study. 
10.Your child is free to opt out of the study at any point should you find the 
procedure intolerable or for any reason best known to you. 
11.All the information collected about your child will be treated with utmost 
confidentiality. 
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Appendix II 
 
USING THE BREATH TEST TO STUDY CAFFEINE METABOLISM IN 
PROTEIN-ENERGY MALNOURISHED CHILDREN 
Consent Form for Children below 6 Years Old 
Investigators: Dr Kazeem Adeola Oshikoya, Dr Helen Sammons and Prof. Imti 
Choonara (Academic Division of Child Health, University of Nottingham) 
The parent/caregiver of the participant is requested to complete the whole of 
this sheet himself/herself. 
Please cross out as necessary. 
1. Have you read or the researcher has read to you and you understood the 
participant information sheet       YES/NO 
2. Have you had the opportunity to ask questions and discuss                        
the study?         YES/NO 
3. Have all the questions been answered satisfactorily?   YES/NO 
4. Have you received enough information about the study?  YES/NO 
5. Do you understand that your child/ward is free to withdraw from                                
the study at any time?        YES/NO 
6. Do you understand that your child/ward is free to withdraw from the                      
study without having to give a reason?     YES/NO 
7. Do you agree to your child/ward participating in the study?  YES/NO 
³7KLVVWXG\KDVEHHQH[SODLQHGWRPHWRP\VDWLVIDFWLRQDQG,DJUHHWRP\
child/ward taking part. I understand that my child/ward is free to withdraw at 
DQ\WLPH´ 
 
6LJQDWXUHRIWKHFKLOG¶VSDUHQWFDregiver «««««««.Date««««««« 
 
Name of the child (in block letters)«««««««««««««««««««««««««. 
I have explained the study to the parent/caregiver of the above child/participant 
and he/she has agreed to allow the child to participate. 
 
Signature of the researcher «««««««««««««««««««Date ««««««.. 
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Appendix III 
 
USING THE BREATH TEST TO STUDY CAFFEINE METABOLISM IN 
PROTEIN-ENERGY MALNOURISHED CHILDREN 
Assent Form for Children over 6 years Old 
 
My name is Dr. Kazeem Oshikoya. I am trying to learn about how drugs work 
and how they are removed from the body of kids who are not well fed because 
inadequate nutrition tends to affect the work and removal of drugs from the 
body of kids. Please let me know if you are willing to participate in this study.   
  
If you decide to be in this study, you will be asked to blow air with your mouth, 
through a straw, into a special bottle. You will be asked to blow the air into the 
bottle at every 15 minutes over a period of 2 hours. After taking your first three 
breath samples, you will be given a medicine called Caffeine, at a dose 
appropriate for your weight, to drink. The medicine will be dissolved in water 
mixed with squash drink to give the medicine a pleasant taste. You cannot take 
any food or other drink during the time of the study. I will need to take your 
age, weight and height before the study begins.   
 
Taking part in the study will enable us to know that the doses of medicine given 
to children who are not well fed will not cause them any harm. At the end of the 
study, the caffeine medicine may make you not to go to bed early or make your 
heart beat faster than normal. I want to assure you that these are not serious 
problems and may happen only for a short time.  
 
If you decide to be in the study, I will not tell anyone else what you say or do in 
the study.  When I tell other people about the study, I will not use your name, 
so no one can tell who I am talking about. 
 
<RXUSDUHQWVRUJXDUGLDQKDYHWRVD\LW¶V2.IRU\RXWREHLQWKHVWXG\$IWHU
they decide, you gHWWRFKRRVHLI\RXZDQWWRGRLWWRR,I\RXGRQ¶WZDQWWREHLQ
the study, no one will be mad at you.  If you want to be in the study now and 
FKDQJH\RXUPLQGODWHUWKDW¶V2.<RXFDQVWRSDWDQ\WLPH  
 
My telephone number is 08090684327.  You can call me if you have questions 
DERXWWKHVWXG\RULI\RXGHFLGH\RXGRQ¶WZDQWWREHLQWKHVWXG\DQ\PRUH 
  
Agreement 
 
,KDYHGHFLGHGWREHLQWKHVWXG\HYHQWKRXJK,NQRZWKDW,GRQ¶WKDYHWRGRLW
Signing here means that I have read this form or have it read to me and I am 
willing to be in this study.   
 ______________________________   ________________   
Name and Signature of Study Participant  Date 
 
______________________________   ________________ 
Name and Signature of Researcher   Date 
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Appendix IV: Ethical approval from Lagos State University 
Teaching Hospital, Ikeja, Lagos, Nigeria 
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Appendix V: Ethical approval from Lagos State Health Service 
Commission, Lagos, Nigeria 
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Appendix VI: Ethical approval from Aminu Kano Teaching Hospital, 
Kano State, Nigeria 
 
Dr Kazeem A Oshikoya 
Academic Division of Child Health 
Medical School in Derby 
University of Nottingham 
Royal Derby Hospital 
Uttoxetter Road 
Derby DE22 3 DT 
United Kingdom 
  
  
Re: Ethical Approval 
Re: Using the Caffeine Breath Test to Study Caffeine Metabolism in 
Protein Energy Malnourished Children 
  
Further to your application in respect of the above titled research 
SURSRVDODQG\RXUVXEVHTXHQWUHVSRQVHWRWKHFRPPLWWHH·VHQTXLULHV
the committee considered your proposal and noted same as a 
prospective study. Similarly, you are required to provide a consent form 
to clearly include consent section for parents/guardians in addition to 
the assent section. You are advised to seek the corporation of paediatric 
department. 
In view of this, Ethical Approval is hereby granted to conduct the 
research. However, the approval is subject to periodic reporting of the 
progress of the study and its completion to the committee. 
  
Best Regards 
%DUD·DWX.DELU0UV 
Secretary 
For: Chairman Ethical Committee, 
Aminu Kano University Teaching Hospital, 
Kano State, Nigeria. 
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Appendix VII: Raw 13C-enrichment (APE) data for underweight children  
 
Raw data for underweight children before nutritional rehabilitation 
 
                                                1                 2                       3                    4                   5                   6              7                 8                  9                  10               11              12               13           14              15   
 
Raw data for underweight children after nutritional rehabilitation 
 
 
                                1                     2                   3                    4                   5                   6                    7               8             9                10                 11                 12                    13                 14                15  
                            
 
 
15 minutes 
 
0.002625    0.000254 0.000982 0.002035 0.009300 0.003100 0.004830 0.001940 0.001600 0.003660 0.000670 0.004770 0.003280 
                     
0.003980        0.001610 
 
   
  30 minutes 
 
0.003058 0.000623 0.000320 0.001773 0.015100 0.003900 0.006760 0.003700 0.004350 0.003620 0.001850 0.003340 0.004570 0.006840 0.004000 
 
 
  45 minutes 
 
0.005647 0.000194 0.000976 0.002089 0.015500 0.009800 0.010920 0.007150 0.003890 0.003040 0.000070 0.003910 0.006110  0.007350 0.006780 
 
 
  60 minutes 
 
0.006502 0.000285 0.003660 0.004163 0.013400 0.004500 0.006530 0.005070 0.006410 0.003770 0.001490 0.006060 0.008720 0.007780 0.007900 
 
 
  75 minutes 
 
0.002414 0.001220 0.002090 0.002133 0.013600 0.004900 0.006110 0.005030 0.006260 0.004130 0.003450 0.006430 0.008960 0.008590 0.007460 
 
 
  90 minutes 
 
0.003740 0.000751 0.003700 0.002068 0.012300 0.005500 0.008830 0.006080 0.003820 0.004410 0.000542 0.005490 0.006780 0.008970 0.008680 
 
 
 105 minutes 
 
0.003267 0.001270 0.002950 0.002262 0.011900 0.005300 0.005280 0.005390 0.006160 0.005070 0.000700 0.009150 0.006340 0.009090 0.008390 
 
 
 120 minutes 
 
0.004682 0.001010 0.004850 0.003188 0.011000 0.005300 0.005340 0.006470 0.004290 0.005060     0.000794 0.005400 0.005490 0.001220 0.008430 
 15 minutes 0.00723 0.001001 0.002708 0.001266 0.003083 0.000296 0.00224 0.00183 0.000976 0.01036 0.009880 0.003959 0.00260 0.00413 0.00321 
  
30 minutes 0.00809 0.001011 0.004737 0.002670 0.005876 0.002930 0.00317 0.00295 0.001001 0.01056 0.010027 0.005746 0.00389 0.00781 0.00668 
 
45 minutes 
 
        0.00878 0.001012 0.006580 0.003130 0.006941 0.002276 0.00582 0.00446 0.001028 0.01072 0.010082 0.006084 0.00419 0.00739 0.00655 
  
 
60 minutes         0.01030 0.001023 0.006966 0.003082 0.007658 0.002668 0.00671 0.00526 0.001050 0.01087 0.010119 0.005975 0.00456 0.00766 0.00636 
  
 
75 minutes 0.01250 0.001027 0.006315 0.003082 0.007658 0.010558 0.00670 0.00531 0.001043 0.01111 0.010085 0.005749 0.00473 0.00790 0.00714 
  
 
90 minutes 0.01260 0.001031 0.006402 0.003637 0.007307 0.002859 0.00704 0.00548 0.001044 0.01118 0.01008 0.005673 0.00476 0.00821 0.00649 
  
 
105 minutes 0.01200 0.001031 0.006256 0.003738 0.006193 0.004510 0.00624 0.00529 0.001044 0.01119 0.010105 0.005969 0.00442 0.00773 0.00632 
  
 
 
120 minutes 0.01290 0.001031 0.006603 0.003828 0.006158 0.002362 0.00606 0.00486 0.001041 0.01127 0.010128 0.006106 0.00457 0.00773 0.00587 
 223 
 
Appendix VIII: Raw 13C-enrichment (APE) data for children with marasmus 
 
 
Raw data for children with marasmus before nutritional rehabilitation 
 
                       1                   2                    3                  4                   5                   6                 7                    8                  9                  10                  11                  12               13                  14                 15 
 
 
Raw data for children with marasmus after nutritional rehabilitation 
 
 
                    1                     2                  3                   4                    5                  6                   7                   8                   9                  10                  11                12                 13                  14             15 
 
15 minutes 0.001157  0.000296 0.001715 0.005910 0.001900 0.000539 0.000818 0.001906 0.006940 0.000931 0.001350 0.001770 0.003590 0.002390 0.002670 
 
   
  30 minutes 0.002120 
 
0.000784 0.003266 0.010100 0.003180 0.002374 0.001866 0.003353 0.001150 0.001955 0.002210 0.002240 0.005360 0.002820 0.003747 
 
 
  45 minutes 0.002734 
 
0.001049 0.004279 0.009760 0.004300 0.003079 0.002615 0.003947 0.009360 0.002204 0.002360 0.002780 0.005120 0.003760 0.005556 
 
 
  60 minutes 0.003562 
 
0.001522 0.004079 0.009440 0.003910 0.003907 0.003458 0.003542 0.005940 0.003090 0.002610 0.002630 0.004920 0.003740 0.005039 
 
 
  75 minutes 0.003556 
 
0.001862 0.003073 0.009420 0.004800 0.004477 0.004029 0.003977 0.007330 0.004104 0.002590 0.003000 0.004950 0.003280 0.005641 
 
 
  90 minutes 0.003643 
 
0.001976 0.003598 0.007560 0.005310 0.004542 0.004411 0.003075 0.006340 0.004110 0.002760 0.002990 0.005590 0.003350 0.005750 
 
 
  105 minutes 0.003539 
 
0.002046 0.003922 0.007710 0.005460 0.004942 0.004461 0.003073 0.006200 0.004571 0.002870 0.002660 0.005560 0.003830 0.005804 
 
 
  120 minutes 0.003645 
 
0.001885 0.003754 0.007780 0.005050 0.004633 0.004686 0.003472 0.005850 0.005130 0.002870 0.002990 0.004990 0.003580 0.005960 
 15 minutes   0.0013100 0.0006410 0.0010500 0.0041270 0.0014720 0.0019130 0.0007010 0.0037700 0.0107620 0.0012800 0.0021600 0.0025900 0.0039400 0.0023700 0.0029200 
 
 
30 minutes 
 
0.0026100 0.0012780 0.0024700 0.0065520 0.0030370 0.0048310 0.0034620 0.0046700 0.0057450 0.0022900 0.0035800 0.0016300 0.0069200 0.0037300 0.0051000 
  
 
45 minutes 
 
    0.0032300 0.0017750 0.0029800 0.0102050 0.0045300 0.0081140 0.0049840 0.0053400 0.0058040 0.0029800 0.0034500 0.0036600 0.0069700 0.0039100 0.0056900 
  
 
60 minutes 
 
    0.0033600 0.0019920 0.0031400 0.0109740 0.0048630 0.0057040 0.0054800 0.0052500 0.0059400 0.0038500 0.0039800 0.0044000 0.0066200 0.0038400 0.0061100 
  
 
75 minutes 
 
0.0034900 0.0020410 0.0033500 0.0106010 0.0051590 0.0056380 0.0056530 0.0057500 0.0055370 0.0042700 0.0038500 0.0045000 0.0061600 0.0044200 0.0067000 
  
 
90 minutes 
 
0.0035900 0.0018270 0.0033600 0.0090720 0.0051410 0.0058840 0.0059460 0.0048700 0.0054860 0.0041600 0.0046300 0.0048300 0.0067600 0.0047700 0.0071300 
  
 
105 minutes 
 
0.0036501 0.0019371 0.0033501 0.0096091 0.0051391 0.0057491 0.0061011 0.0042601 0.0058451 0.0040201 0.0047801 0.0049801 0.0062701 0.0044701 0.0069801 
  
120 minutes 
 
0.0035019 0.0022109 0.0033519 0.0087909 0.0052839 0.0059998 0.0066849 0.0037019 0.0056619 0.0048419 0.0047019 0.0050419 0.0061019 0.0036719 0.0072719 
 223 
 
Appendix IX: Raw 13C-enrichment (APE) data for children with marasmic-kwashiorkor 
 
Raw data for children with marasmic-kwashiorkor before nutritional rehabilitation 
 
                              1                   2                    3                  4                   5                   6                 7                    8                  9                  10                  11                  12               13                  14                 15 
 
 
Raw data for children with marasmic-kwashiorkor after nutritional rehabilitation 
   
                                 1                   2                    3                  4                   5                   6                 7                    8                  9                  10                  11                  12               13                  14                 
15 
 
15 minutes 0.001494 0.000252 0.004627 0.001823 0.001283 0.001553 0.002332 -0.000310 0.001243 0.003173 0.000973 0.004533 0.000803 0.000893 0.003463 
 
   
  30 minutes 0.005161 0.001995 0.005490 0.003063 0.003283 0.002973 0.003853 0.000693 0.002693 0.005673 0.001443 0.008253 0.002273 0.002783 0.005453 
 
 
  45 minutes 0.006302 0.003868 0.006988 0.004143 0.004673 0.004493 0.004283 0.001643 0.003023 0.005523 0.001803 0.009423 0.002603 0.004193 0.005443 
 
 
  60 minutes 0.006049 0.005534 0.007306 0.003733 0.004593 0.004463 0.004843 0.001573 0.003083 0.006163 0.002463 0.008763 0.002813 0.004993 0.005663 
 
 
  75 minutes 0.007080 0.006392 0.007425 0.004393 0.004723 0.004083 0.005223 0.001673 0.002903 0.006873 0.002523 0.009523 0.002853 0.004733 0.005833 
 
 
  90 minutes 0.006634 0.007062 0.008313 0.004573 0.005153 0.004153 0.004963 0.002043 0.003593 0.006313 0.002733 0.009423 0.002923 0.004693 0.005753 
 
 
  105 minutes 0.006624 0.007560 0.007473 0.004473 0.004173 0.004103 0.004983 0.002213 0.003853 0.005953 0.002723 0.009123 0.002793 0.004633 0.006683 
 
 
  120 minutes 0.006417 0.006730 0.008108 0.003726 0.004336 0.003846 0.004036 0.001866 0.003436 0.005746 0.002496 0.008366 0.007336 0.004346 0.006356 
 
 15 minutes 0.000612 0.002918 0.003680 0.001126 0.003564 0.002190 0.001906 -0.000036 0.002640 0.002480 0.001720 0.004450 0.001280 0.002140 0.008860 
  
   
  30 minutes 0.001487 0.005101 0.004122 0.003524 0.002750 0.004450 0.003353 0.000892 0.003560 0.003460 0.002520 0.006760 0.003120 0.003640 0.002570 
  
 
  45 minutes 0.002520 0.005687 0.005154 0.003942 0.003268 0.004620 0.003947 0.001590 0.003540 0.004180 0.002550 0.007800 0.003490 0.004540 0.002970 
  
 
  60 minutes 0.003497 0.006114 0.004650 0.003832 0.003252 0.004770 0.003542 0.001520 0.003290 0.004810 0.002840 0.008080 0.004470 0.004420 0.003660 
  
 
  75 minutes 0.003705 0.006699 0.005049 0.003920 0.003694 0.004720 0.003977 0.001940 0.003370 0.004690 0.003120 0.007580 0.004280 0.004280 0.003710 
  
 
  90 minutes 0.004319 0.007134 0.005608 0.004382 0.003935 0.005280 0.003757 0.002170 0.003420 0.005140 0.003870 0.008020 0.004040 0.004100 0.004410 
  
 
  105 minutes 0.004066 0.007090 0.005455 0.004294 0.004012 0.005040 0.003073 0.002560 0.003540 0.005160 0.003560 0.008270 0.003780 0.004170 0.004780 
  
 
  120 minutes 0.004209 0.007473 0.005275 0.002149 0.004202 0.004000 0.003472 0.002570 0.003310 0.005270 0.003630 0.007940 0.004330 0.004430 0.005210 
 223 
 
Appendix X: Raw 13C-enrichment (APE) data for children with kwashiorkor 
 
Raw data for children with kwashiorkor before nutritional rehabilitation 
                   
                       1                   2                    3                  4                   5                   6                 7                    8                  9                  10                  11                  12               13                  14                 15 
 
Raw data for children with kwashiorkor after nutritional rehabilitation 
 
                     1                   2                    3                  4                   5                   6                 7                    8                  9                  10                  11                  12               13                  14                 15 
                                  
 15 minutes 0.005660 0.001260 0.001340 0.002680 0.001670 0.001340 0.002870 0.003620 0.002870 0.004970 0.002940 0.001900 0.005060 0.001913 0.002030 
  
   
  30 minutes 0.007300 0.002070 0.002960 0.003980 0.003490 0.003020 0.005480 0.005930 0.004730 0.007450 0.005670 0.003030 0.008800 0.004831 0.001060 
  
 
  45 minutes 0.007012 0.002302 0.003182 0.004722 0.004302 0.002692 0.005152 0.005782 0.004832 0.006412 0.005502 0.003342 0.007362 0.007566 0.009332 
  
 
  60 minutes 0.006570 0.002910 0.003880 0.005880 0.005680 0.004310 0.006160 0.006400 0.005690 0.007040 0.006580 0.004300 0.007300 0.005704 0.001340 
  
 
  75 minutes 0.007460 0.003540 0.004160 0.005930 0.006620 0.004500 0.006000 0.006360 0.006100 0.007110 0.006390 0.004400 0.007260 0.005638 0.001580 
  
 
  90 minutes 0.007950 0.003510 0.003830 0.006500 0.006050 0.004500 0.005210 0.006530 0.005520 0.007230 0.006380 0.004090 0.008320 0.005884 0.001250 
  
 
  105 minutes 0.007950 0.003500 0.004000 0.006030 0.006610 0.004250 0.005820 0.005870 0.005130 0.007290 0.005500 0.004840 0.007770 0.005859 0.001670 
  
 
  120 minutes 0.007710 0.003500 0.004230 0.006270 0.006210 0.004850 0.004780 0.005950 0.004910 0.006730 0.004300 0.004710 0.007610 0.006196 0.002140 
 
 
 15 minutes 0.001280 0.001830 0.000024 0.002680 0.002220 0.001530 0.001850 0.002720 0.002280 0.003120 0.001240 0.000720 0.003260 0.002150 0.000940 
  
   
  30 minutes 0.004470 0.004080 0.008480 0.004340 0.004220 0.002220 0.003440 0.003660 0.003740 0.004820 0.003300 0.002130 0.005040 0.004040 0.001440 
  
 
  45 minutes 0.004902 0.002832 0.002112 0.005932 0.004932 0.003462 0.004942 0.004892 0.004222 0.005232 0.003932 0.002882 0.006772 0.005026 0.002092 
  
 
  60 minutes 0.004860 0.002130 0.001630 0.005350 0.005550 0.002850 0.003900 0.004820 0.004230 0.005530 0.005210 0.003890 0.005790 0.004510 0.001510 
  
 
  75 minutes 0.004570 0.002330 0.002290 0.005610 0.005990 0.003160 0.004410 0.004900 0.004380 0.005880 0.004100 0.004300 0.005440 0.004670 0.002030 
  
 
  90 minutes 0.004590 0.002650 0.002710 0.005590 0.006230 0.003040 0.004820 0.004800 0.004290 0.006240 0.004320 0.004570 0.004710 0.004710 0.002030 
  
 
  105 minutes 0.005430 0.002810 0.002670 0.005690 0.006380 0.002540 0.004770 0.004980 0.004210 0.006240 0.004960 0.004510 0.006390 0.004670 0.002150 
  
 
  120 minutes 0.007080 0.002900 0.003120 0.006470 0.005900 0.002980 0.005620 0.005300 0.004710 0.006000 0.005000 0.004180 0.005610 0.004520 0.002180 
